CA2346456A1 - Method and compositions for increasing bone mass - Google Patents
Method and compositions for increasing bone mass Download PDFInfo
- Publication number
- CA2346456A1 CA2346456A1 CA002346456A CA2346456A CA2346456A1 CA 2346456 A1 CA2346456 A1 CA 2346456A1 CA 002346456 A CA002346456 A CA 002346456A CA 2346456 A CA2346456 A CA 2346456A CA 2346456 A1 CA2346456 A1 CA 2346456A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- estrogen
- cells
- bone
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 153
- 238000000034 method Methods 0.000 title claims abstract description 105
- 230000001965 increasing effect Effects 0.000 title claims description 33
- 239000000203 mixture Substances 0.000 title description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 252
- 239000000262 estrogen Substances 0.000 claims abstract description 108
- 108010038795 estrogen receptors Proteins 0.000 claims abstract description 108
- 229940011871 estrogen Drugs 0.000 claims abstract description 99
- 108010080146 androgen receptors Proteins 0.000 claims abstract description 76
- 102100032187 Androgen receptor Human genes 0.000 claims abstract description 70
- 230000037118 bone strength Effects 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 165
- 102000015694 estrogen receptors Human genes 0.000 claims description 107
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 64
- 230000006907 apoptotic process Effects 0.000 claims description 64
- 210000000963 osteoblast Anatomy 0.000 claims description 64
- 239000003098 androgen Substances 0.000 claims description 63
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims description 55
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 claims description 55
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 55
- 230000037396 body weight Effects 0.000 claims description 48
- 238000000338 in vitro Methods 0.000 claims description 48
- 241001465754 Metazoa Species 0.000 claims description 47
- 230000002103 transcriptional effect Effects 0.000 claims description 46
- 238000001727 in vivo Methods 0.000 claims description 44
- 102000005962 receptors Human genes 0.000 claims description 42
- 108020003175 receptors Proteins 0.000 claims description 42
- 230000001582 osteoblastic effect Effects 0.000 claims description 35
- 210000004409 osteocyte Anatomy 0.000 claims description 35
- -1 phenanthrene compound Chemical class 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 229960003604 testosterone Drugs 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 239000003263 anabolic agent Substances 0.000 claims description 22
- 230000026731 phosphorylation Effects 0.000 claims description 22
- 238000006366 phosphorylation reaction Methods 0.000 claims description 22
- 230000027455 binding Effects 0.000 claims description 21
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 20
- 239000003963 antioxidant agent Substances 0.000 claims description 19
- 230000001076 estrogenic effect Effects 0.000 claims description 19
- 230000003256 osteocytic effect Effects 0.000 claims description 19
- 210000002997 osteoclast Anatomy 0.000 claims description 18
- 239000008177 pharmaceutical agent Substances 0.000 claims description 18
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 17
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 17
- 239000000199 parathyroid hormone Substances 0.000 claims description 17
- 229960001319 parathyroid hormone Drugs 0.000 claims description 17
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 15
- 239000011575 calcium Substances 0.000 claims description 15
- 229910052791 calcium Inorganic materials 0.000 claims description 15
- 229940122361 Bisphosphonate Drugs 0.000 claims description 14
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 14
- 230000001548 androgenic effect Effects 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 11
- 230000003078 antioxidant effect Effects 0.000 claims description 10
- 150000004663 bisphosphonates Chemical class 0.000 claims description 10
- 102000055006 Calcitonin Human genes 0.000 claims description 9
- 108060001064 Calcitonin Proteins 0.000 claims description 9
- 230000001195 anabolic effect Effects 0.000 claims description 9
- 230000000123 anti-resoprtive effect Effects 0.000 claims description 9
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 9
- 229960004015 calcitonin Drugs 0.000 claims description 9
- 239000000583 progesterone congener Substances 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 229960001603 tamoxifen Drugs 0.000 claims description 9
- 210000003205 muscle Anatomy 0.000 claims description 8
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 8
- 229960004622 raloxifene Drugs 0.000 claims description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 8
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 6
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 5
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims description 5
- 108010049264 Teriparatide Proteins 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 4
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 claims description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 4
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 4
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims description 4
- 229940046836 anti-estrogen Drugs 0.000 claims description 4
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 239000000328 estrogen antagonist Substances 0.000 claims description 4
- 229960005431 ipriflavone Drugs 0.000 claims description 4
- 102000006240 membrane receptors Human genes 0.000 claims description 4
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 claims description 4
- 229950010733 neridronic acid Drugs 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 230000001599 osteoclastic effect Effects 0.000 claims description 4
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 4
- 230000003637 steroidlike Effects 0.000 claims description 4
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 claims description 3
- 206010047486 Virilism Diseases 0.000 claims description 3
- 229960004343 alendronic acid Drugs 0.000 claims description 3
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 229940024545 aluminum hydroxide Drugs 0.000 claims description 3
- 230000009286 beneficial effect Effects 0.000 claims description 3
- 229960005069 calcium Drugs 0.000 claims description 3
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 3
- 239000001639 calcium acetate Substances 0.000 claims description 3
- 235000011092 calcium acetate Nutrition 0.000 claims description 3
- 229960005147 calcium acetate Drugs 0.000 claims description 3
- RXSYPQBNTPQOTQ-UHFFFAOYSA-L disodium;hydroxy-[[hydroxy(oxido)phosphoryl]methyl]phosphinate Chemical compound [Na+].[Na+].OP([O-])(=O)CP(O)([O-])=O RXSYPQBNTPQOTQ-UHFFFAOYSA-L 0.000 claims description 3
- GWBBVOVXJZATQQ-UHFFFAOYSA-L etidronate disodium Chemical compound [Na+].[Na+].OP(=O)([O-])C(O)(C)P(O)([O-])=O GWBBVOVXJZATQQ-UHFFFAOYSA-L 0.000 claims description 3
- 229940044658 gallium nitrate Drugs 0.000 claims description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 3
- 239000001095 magnesium carbonate Substances 0.000 claims description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 3
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 3
- 229940071572 oxidronate Drugs 0.000 claims description 3
- HJZKOAYDRQLPME-UHFFFAOYSA-N oxidronic acid Chemical compound OP(=O)(O)C(O)P(O)(O)=O HJZKOAYDRQLPME-UHFFFAOYSA-N 0.000 claims description 3
- BUUKFBVDKSFMHN-LKMAISLMSA-N parathar acetate Chemical compound CC(O)=O.C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 BUUKFBVDKSFMHN-LKMAISLMSA-N 0.000 claims description 3
- 229960003171 plicamycin Drugs 0.000 claims description 3
- 239000011736 potassium bicarbonate Substances 0.000 claims description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 3
- 229940094025 potassium bicarbonate Drugs 0.000 claims description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 3
- 230000004224 protection Effects 0.000 claims description 3
- 229960000759 risedronic acid Drugs 0.000 claims description 3
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 claims description 3
- 229960004291 sucralfate Drugs 0.000 claims description 3
- 229960000338 teriparatide acetate Drugs 0.000 claims description 3
- 239000003451 thiazide diuretic agent Substances 0.000 claims description 3
- 229960005324 tiludronic acid Drugs 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 4
- 230000036470 plasma concentration Effects 0.000 claims 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 2
- 229960003563 calcium carbonate Drugs 0.000 claims 2
- 229940091249 fluoride supplement Drugs 0.000 claims 2
- 229960001708 magnesium carbonate Drugs 0.000 claims 2
- PJDWNSYGMXODTB-UHFFFAOYSA-N 1,2,3,4,4a,4b,5,6-octahydrophenanthrene Chemical compound C1=CCCC2C(CCCC3)C3=CC=C21 PJDWNSYGMXODTB-UHFFFAOYSA-N 0.000 claims 1
- UXNCDAQNSQBHEN-UHFFFAOYSA-N 1,2,3,4-tetrahydrophenanthrene Chemical compound C1=CC2=CC=CC=C2C2=C1CCCC2 UXNCDAQNSQBHEN-UHFFFAOYSA-N 0.000 claims 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 claims 1
- CTUVMTKDPFHVPM-UHFFFAOYSA-N methanol;phenanthrene Chemical compound OC.C1=CC=C2C3=CC=CC=C3C=CC2=C1 CTUVMTKDPFHVPM-UHFFFAOYSA-N 0.000 claims 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 abstract description 19
- 230000003054 hormonal effect Effects 0.000 abstract description 5
- 102100038595 Estrogen receptor Human genes 0.000 abstract description 2
- 229960005309 estradiol Drugs 0.000 description 69
- 230000000694 effects Effects 0.000 description 47
- 208000001132 Osteoporosis Diseases 0.000 description 36
- 238000002474 experimental method Methods 0.000 description 27
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 24
- 229960005420 etoposide Drugs 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 description 23
- 238000011282 treatment Methods 0.000 description 22
- 239000003446 ligand Substances 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 235000006708 antioxidants Nutrition 0.000 description 17
- 241001529936 Murinae Species 0.000 description 14
- 239000003981 vehicle Substances 0.000 description 14
- 229940124325 anabolic agent Drugs 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 206010017076 Fracture Diseases 0.000 description 12
- 229930182833 estradiol Natural products 0.000 description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 12
- 206010065687 Bone loss Diseases 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 238000007634 remodeling Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000000540 analysis of variance Methods 0.000 description 9
- 230000011164 ossification Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 208000020084 Bone disease Diseases 0.000 description 8
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 8
- 229940030486 androgens Drugs 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- IBMYQCSJEBKMFF-UQCQJGFQSA-N (9r,10s,13r)-13-methyl-1,2,3,4,5,6,9,10,11,12-decahydrocyclopenta[a]phenanthren-3-ol Chemical compound C([C@@H]12)CC(O)CC1CC=C1[C@@H]2CC[C@@]2(C)C1=CC=C2 IBMYQCSJEBKMFF-UQCQJGFQSA-N 0.000 description 7
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 7
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 7
- 229960004308 acetylcysteine Drugs 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000010072 bone remodeling Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000000399 orthopedic effect Effects 0.000 description 7
- 208000010392 Bone Fractures Diseases 0.000 description 6
- 208000006386 Bone Resorption Diseases 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 108010024636 Glutathione Proteins 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 6
- 102000001307 androgen receptors Human genes 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000024279 bone resorption Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229960002258 fulvestrant Drugs 0.000 description 6
- 229960003180 glutathione Drugs 0.000 description 6
- 235000003969 glutathione Nutrition 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 208000029725 Metabolic bone disease Diseases 0.000 description 5
- 229940062527 alendronate Drugs 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 206010030247 Oestrogen deficiency Diseases 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 108091027981 Response element Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000002968 anti-fracture Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000012990 dithiocarbamate Substances 0.000 description 4
- 150000004659 dithiocarbamates Chemical class 0.000 description 4
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 230000010258 osteoblastogenesis Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 4
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 3
- 208000006389 Peri-Implantitis Diseases 0.000 description 3
- 241000286209 Phasianidae Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010039984 Senile osteoporosis Diseases 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940070021 anabolic steroids Drugs 0.000 description 3
- 230000003206 anti-remodeling effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 210000002805 bone matrix Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000004821 effect on bone Effects 0.000 description 3
- 229940009626 etidronate Drugs 0.000 description 3
- 229960002074 flutamide Drugs 0.000 description 3
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 201000003617 glucocorticoid-induced osteoporosis Diseases 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 3
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 2
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- JZIBVTUXIVIFGC-UHFFFAOYSA-N 2H-pyrrole Chemical compound C1C=CC=N1 JZIBVTUXIVIFGC-UHFFFAOYSA-N 0.000 description 2
- KWIVRAVCZJXOQC-UHFFFAOYSA-N 3h-oxathiazole Chemical compound N1SOC=C1 KWIVRAVCZJXOQC-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010028780 Complement C3 Proteins 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 108010090932 Vitellogenins Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003936 androgen receptor antagonist Substances 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 230000006909 anti-apoptosis Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 125000006267 biphenyl group Chemical group 0.000 description 2
- 239000002617 bone density conservation agent Substances 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 230000008416 bone turnover Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 230000001925 catabolic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000001135 feminizing effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 230000001009 osteoporotic effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 239000003075 phytoestrogen Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000013001 point bending Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 108010068072 salmon calcitonin Proteins 0.000 description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
- 150000007659 semicarbazones Chemical class 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 2
- 229960005460 teriparatide Drugs 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- HLHSUNWAPXINQU-GQCTYLIASA-N (E)-3-(3,4-dihydroxyphenyl)-N-prop-2-ynylprop-2-enamide Chemical compound OC=1C=C(C=CC=1O)/C=C/C(=O)NCC#C HLHSUNWAPXINQU-GQCTYLIASA-N 0.000 description 1
- JZTKNVMVUVSGJF-UHFFFAOYSA-N 1,2,3,5-oxatriazole Chemical compound C=1N=NON=1 JZTKNVMVUVSGJF-UHFFFAOYSA-N 0.000 description 1
- WTPCCFHCHCMJIT-UHFFFAOYSA-N 1,2,5-oxathiazine Chemical compound O1SC=CN=C1 WTPCCFHCHCMJIT-UHFFFAOYSA-N 0.000 description 1
- PPYNEJLGBMVWMC-UHFFFAOYSA-N 1,2,6-oxathiazine Chemical compound O1SC=CC=N1 PPYNEJLGBMVWMC-UHFFFAOYSA-N 0.000 description 1
- VCZQYTJRWNRPHF-UHFFFAOYSA-N 1,2-dioxin Chemical compound O1OC=CC=C1 VCZQYTJRWNRPHF-UHFFFAOYSA-N 0.000 description 1
- FFJBRYXQVYFDEQ-UHFFFAOYSA-N 1,3,2-dioxazole Chemical compound N1OC=CO1 FFJBRYXQVYFDEQ-UHFFFAOYSA-N 0.000 description 1
- ZWEGOVJVJZJDQJ-UHFFFAOYSA-N 1,4,2-dioxazole Chemical compound C1OC=NO1 ZWEGOVJVJZJDQJ-UHFFFAOYSA-N 0.000 description 1
- OQCYTSHIQNPJIC-QURGRASLSA-N 1-[(e)-2-bromo-1,2-diphenylethenyl]-4-ethylbenzene Chemical compound C1=CC(CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Br)C1=CC=CC=C1 OQCYTSHIQNPJIC-QURGRASLSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- BBYWOYAFBUOUFP-JOCHJYFZSA-N 1-stearoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OCCN BBYWOYAFBUOUFP-JOCHJYFZSA-N 0.000 description 1
- 150000000297 16-estratetraenes Chemical class 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- IEMAOEFPZAIMCN-UHFFFAOYSA-N 1H-pyrazole Chemical compound C=1C=NNC=1.C=1C=NNC=1 IEMAOEFPZAIMCN-UHFFFAOYSA-N 0.000 description 1
- TVLSKGDBUQMDPR-UHFFFAOYSA-N 2,3-Dimethoxy-5-methyl-6-(3-methyl-2-buten-1-yl)-1,4-benzenediol Chemical class COC1=C(O)C(C)=C(CC=C(C)C)C(O)=C1OC TVLSKGDBUQMDPR-UHFFFAOYSA-N 0.000 description 1
- AFPGRLRUFIIXIF-UHFFFAOYSA-N 2-acetamido-2-sulfanylpropanoic acid Chemical compound CC(=O)NC(C)(S)C(O)=O AFPGRLRUFIIXIF-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- HPYLZSUEFFQHRS-UHFFFAOYSA-N 2h-1,2,4-oxadiazine Chemical compound N1OC=CN=C1 HPYLZSUEFFQHRS-UHFFFAOYSA-N 0.000 description 1
- YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- DNUJVGBNIXGTHC-UHFFFAOYSA-N 3,6-dihydro-2h-oxazine Chemical compound C1NOCC=C1 DNUJVGBNIXGTHC-UHFFFAOYSA-N 0.000 description 1
- QLXDONQYFHWXFW-UHFFFAOYSA-N 3h-1,2,4-dioxazole Chemical compound C1OOC=N1 QLXDONQYFHWXFW-UHFFFAOYSA-N 0.000 description 1
- AKQOGTWDMNTUSF-UHFFFAOYSA-N 3h-1,2,5-oxathiazole Chemical compound C1SON=C1 AKQOGTWDMNTUSF-UHFFFAOYSA-N 0.000 description 1
- BWCDLEQTELFBAW-UHFFFAOYSA-N 3h-dioxazole Chemical compound N1OOC=C1 BWCDLEQTELFBAW-UHFFFAOYSA-N 0.000 description 1
- UNTNRNUQVKDIPV-UHFFFAOYSA-N 3h-dithiazole Chemical compound N1SSC=C1 UNTNRNUQVKDIPV-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- UCZQXJKDCHCTAI-UHFFFAOYSA-N 4h-1,3-dioxine Chemical compound C1OCC=CO1 UCZQXJKDCHCTAI-UHFFFAOYSA-N 0.000 description 1
- BYVSMDBDTBXASR-UHFFFAOYSA-N 5,6-dihydro-4h-oxazine Chemical compound C1CON=CC1 BYVSMDBDTBXASR-UHFFFAOYSA-N 0.000 description 1
- ZYUVGYBAPZYKSA-UHFFFAOYSA-N 5-(3-hydroxybutan-2-yl)-4-methylbenzene-1,3-diol Chemical group CC(O)C(C)C1=CC(O)=CC(O)=C1C ZYUVGYBAPZYKSA-UHFFFAOYSA-N 0.000 description 1
- 150000000638 6-estratetraenes Chemical class 0.000 description 1
- 150000000654 7-estratetraenes Chemical class 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 208000028060 Albright disease Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012205 Delayed puberty Diseases 0.000 description 1
- 208000018035 Dental disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- UHQGCIIQUZBJAE-RRQVMCLOSA-N Epimestrol Chemical compound C1C[C@]2(C)[C@H](O)[C@H](O)C[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 UHQGCIIQUZBJAE-RRQVMCLOSA-N 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- WKRLQDKEXYKHJB-UHFFFAOYSA-N Equilin Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3=CCC2=C1 WKRLQDKEXYKHJB-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000006367 Essential Osteolysis Diseases 0.000 description 1
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 1
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 1
- 102100029951 Estrogen receptor beta Human genes 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- RGLLOUBXMOGLDQ-IVEVATEUSA-N Furazabol Chemical compound C([C@@H]1CC2)C3=NON=C3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 RGLLOUBXMOGLDQ-IVEVATEUSA-N 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 208000019683 Gorham-Stout disease Diseases 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000011327 Increased bone mineral density Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000001853 McCune-Albright syndrome Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- XWALNWXLMVGSFR-HLXURNFRSA-N Methandrostenolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 XWALNWXLMVGSFR-HLXURNFRSA-N 0.000 description 1
- PGAUJQOPTMSERF-QWQRBHLCSA-N Methenolone acetate Chemical compound C([C@@H]1CC2)C(=O)C=C(C)[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)C)[C@@]2(C)CC1 PGAUJQOPTMSERF-QWQRBHLCSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000035823 Non-specific autoimmune cerebellar ataxia without characteristic antibodies Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- CVQUWLDCFXOXEN-UHFFFAOYSA-N Pyran-4-one Chemical compound O=C1C=COC=C1 CVQUWLDCFXOXEN-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- CMRJPMODSSEAPL-FYQPLNBISA-N Trenbolone acetate Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)C=C2 CMRJPMODSSEAPL-FYQPLNBISA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- NDDAQHROMJDMKS-XFYXLWKMSA-N [(2s,3s,5s,8r,9s,10s,13s,14s)-2-hydroxy-10,13-dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl]azanium;chloride Chemical compound Cl.C1[C@H](N)[C@@H](O)C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 NDDAQHROMJDMKS-XFYXLWKMSA-N 0.000 description 1
- FXMSQUVSUXBBAB-TXDQRGGKSA-N [(8r,9s,13s,14s,17s)-13-methyl-3-propanoyloxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pyridine-3-carboxylate Chemical compound O([C@@H]1[C@@]2(C)CC[C@@H]3C4=CC=C(C=C4CC[C@H]3[C@@H]2CC1)OC(=O)CC)C(=O)C1=CC=CN=C1 FXMSQUVSUXBBAB-TXDQRGGKSA-N 0.000 description 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 1
- AUYLVPGDOVEOML-UHFFFAOYSA-N [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(piperidin-1-ylmethoxy)phenyl]methanone Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 AUYLVPGDOVEOML-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 238000003314 affinity selection Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- FPQFYIAXQDXNOR-QDKLYSGJSA-N alpha-Zearalenol Chemical compound O=C1O[C@@H](C)CCC[C@H](O)CCC\C=C\C2=CC(O)=CC(O)=C21 FPQFYIAXQDXNOR-QDKLYSGJSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical class N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- FNYSFBUQYJDECF-UHFFFAOYSA-N benzyl(trifluoromethoxy)phosphinic acid Chemical class FC(F)(F)OP(O)(=O)CC1=CC=CC=C1 FNYSFBUQYJDECF-UHFFFAOYSA-N 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- 229950007271 boldenone Drugs 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000037186 bone physiology Effects 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229950003738 broparestrol Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- DDPFHDCZUJFNAT-PZPWKVFESA-N chembl2104402 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 DDPFHDCZUJFNAT-PZPWKVFESA-N 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- 229960002559 chlorotrianisene Drugs 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- KCZCIYZKSLLNNH-FBPKJDBXSA-N clostebol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1Cl KCZCIYZKSLLNNH-FBPKJDBXSA-N 0.000 description 1
- 229960001481 clostebol Drugs 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- MRKZAZMYXYSBDG-UHFFFAOYSA-N cyclopentyl propanoate Chemical compound CCC(=O)OC1CCCC1 MRKZAZMYXYSBDG-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 description 1
- 229960003839 dienestrol Drugs 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- NLORYLAYLIXTID-ISLYRVAYSA-N diethylstilbestrol diphosphate Chemical compound C=1C=C(OP(O)(O)=O)C=CC=1C(/CC)=C(\CC)C1=CC=C(OP(O)(O)=O)C=C1 NLORYLAYLIXTID-ISLYRVAYSA-N 0.000 description 1
- PBWZKZYHONABLN-UHFFFAOYSA-M difluoroacetate Chemical compound [O-]C(=O)C(F)F PBWZKZYHONABLN-UHFFFAOYSA-M 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000001177 diphosphate Chemical class 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- IWLDTXOHXPDPQG-UHFFFAOYSA-L disodium;hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]-3-pyrrolidin-1-ylpropyl]phosphinate Chemical compound [Na+].[Na+].OP(=O)(O)C(P([O-])([O-])=O)(O)CCN1CCCC1 IWLDTXOHXPDPQG-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- VSHJAJRPRRNBEK-LMVCGNDWSA-N eel calcitonin Chemical class C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CS)[C@@H](C)O)C(C)C)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C1=CN=CN1 VSHJAJRPRRNBEK-LMVCGNDWSA-N 0.000 description 1
- 108700032313 elcatonin Proteins 0.000 description 1
- 229960000756 elcatonin Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960004595 epimestrol Drugs 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- WKRLQDKEXYKHJB-HFTRVMKXSA-N equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229950008961 estrapronicate Drugs 0.000 description 1
- 150000002164 estratrienes Chemical class 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229940081345 estropipate Drugs 0.000 description 1
- HZEQBCVBILBTEP-ZFINNJDLSA-N estropipate Chemical compound C1CNCCN1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 HZEQBCVBILBTEP-ZFINNJDLSA-N 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229940035423 ethyl ether Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229960001460 ethylestrenol Drugs 0.000 description 1
- AOXRBFRFYPMWLR-XGXHKTLJSA-N ethylestrenol Chemical compound C1CC2=CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(C)CC2 AOXRBFRFYPMWLR-XGXHKTLJSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000010006 flight Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- AMVODTGMYSRMNP-GNIMZFFESA-N formebolone Chemical compound C1CC2=CC(=O)C(C=O)=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@H]2O AMVODTGMYSRMNP-GNIMZFFESA-N 0.000 description 1
- 229950010292 formebolone Drugs 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229960000297 fosfestrol Drugs 0.000 description 1
- 229950010710 furazabol Drugs 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- OGWJYLKDZYZYBA-UHFFFAOYSA-N hexa-1,3-dien-5-yne Chemical compound C=CC=CC#C OGWJYLKDZYZYBA-UHFFFAOYSA-N 0.000 description 1
- AHAREKHAZNPPMI-UHFFFAOYSA-N hexa-1,3-diene Chemical compound CCC=CC=C AHAREKHAZNPPMI-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229940045644 human calcitonin Drugs 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229950006971 incadronic acid Drugs 0.000 description 1
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- UXYRZJKIQKRJCF-TZPFWLJSSA-N mesterolone Chemical compound C1C[C@@H]2[C@@]3(C)[C@@H](C)CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C UXYRZJKIQKRJCF-TZPFWLJSSA-N 0.000 description 1
- 229960005272 mesterolone Drugs 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 mestranol Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960003377 metandienone Drugs 0.000 description 1
- 229960003578 metenolone Drugs 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 229960004719 nandrolone Drugs 0.000 description 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
- 150000004780 naphthols Chemical class 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960000492 norethandrolone Drugs 0.000 description 1
- ZDHCJEIGTNNEMY-XGXHKTLJSA-N norethandrolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(C)CC2 ZDHCJEIGTNNEMY-XGXHKTLJSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- GXHBCWCMYVTJOW-YGRHGMIBSA-N oxabolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1O GXHBCWCMYVTJOW-YGRHGMIBSA-N 0.000 description 1
- 229950010171 oxabolone Drugs 0.000 description 1
- CQDAMYNQINDRQC-UHFFFAOYSA-N oxatriazole Chemical compound C1=NN=NO1 CQDAMYNQINDRQC-UHFFFAOYSA-N 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229960005244 oxymetholone Drugs 0.000 description 1
- ICMWWNHDUZJFDW-DHODBPELSA-N oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 description 1
- ICMWWNHDUZJFDW-UHFFFAOYSA-N oxymetholone Natural products C1CC2CC(=O)C(=CO)CC2(C)C2C1C1CCC(C)(O)C1(C)CC2 ICMWWNHDUZJFDW-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002530 phenolic antioxidant Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000001863 phosphorothioyl group Chemical group *P(*)(*)=S 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229940093688 polyestradiol Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 208000001061 polyostotic fibrous dysplasia Diseases 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000010938 positive regulation of bone remodeling Effects 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 239000011591 potassium Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960004765 promestriene Drugs 0.000 description 1
- IUWKNLFTJBHTSD-AANPDWTMSA-N promestriene Chemical compound C1C[C@]2(C)[C@@H](OC)CC[C@H]2[C@@H]2CCC3=CC(OCCC)=CC=C3[C@H]21 IUWKNLFTJBHTSD-AANPDWTMSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 229960001819 quinbolone Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960004726 quinestradol Drugs 0.000 description 1
- ODYKCPYPRCJXLY-PZORDLPLSA-N quinestradol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1C[C@@H](O)[C@@H]4O)C)CC2=CC=3OC1CCCC1 ODYKCPYPRCJXLY-PZORDLPLSA-N 0.000 description 1
- 229960001424 quinestrol Drugs 0.000 description 1
- PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960000912 stanozolol Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004154 testing of material Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
- 208000009189 tinea favosa Diseases 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 229960000312 trenbolone Drugs 0.000 description 1
- 239000001226 triphosphate Chemical class 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229960002300 zeranol Drugs 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Nutrition Science (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention as disclosed provides a method to increase bone mass without compromising bone strength or quality, through the administration to a host of a compound that binds to the estrogen or androgen receptor without causing hormonal transcriptional activation.
Description
METHOD AND COMPOSITIONS FOR INCREASING BONE MASS
BACKGROUND OF THE INVENTION
Federal Funding This invention was funded in part through a grant from the National Institutes of Health. Therefore, the federal government has certain rights in this invention.
Field of the Invention This invention is in the field of bone physiology, and i n particular provides methods and compositions that include compounds to increase bone mass, i.e., to achieve bone anabolism.
The compounds bind to the estrogen or androgen receptor without causing significant hormonal transcriptional activation.
Descr,~' ption of the Related A r t Bones consist of living cells embedded within a matrix of proteins and minerals. Bones provide support and protection to the vital organs of the animal, and give strength and form to its structure.
Osteoporosis is a decrease in bone mass in combination with microarchitectural deterioration which leads to bone fragility and fractures. Treatments for osteoporosis have historically focused on the prevention of further bone loss. I n contrast, a bone anabolic agent is one that substantially increases bone mass. To date, while there have been several dru g s approved by the U.S. Food and Drug Administration for the treatment of osteoporosis, it is believed that no drug has yet been approved in the United States to be used as a bone anabolic agent, for either humans or other animals. Bone is a dynamic tissue .
which undergoes continual resorption and formation through a remodeling process, which is accomplished by two types of cells:
osteoclasts, which erode cavities, and osteoblasts that synthesize new bone matrix. Remodeling takes place mainly on the internal surfaces of bone and it is carried out not by individual cells, b a t rather by temporary anatomical structures, termed basic multi-cellular units (BMUs), comprising teams of osteoclasts in the front and osteoblasts in the rear. In an established BMU, bone resorption and formation happens at the same time.
After osteoclasts stop resorbing bone, they die b y apoptosis and are quickly removed by phagocytes. During the longer lifespan of the osteoblasts (about three months, a s compared to three weeks for osteoclasts), some osteoblasts convert to lining cells that cover quiescent bone surfaces and some are entombed within the mineralized matrix as osteocytes (Parfitt, In: Bone, Telford and CRC Press, PP351-429, 1990). However, the majority (65%) of osteoblasts that originally assembled at the remodeling site die by apoptosis (Jilka et al, JBMR 13:793-802, 1998).
Most metabolic disorders of the adult skeleton result from an imbalance between the resorption of old bone b y osteoclasts and its subsequent replacement by osteoblasts.
Changes in cell numbers, as opposed to individual cell activity (Manolagas and Jilka, NEJM 332:305-311, 1995), appear to be the cause of most metabolic bone diseases, including the three most common forms of osteoporosis: osteoporosis due to sex steroid deficiency in females and males (Jilka et al., Science 257:88-91, 1992; Jilka et al., JCI 101:1942-1950, 1998; Bellido et al., JCI .
95:2886-2895, 1995; Weinstein et. al., Endocrinology 138:4013-4021, 1997); osteoporosis due to old age (Jilka et al., JCI 97:1732-1740, 1996); and osteoporosis due to glucocorticoid-excess (Weinstein et al., JCI 102:274-282, 1998; Weinstein et al, Bone, 23:S461, 1998; Bellido et al, Bone, 23:5324, 1998).
Agents that reduce bone turnover by inhibiting the activation of bone remodeling (commonly but inaccurately referred to as "antiresorptive") increase bone mass by a maximum of 6-10%, and more typically, 2-3%, as measured by Dual Energy X-Ray Absorptiometry (DEXA). Most of this increase is in the first 1-2 years and is due to contraction of the remodeling space.
Modest further increases may result from more complete secondary mineralization. Improvement of focal balance due to reduction of resorption depth has been demonstrated in animal experiments, but not yet in human subjects. Regardless of the mechanism, an increase of less than 10% will in almost all cases fail to restore bone mass to its peak value and fail to reestablish trabecular connectivity so that fracture risk will remain increased.
There are a wide variety of needs for bone anabolic agents for humans as well as animals. Examples of uses for bone anabolic agents in humans, besides patients with osteoporosis, include the strengthening of bone in healthy subjects who engage in strenuous physical activities such as sports or manual labor, and the strengthening of bone in persons who do not h av a osteoporosis but might be subject to osteoporosis in the future because the person is in a risk group for that disease. Other a s a s for a bone anabolic agent in humans include the treatment of persons who fail to obtain an adequate bone mass at the completion of growth or persons who are born with unusually fragile bones, persons who have a genetic predisposition to a bone catabolic disease, or an orthopedic bone disease such as joint degeneration, non-union fractures, orthopedic problems caused b y diabetes, periimplantitis, poor responses to bone grafts, implants, fracture.
Likewise, there are many uses for bone anabolic agents in animals. For example, it would be useful to increase the bone mass in horses and dogs used for labor as well as those asad in sports such as racing. It would also be useful to increase the bone mass in chickens and turkeys used in meat production to maximize the amount of meat yield per animal.
There are currently ten classes of drugs that are a s a d in the treatment of osteoporosis: anabolic steroids, bisphosphonates, calcitonins, estrogens/progestogens, Selective Estrogen Receptor Modulators (SERMs) such as raloxifene, phytoestrogen, parathyroid hormone ("PTH"), fluoride, Vitamin D
metabolites, and calcium preparations. No compound within th a s a classes has been approved as a bone anabolic agent.
Anabolic Steroids (Androgens) Anabolic steroids (androgens) have been known to build muscle mass in the host. However, there has been no reported evidence that they function as bone anabolic agents a s defined herein (Snyder et al, JCEM 84:1966-1972, 1999).
Androgens are typically used as a replacement therapy for male hypogonadal disorders and they are used in adolescent males with a history of delayed puberty or growth. Androgens can produce significant side effects when taken over a period of time, including water retention, jaundice, decreased high density lipoprotein and increased low density lipoprotein, hepatic toxicity (most usually associated with the 17 a-alkylated androgens), hepatic carcinoma, increased risk of cardiovascular disease, and when taken in large dosages, irrationality, psychotic episodes, violent behavior, and death. U.S. Patent No. 5,565,444 discloses the use of an androgen for the treatment of bone loss or for increasing bone mass.
Calcitonin Endogenous calcitonin is a polypeptide hormone involved in the regulation of calcium and bone metabolism. Forms used therapeutically include calcitonin (po.rk), extracted from pig thyroid, a synthetic human calcitonin; elcatonin, a synthetic analogue of eel calcitonin; and salcatonin, a synthetic salmon calcitonin. They all have the property of lowering plasma-calcium concentration by diminishing the rate of bone resorption.
Calcitonins are typically administered subcutaneously or b y intramuscular injection.
B~ ,s~hosphonates Bisphosphonates have been widely used to treat osteoporosis. The bisphosphonate disodium etidronate has similar effects on bone mass and fractures in established osteoporosis to those of calcitonin, but cannot be given for a prolonged period because of the risk of osteomalacia. Bisphosphonate alendronate treatment at a dose of 10 mg/day results in a 5% increase i n spinal bone mineral density (BMD) over the first year (Dempster, Exploiting and Bypassing the Bone Remodeling Cycle to Optimize the Treatment of Osteoporosis, Journal of Bone and Mineral Research, Volume 12, Number 8, 1997, pages 1152-1154). BMD
continues to increase, albeit at a slower rate, at this site during the second and third years of treatment. The magnitude and duration of the increase in BMD has led to speculation that alendronate i s doing more than simply reducing remodeling space and that i t may possess anabolic activity. The bisphosphonate etidronate reduced resorption depth in human iliac trabecular bone b y almost 30% after one year of treatment, but no such data are y a t available for alendronate. Etidronate did not change the thickness of trabecular packets, but recent studies in osteoporotic women suggest that this is increased after two years of alendronate treatment at 10 and 20 mg/day. This result was not confirmed after three years of treatment.
In another article, Dempster (Dempster D.W., New concepts in bone remodeling, In: Dynamics of Bone and Cartilage Metabolism, Chapter 18, pp.261-273, Acad. Press, 1999) confirms that the potential for an agent that can increase bone mass a n d hence reverse the skeletal defect in patients with osteoporosis is great, particularly if in doing so it also repairs microarchitectural damage. He notes that estrogens and calcitonin primarily stabilize bone mass and prevent further loss of bone, although a transient small increment in mass is often reported, particularly in patients with elevated levels of bone remodeling. Dempster et al conclude that this is not a true anabolic effect but is related to the temporal effects on turnover in which resorption declines initially followed by a reduction in formation that may take several months.
Albeit, bisphosphonates have anti-apoptotic effects o n osteoblasts and osteocytes (Plotkin et al. Bone, 23:S157, 1998).
Significantly, the anti-apoptotic effect of bisphosphonates in vitro is achieved with doses 100-1000 lower than the doses at which IO these same agents inhibit osteoclast activity; and additionally can be demonstrated with bisphosphonates that do not block osteoclast activity at all (compound IG9204). U.S. Patent No.
4,870,063 discloses a bisphosphonic acid derivative to increase bone mass. U.S. Patent Nos. 5,532,226 and 5,300,687 describe the use of trifluoromethylbenzylphosphonates to increase bone mass.
U.S. .Patent No. 5,885,973 to Papapoulos, et al, discloses a bone mass anabolic composition that includes olpandronate, which is a bisphosphonate.
Estrogens/,Progestogens Estrogens/progestogens (anti-remodeling and anti-resorptive compounds) as a class have not to date been shown to increase bone mass by more than 10%, but instead have b a a n used to retard the effect of osteoporosis. Estrogens are currently the most effective method of preventing osteoporosis i n postmenopausal women.
U.S. Patent No. 5,183,815 discloses the use of a steroidal hormone covalently linked to a hydroxy alkyl-1,1-bisphosphonate. U.S. Patent No. 5,843,934 claims that an estrogen WO 00/20007 . PCT/US99/23355 having insubstantial sex-related activity can be administered to a patient to retard the adverse effects of osteoporosis in a male o r female. The '934 patent does not address how to select a compound to increase bone mass, but instead teaches how to retard the effect of bone loss. WO 98/22113 filed by the University of Florida Research Foundation, Inc. discloses methods to utilize an isomer of an estrogen compound to confer cytoprotection on a population of cells associated with an ischemic event.
Phytoestro~e~ns_ Little is known about the actions of phytoestrogens on bone (Fitzpatrick, L.A., Mayo Clinic Proceedings, 74:601-607, 1999). Soy protein did not prevent increased bone turnover in cynomolgus monkeys; they actually increased it. However, BMD
declined after two years in postmenopausal women taking only calcium but did not change in those receiving ipriflavone.
Isoflavone significantly increased spinal BMD in postmenopausal women after 6 months of 40 mg/day of soy protein supplementation (containing 90 mg isoflavones) but not with lower doses (56 mg/day) (Feinkel, E. Lancet, 352:762, 1998).
Parathyroid Hormone fPTHI _ Daily injections of parathyroid hormone (PTH), a n agent known for its role in calcium homeostasis, increases bone mass in animals and humans, as does the related PTH-related hormone PHTrP, the only other known ligand of the PTH receptor.
Whereas increased prevalence of apoptosis of osteoblasts a n d osteocytes are key pathogenic mechanisms for osteoporosis (Weinstein et al., J Clin Invest, 102:274-282, 1998; Weinstein et al, Bone, 23:S461, 1998; Bellido et al, Bone, 23:5324, 1998), the reverse, i. e., postponement of osteoblast apoptosis, is the principal, if not the sole, mechanism for the anabolic effects of intermittent parathyroid hormone administration on bone (Jilka et al., J. Clin.
Invest. 104:439-446, 1999). The increased bone mineral density, osteoblast perimeter and bone formation rate that occur with intermittent PTH administration in mice happen without a change in osteoblast production. Instead, the anabolic effect of the drug is due to decreased prevalence of osteoblast apoptosis from 1.7-2.2%
to as little as 0.1-0.4%, while the osteocytes in the newly made lamellar cancellous bone are closer together and more numerous than those found in the animals receiving vehicle alone. The closely spaced, more numerous osteocytes are the predictable consequence of protecting osteoblasts from apoptosis. The anti-apoptotic effect of PTH on osteoblasts as well as osteocytes h a s been confirmed in vitro using primary bone cell cultures and established cell lines.
The use of teriparatide (the 1-34 amino acid fragment of human parathyroid growth hormone) to stimulate bone formation has also been investigated; teriparatide administered as daily injections has been reported to selectively increase the trabecular bone density of the spine in osteoporotic patients.
U.S. Patent No. 5,510,370 discloses the use of a combination of PTH and raloxifene to increase bone mass. U.S.
Patent No. 4,833,125 discloses the use of PTH in combination with either a hydroxylated vitamin D derivative, or a dietary calcium supplement.
BACKGROUND OF THE INVENTION
Federal Funding This invention was funded in part through a grant from the National Institutes of Health. Therefore, the federal government has certain rights in this invention.
Field of the Invention This invention is in the field of bone physiology, and i n particular provides methods and compositions that include compounds to increase bone mass, i.e., to achieve bone anabolism.
The compounds bind to the estrogen or androgen receptor without causing significant hormonal transcriptional activation.
Descr,~' ption of the Related A r t Bones consist of living cells embedded within a matrix of proteins and minerals. Bones provide support and protection to the vital organs of the animal, and give strength and form to its structure.
Osteoporosis is a decrease in bone mass in combination with microarchitectural deterioration which leads to bone fragility and fractures. Treatments for osteoporosis have historically focused on the prevention of further bone loss. I n contrast, a bone anabolic agent is one that substantially increases bone mass. To date, while there have been several dru g s approved by the U.S. Food and Drug Administration for the treatment of osteoporosis, it is believed that no drug has yet been approved in the United States to be used as a bone anabolic agent, for either humans or other animals. Bone is a dynamic tissue .
which undergoes continual resorption and formation through a remodeling process, which is accomplished by two types of cells:
osteoclasts, which erode cavities, and osteoblasts that synthesize new bone matrix. Remodeling takes place mainly on the internal surfaces of bone and it is carried out not by individual cells, b a t rather by temporary anatomical structures, termed basic multi-cellular units (BMUs), comprising teams of osteoclasts in the front and osteoblasts in the rear. In an established BMU, bone resorption and formation happens at the same time.
After osteoclasts stop resorbing bone, they die b y apoptosis and are quickly removed by phagocytes. During the longer lifespan of the osteoblasts (about three months, a s compared to three weeks for osteoclasts), some osteoblasts convert to lining cells that cover quiescent bone surfaces and some are entombed within the mineralized matrix as osteocytes (Parfitt, In: Bone, Telford and CRC Press, PP351-429, 1990). However, the majority (65%) of osteoblasts that originally assembled at the remodeling site die by apoptosis (Jilka et al, JBMR 13:793-802, 1998).
Most metabolic disorders of the adult skeleton result from an imbalance between the resorption of old bone b y osteoclasts and its subsequent replacement by osteoblasts.
Changes in cell numbers, as opposed to individual cell activity (Manolagas and Jilka, NEJM 332:305-311, 1995), appear to be the cause of most metabolic bone diseases, including the three most common forms of osteoporosis: osteoporosis due to sex steroid deficiency in females and males (Jilka et al., Science 257:88-91, 1992; Jilka et al., JCI 101:1942-1950, 1998; Bellido et al., JCI .
95:2886-2895, 1995; Weinstein et. al., Endocrinology 138:4013-4021, 1997); osteoporosis due to old age (Jilka et al., JCI 97:1732-1740, 1996); and osteoporosis due to glucocorticoid-excess (Weinstein et al., JCI 102:274-282, 1998; Weinstein et al, Bone, 23:S461, 1998; Bellido et al, Bone, 23:5324, 1998).
Agents that reduce bone turnover by inhibiting the activation of bone remodeling (commonly but inaccurately referred to as "antiresorptive") increase bone mass by a maximum of 6-10%, and more typically, 2-3%, as measured by Dual Energy X-Ray Absorptiometry (DEXA). Most of this increase is in the first 1-2 years and is due to contraction of the remodeling space.
Modest further increases may result from more complete secondary mineralization. Improvement of focal balance due to reduction of resorption depth has been demonstrated in animal experiments, but not yet in human subjects. Regardless of the mechanism, an increase of less than 10% will in almost all cases fail to restore bone mass to its peak value and fail to reestablish trabecular connectivity so that fracture risk will remain increased.
There are a wide variety of needs for bone anabolic agents for humans as well as animals. Examples of uses for bone anabolic agents in humans, besides patients with osteoporosis, include the strengthening of bone in healthy subjects who engage in strenuous physical activities such as sports or manual labor, and the strengthening of bone in persons who do not h av a osteoporosis but might be subject to osteoporosis in the future because the person is in a risk group for that disease. Other a s a s for a bone anabolic agent in humans include the treatment of persons who fail to obtain an adequate bone mass at the completion of growth or persons who are born with unusually fragile bones, persons who have a genetic predisposition to a bone catabolic disease, or an orthopedic bone disease such as joint degeneration, non-union fractures, orthopedic problems caused b y diabetes, periimplantitis, poor responses to bone grafts, implants, fracture.
Likewise, there are many uses for bone anabolic agents in animals. For example, it would be useful to increase the bone mass in horses and dogs used for labor as well as those asad in sports such as racing. It would also be useful to increase the bone mass in chickens and turkeys used in meat production to maximize the amount of meat yield per animal.
There are currently ten classes of drugs that are a s a d in the treatment of osteoporosis: anabolic steroids, bisphosphonates, calcitonins, estrogens/progestogens, Selective Estrogen Receptor Modulators (SERMs) such as raloxifene, phytoestrogen, parathyroid hormone ("PTH"), fluoride, Vitamin D
metabolites, and calcium preparations. No compound within th a s a classes has been approved as a bone anabolic agent.
Anabolic Steroids (Androgens) Anabolic steroids (androgens) have been known to build muscle mass in the host. However, there has been no reported evidence that they function as bone anabolic agents a s defined herein (Snyder et al, JCEM 84:1966-1972, 1999).
Androgens are typically used as a replacement therapy for male hypogonadal disorders and they are used in adolescent males with a history of delayed puberty or growth. Androgens can produce significant side effects when taken over a period of time, including water retention, jaundice, decreased high density lipoprotein and increased low density lipoprotein, hepatic toxicity (most usually associated with the 17 a-alkylated androgens), hepatic carcinoma, increased risk of cardiovascular disease, and when taken in large dosages, irrationality, psychotic episodes, violent behavior, and death. U.S. Patent No. 5,565,444 discloses the use of an androgen for the treatment of bone loss or for increasing bone mass.
Calcitonin Endogenous calcitonin is a polypeptide hormone involved in the regulation of calcium and bone metabolism. Forms used therapeutically include calcitonin (po.rk), extracted from pig thyroid, a synthetic human calcitonin; elcatonin, a synthetic analogue of eel calcitonin; and salcatonin, a synthetic salmon calcitonin. They all have the property of lowering plasma-calcium concentration by diminishing the rate of bone resorption.
Calcitonins are typically administered subcutaneously or b y intramuscular injection.
B~ ,s~hosphonates Bisphosphonates have been widely used to treat osteoporosis. The bisphosphonate disodium etidronate has similar effects on bone mass and fractures in established osteoporosis to those of calcitonin, but cannot be given for a prolonged period because of the risk of osteomalacia. Bisphosphonate alendronate treatment at a dose of 10 mg/day results in a 5% increase i n spinal bone mineral density (BMD) over the first year (Dempster, Exploiting and Bypassing the Bone Remodeling Cycle to Optimize the Treatment of Osteoporosis, Journal of Bone and Mineral Research, Volume 12, Number 8, 1997, pages 1152-1154). BMD
continues to increase, albeit at a slower rate, at this site during the second and third years of treatment. The magnitude and duration of the increase in BMD has led to speculation that alendronate i s doing more than simply reducing remodeling space and that i t may possess anabolic activity. The bisphosphonate etidronate reduced resorption depth in human iliac trabecular bone b y almost 30% after one year of treatment, but no such data are y a t available for alendronate. Etidronate did not change the thickness of trabecular packets, but recent studies in osteoporotic women suggest that this is increased after two years of alendronate treatment at 10 and 20 mg/day. This result was not confirmed after three years of treatment.
In another article, Dempster (Dempster D.W., New concepts in bone remodeling, In: Dynamics of Bone and Cartilage Metabolism, Chapter 18, pp.261-273, Acad. Press, 1999) confirms that the potential for an agent that can increase bone mass a n d hence reverse the skeletal defect in patients with osteoporosis is great, particularly if in doing so it also repairs microarchitectural damage. He notes that estrogens and calcitonin primarily stabilize bone mass and prevent further loss of bone, although a transient small increment in mass is often reported, particularly in patients with elevated levels of bone remodeling. Dempster et al conclude that this is not a true anabolic effect but is related to the temporal effects on turnover in which resorption declines initially followed by a reduction in formation that may take several months.
Albeit, bisphosphonates have anti-apoptotic effects o n osteoblasts and osteocytes (Plotkin et al. Bone, 23:S157, 1998).
Significantly, the anti-apoptotic effect of bisphosphonates in vitro is achieved with doses 100-1000 lower than the doses at which IO these same agents inhibit osteoclast activity; and additionally can be demonstrated with bisphosphonates that do not block osteoclast activity at all (compound IG9204). U.S. Patent No.
4,870,063 discloses a bisphosphonic acid derivative to increase bone mass. U.S. Patent Nos. 5,532,226 and 5,300,687 describe the use of trifluoromethylbenzylphosphonates to increase bone mass.
U.S. .Patent No. 5,885,973 to Papapoulos, et al, discloses a bone mass anabolic composition that includes olpandronate, which is a bisphosphonate.
Estrogens/,Progestogens Estrogens/progestogens (anti-remodeling and anti-resorptive compounds) as a class have not to date been shown to increase bone mass by more than 10%, but instead have b a a n used to retard the effect of osteoporosis. Estrogens are currently the most effective method of preventing osteoporosis i n postmenopausal women.
U.S. Patent No. 5,183,815 discloses the use of a steroidal hormone covalently linked to a hydroxy alkyl-1,1-bisphosphonate. U.S. Patent No. 5,843,934 claims that an estrogen WO 00/20007 . PCT/US99/23355 having insubstantial sex-related activity can be administered to a patient to retard the adverse effects of osteoporosis in a male o r female. The '934 patent does not address how to select a compound to increase bone mass, but instead teaches how to retard the effect of bone loss. WO 98/22113 filed by the University of Florida Research Foundation, Inc. discloses methods to utilize an isomer of an estrogen compound to confer cytoprotection on a population of cells associated with an ischemic event.
Phytoestro~e~ns_ Little is known about the actions of phytoestrogens on bone (Fitzpatrick, L.A., Mayo Clinic Proceedings, 74:601-607, 1999). Soy protein did not prevent increased bone turnover in cynomolgus monkeys; they actually increased it. However, BMD
declined after two years in postmenopausal women taking only calcium but did not change in those receiving ipriflavone.
Isoflavone significantly increased spinal BMD in postmenopausal women after 6 months of 40 mg/day of soy protein supplementation (containing 90 mg isoflavones) but not with lower doses (56 mg/day) (Feinkel, E. Lancet, 352:762, 1998).
Parathyroid Hormone fPTHI _ Daily injections of parathyroid hormone (PTH), a n agent known for its role in calcium homeostasis, increases bone mass in animals and humans, as does the related PTH-related hormone PHTrP, the only other known ligand of the PTH receptor.
Whereas increased prevalence of apoptosis of osteoblasts a n d osteocytes are key pathogenic mechanisms for osteoporosis (Weinstein et al., J Clin Invest, 102:274-282, 1998; Weinstein et al, Bone, 23:S461, 1998; Bellido et al, Bone, 23:5324, 1998), the reverse, i. e., postponement of osteoblast apoptosis, is the principal, if not the sole, mechanism for the anabolic effects of intermittent parathyroid hormone administration on bone (Jilka et al., J. Clin.
Invest. 104:439-446, 1999). The increased bone mineral density, osteoblast perimeter and bone formation rate that occur with intermittent PTH administration in mice happen without a change in osteoblast production. Instead, the anabolic effect of the drug is due to decreased prevalence of osteoblast apoptosis from 1.7-2.2%
to as little as 0.1-0.4%, while the osteocytes in the newly made lamellar cancellous bone are closer together and more numerous than those found in the animals receiving vehicle alone. The closely spaced, more numerous osteocytes are the predictable consequence of protecting osteoblasts from apoptosis. The anti-apoptotic effect of PTH on osteoblasts as well as osteocytes h a s been confirmed in vitro using primary bone cell cultures and established cell lines.
The use of teriparatide (the 1-34 amino acid fragment of human parathyroid growth hormone) to stimulate bone formation has also been investigated; teriparatide administered as daily injections has been reported to selectively increase the trabecular bone density of the spine in osteoporotic patients.
U.S. Patent No. 5,510,370 discloses the use of a combination of PTH and raloxifene to increase bone mass. U.S.
Patent No. 4,833,125 discloses the use of PTH in combination with either a hydroxylated vitamin D derivative, or a dietary calcium supplement.
calcium Preparations Calcium preparations, while useful as a dietary supplement for persons who are calcium deficient, have not b a a n shown effective to increase bone mass. However, they may reduce the rate of bone loss. U.S. Patent No. 5,618,549 (a calcium salt) describes the use of calcium.
Fluor' .
The most thoroughly studied anabolic agent, sodium fluoride, can increase vertebral bone mass by 10% a year for a t least four years but there is controversy about the quality of the bone formed. Sodium fluoride has not been approved as a bone anabolic agent. It has been difficult to establish anti-fracture efficacy because of serious qualitative abnormalities. First, much of the new bone is initially woven rather than lamellar. Second and more important, there is severe impairment of bone mineralization, in spite of sodium fluoride's effectiveness i n increasing bone mass.
U.S. Patent No. 5,071,655 discloses a composition to increase bone mass that includes a fluoride source and a mitogenic hydantoin.
SERMs SERMs such as tamoxifen and raloxifene have also been used to treat osteoporosis. A recent study carried out with raloxifene indicated that after three years of treatment, women o n raloxifene had 30-50% fewer spinal fractures, and had 2-3%
increase in bone density in their hips and spine, but showed n o fewer nonspinal fractures, a category that includes hip fractures (Ettinger, B., JAMA, 282:637-645, 1999).
WO 00/20007 PG"T/US99/23355 U.S. Patent 4,970,237 discloses the use of No.
clomiphene to increase mass in premenopausalwomen.
bone Vitamin D deriva tives There have been conflicting reports the value of about Vitamin D or its derivativeson bone loss and bone anabolism.
Some studies on the hormonal D, calcitrioi, metabolite of vitamin have reported an increase spinal bone density, others h a v in but a .
found no effect.
The following patents describe the use of Vitamin D
derivatives to treat bone disease: U.S. Patent Nos. 4,973,584;
5,750,746; 5,593,833; 5,532,391; 5,414,098; 5,403,831; 5,260,290;
5,104,864; 5,001,118; 4,973,584; 4,619,920; and 4,588,716.
Other Compounds The following patents disclose the use of other compounds for the treatment of bone disease: U.S. Patent Nos.
5,753,649 and 5,593,988 (azepine derivative); 5,674,844 (morphogen); 5,663,195 (cyclooxygenase-2 inhibitor); 5,604,259 (ibuprofen or flurbiprofen); 5,354,773 (bafilomycine); 5,208,219 (activin); 5,164,368 (growth hormone releasing factor); an d 5,118,667, 4,870,054 and 4,710,382 (administration of a bone growth factor and an inhibitor of bone resorption).
U.S. Patent No. 5,859,001 discloses the use of non estrogen compounds having a terminal phenol group in a four-ring cyclopentanophenanthrene compound structure to confer neuroprotection to cells.
U.S. Patent No. 5,824,672 discloses a method for preserving tissues during transplantation procedures that includes administering an effective dose of a cyclopentanophenanthrene compound having a terminal phenol A ring.
WO 98/31381 filed by the University of Florida Research Foundation, Inc. discloses a method for enhancing the cytoprotective effect of polycyclic phenolic compounds on a population of cells that involves the steps of administering a combination of polycyclic phenolic compounds and anti-oxidants to achieve an enhanced effect. One disclosed combination is glutathione and estrogen.
It is an object of the present invention to provide a method to increase bone mass in a host by at least 10% per year without a loss in bone strength (defined by fracture incidence i n vivo and mechanical strength in vitro) and/or deterioration of bone quality (as defined by abnormal collagen orientation and excessive accumulation of unmineralized bone matrix, determined, for example, with histomorphometry).
It is another object of the present invention to provide a method to rebuild strong bones instead of preventing further loss of bone.
It is a further object of the present invention to provide a method to select compounds that increase bone mass in a host at least 10% per year without a loss in bone strength or quality.
It is a still further object of the present invention to provide a method to increase bone strength by at least 20%.
SUMMARY OF THE INVENTION
In a first embodiment, a method for increasing bone mass in a host at least 10% without a loss in bone strength o r quality is provided that includes administering an effective amount of a compound that (i) binds to the estrogen a or B
receptor (or the equivalent receptor in the host animal) with a n association constant of at least 108 M-', and preferably, at least 10'° M-': (ii) (a) induces estrogenic gene transcriptional activity at a level that is no greater than 10% that of 17B-estradiol, and preferably no greater than 5, 1 or even O.l.% that of 1713-estradiol when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic or osteocytic cells with natural estrogen receptors or cells transfected with estrogen receptors or 1 S (b) induces an increase in uterine weight of no more than 10% that of 1713-estradiol (or the equivalent compound in a host animal);
(iii) induces the phosphorylation of extracellular signal regulated kinase (ERK) when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic cells with natural estrogen receptors or cells transfected with estrogen receptors;
and (iv) has an anti-apoptotic effect on osteoblasts and osteocytes at an in vivo dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic or osteocytic cells with natural estrogen receptors or cells transfected with the estrogen receptor. In another aspect of this first embodiment of this invention, the compound is not a n estrogen compound, as that term is defined below. In yet another aspect of this first embodiment, the compound is an estrogen compound which is converted to a nonestrogen by attaching a substituent which prevents the compound from entering the cell but does not significantly affect the binding of the compound to the estrogen cell-surface receptor.
In a second embodiment, a method for increasing b o n a mass in a host at least 10% without a loss in bone strength o r quality is provided that includes administering an effective amount of a compound that (i) binds to the androgen receptor (or the equivalent receptor in the host animal) with an association constant of at least 108 M'', and preferably, at least 10'° M'': (ii) (a) induces androgenic gene transcriptional activity at a level that is no greater than 10% that of testosterone, and preferably no greater than 5, 1 or even 0.1 % that of testosterone w h a n administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic cells with the natural androgen receptor or cells transfected with the androgen receptor or (b) induces a n increase in muscle weight of no more than 10% that which is induced by testosterone (or the equivalent compound in a host animal); (iii) induces the phosphorylation. of extracellular signal regulated kinase (ERK) when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic cells with the natural androgen receptor or cells transfected with the androgen receptor; and (iv) has an anti-apoptotic effect o n osteoblasts and osteocytes at an in vivo dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic cells with the natural androgen receptor or transfected with the androgen receptor. I n another aspect of the second embodiment, the compound is not a n androgen. In yet another aspect of this second embodiment, the compound is an androgen compound which is converted to a nonandrogen by attaching a substituent which prevents the compound from entering the cell but which does not significantly affect the ability of the compound . to bind to the androgen cell-surface receptor.
In other aspects of the first or second embodiment of this invention, the compound has a pro-apoptotic effect o n osteoclasts at an in vivo dosage of at least 0.1 ng/kg body weight, or in osteoclastic cells with natural estrogen receptors or cells transfected with estrogen receptors.
The disclosed invention is based on the fundamental discovery that bone loss occurs because of an increase i n osteoblast and perhaps osteocyte apoptosis, which can be inhibited by a compound that binds to an estrogen or androgen receptor, which induces the phosphorylation of ERKs without significant hormonal transcriptional activation. The discovery of this fundamental pathway allows the selection of compounds which provide a maximum effect on bone mass and strength.
Therefore, in a third embodiment, a method for selecting a compound that increases bone mass in a host at least 10% without a loss in bone strength or quality is provided that includes evaluating whether the compound (i) binds to the estrogen or androgen receptor (or the equivalent receptor in the host animal) with an association constant of at least 10g M-1, and preferably, at least 10' ° M-' : (ii) (a) induces estrogenic o r androgenic gene transcriptional activity at a level that is no greater than 10% that of 173-estradiol or testosterone, and preferably no greater than 5, 1 or even 0.1% that of 17(3-estradiol or testosterone, as appropriate, when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic cells with the natural androgen or estrogen receptor or cells transfected with the androgen or estrogen receptor or (b) induces an increase in uterine weight of no more than 10% that which is induced by 173-estradiol or muscle weight of no more than 10%
that which is induced by testosterone (or the equivalent compound in a host animal); (iii) induces the phosphorylation of .
extracellular signal regulated kinase (ERK) when administered i n vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic or osteocytic cells with the natural androgen o r estrogen receptor or cells transfected with the androgen o r estrogen receptor; and (iv) has an anti-apoptotic effect o n osteoblasts and osteocytes at an in vivo dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic and osteocytic cells with the natural androgen or estrogen receptor or cells transfected with the androgen or estrogen receptor.
Estrogenic compounds like 17a-estradiol and synthetic polycyclic phenols, such as estratriene-3-of inhibit osteoblast and osteocyte apoptosis in vitro. Yet unlike the classical mechanism of estrogen receptor action that involves direct or indirect interaction with the transcriptional apparatus, the receptor-dependent anti-apoptotic effects of these compounds are nongenomic, as they are due to rapid (within S minutes) phosphorylation of ERKs.
Estratriene-3-of increases bone mass in both estrogen-replete and estrogen-deficient mice. Esstratriene-3-ol, when given in low doses, has little effect on estrogenic-type activity but also has little effect on bone mass. As the dosage increases, both effects increase. To optimize the use of this compound or others exhibiting this type of activity, one can derivatize the compound to preserve the estrogen-binding activity and decrease the transcriptional activity as described in detail herein, including b y attaching a substituent or moiety that inhibits cell penetration.
Compounds selected according to the criteria provided herein can also be used for the augmentation of bone mass a n d / o r fracture prevention in diseases characterized by low bone mass and increased fragility. The compounds can also be used to treat bone disease states in which osteoblastogenesis is decreased, such as senile osteoporosis, and glucocorticoid-induced osteoporosis--especially in growing children and adolescents, during which time in whom interfering with bone remodeling is detrimental.
BRIEF DESCRIPTION OF THE DRAWINGS
The Figures provided herein illustrate embodiments of the invention and are not intended to limit the scope of the invention.
Figure 1 provides nonlimiting examples of one class of compounds that can be used to increase bone mass without adversely affecting bone strength.
Figure 2 is a bar chart graph of the degree of apoptosis of osteoblasts and osteocytes in murine vertebral bone as a function of estrogen deficiency. Swiss Webster mice (four months old) were ovariectomized. Twenty eight days later, th a animals were sacrificed, vertebrae were isolated, fixed a n d embedded, and then undecalcified in methacrylate. The prevalence of osteoblast and osteocyte apoptosis was determined by the TUNEL method with CuS04 enhancement, and was found to be dramatically increased following loss of estrogen. ***P<
0.00001; *P < 0.0382.
Figure 3 is a series of bar chart graphs which illustrate the percentage of Etoposide-induced osteoblast apoptosis versus the log of the concentration of added estrogens 17 Vii-estradiol, 173-estradiol-BSA, 17a-estradiol, and estratriene-3-ol.
Osteoblastic cells derived from murine calvaria were pretreated with the sterols for 1 hour before the addition of the pro-apoptotic agent, etoposide. Apoptosis was determined after 6 hours b y trypan blue uptake (Jilka et al, J.Bone and Min. Res. 13:793:802, 1998). * indicates p<0.05 versus etoposide alone, by analysis of variance (ANOVA) (Student-Newman-Keuls method).
Figure 4 is a series of bar chart graphs of the inhibition of etoposide-induced apoptosis of osteocytes (MLO-Y4) by 173-estradiol, 173-estradiol-BSA, 17a-estradiol, and estratriene-3-ol. Cells were pretreated with the indicated concentrations of the compounds for 1 hour before the addition of the pro-apoptotic agent etoposide. Apoptosis was determined after 6 hour by trypan blue uptake as described in Figure 3.
indicates p<0.05 versus etoposide alone, by ANOVA (Student-Newman-Keuls method).
Figure 5 is a series of bar chart graphs that indicates that the anti-apoptotic effect of 17~i-estradiol, 173-estradiol-BSA, 17a-estradiol, and estratriene-3-of (E-3-ol) on etoposide-induced apoptosis of osteoblasts is abrogated by the estrogen receptor antagonist, ICI182,780. Osteoblastic cells derived from murine calvaria were pretreated for 1 hour with the pure receptor antagonist ICI182,780 (10-' M) before the addition of the test agents ( 10-g M). Apoptosis was induced and quantified a s described in Figure 3. * indicates p<0.05 versus etoposide alone, by ANOVA (Student-Newman-Keuls method).
Figure 6 is a series of bar chart graphs that indicates that the anti-apoptotic effect of 17(3-estradiol, 17~i-estradiol-BSA, 17a-estradiol, and estratriene-3-of (E-3-ol) on MLO-Y4 osteocytic cells is abrogated by the estrogen receptor antagonist, ICI182,780.
MLO-Y4 cells were pretreated for 1 hour with the pure receptor antagonist ICI182,780 ( 10-' M) before the addition of the test agents ( 10-8 M). Apoptosis was induced and quantified a s described in Figure 3. * indicates p<0.05 versus etoposide alone, by ANOVA (Student-Newman-Keuls method).
Figure 7 is a series of bar chart graphs which demonstrate that estrogen receptor a or ~i is required for the anti-apoptotic effects of 17~i-estradiol, 17a-estradiol, and estratriene-3-0l on the etoposide-induced apoptosis of osteoblasts. CMV
promoter alone and CMV promoter-driven cDNA for mERa or mEr~i were stably transfected into HeLa cells. Subconfluent cultures were treated for 1 hr with 10-g M 17 a-estradiol, 17 (3-estradiol, o r estratriene-3-of followed by a 6 hr incubation with etoposide (5x10-5 M). Cells were trypsinized, pelleted and trypan blue positive cells enumerated. Each bar represents mean of duplicate experiments ~ SEM. *P < 0.02 versus etoposide alone.
Figure 8 is Western blot which demonstrates th at 17~i-estradiol, 17a-estradiol, 17~-estradiol-BSA or estratriene-3-of activate the extracellular signal regulated kinases (ERKs). MLO-Y4 osteocytic cells were incubated for 25 minutes in serum-free medium. Subsequently, 17~i-estradiol, 17a-estradiol, 17~-estradiol-BSA or estratriene-3-of ( 10-g M) were added and cells incubated for an additional 5, I5, or 30 min. Cell lysates were prepared and proteins were separated by electrophoresis i n polyacrylamide gels and transferred to PVDF membranes.
Western blotting was performed using a specific antibody .
recognizing phosphorylated ERKs I and 2, followed by reblotting with an antibody recognizing total ERKs. Blots were developed b y enhanced chemiluminescence.
Figure 9 is a Western blot which demonstrates that the effect of estrogenic compounds on the activation of ERK1/2 is blocked by the specific inhibitor of ERK kinase, PD98059. MLO-Y4 cells were incubated for 25 minutes in serum-free medium in the presence or absence of 50 ~,M PD98059. Subsequently, 17 (3-estradiol, 17a-estradiol, 17~i-estradiol-BSA or estratriene-3-of ( 10-8 M) were added and cells incubated for an additional 5 min. Cell lysates were prepared and proteins were separated b y electrophoresis in polyacrylamide gels and transferred to PVDF
membranes. Western blotting was performed using a specific antibody recognizing phosphorylated ERKs 1 and 2, followed b y reblotting with an antibody recognizing total ERKs. Blots were developed by enhanced chemiluminescence.
Figure 10 is a series of bar chart graphs which demonstrate that the specific inhibitor of ERK activation, PD98059, abolishes the anti-apoptotic effect of 17~-estradiol and related compounds. MLO-Y4 osteocytic cells were pretreated for 1 hour with 50 ~,M PD98059 before the addition of 10-8 M 17~i-estradiol, 17a-estradiol, or 17~i-estradiol-BSA. Apoptosis was induced b y incubation with the pro-apoptotic agent dexamethasone for 6 hour and quantified as described in Figure 3. * indicates p<0.05 versus the corresponding control group without dexamethasone, b y ANOVA (Student-Newman-Keuls method).
Figure 11 illustrates that unlike 17 a estradiol, estratriene-3-of does not transactivate an estrogen response element through ERa. The human ERa was overexpressed in 2 9 3 cells lacking ERa along with a reporter construct containing 3 copies of an estrogen response element driving the luciferase gene. Light units were counted and normalized to coexpressed b -galactosidase activity to control for differences in transfection efficiency. Results represent percent stimulation compared to ERa transfected cells, but not treated with the two agents. Each b ar represents mean of duplicate experiments +/- SEM. *p<0.001 vs.
cells not exposed to the sterols.
Figure 12 is an illustration of the chemical structures of certain 3-ring compounds: [2S-(2a,4aa, l0a(3)]-1,2,3,4,4a,9,10, l0a-octahydro-7-hydroxy-2-methyl-2-phenanthrenemethanol (PAM) and [2S-(2a,4aa, l0a~i)]-1,2,3,4,4a,9,10, l0a-octahydro-7-hydroxy-2-methyl-2-phenanthrenecarboxaldehyde {PACA).
Figure 13 illustrates the generalized core ring structures with numbered carbons (Figure 13a) 4-ring structure, (Figure 13b) 3-ring structure, (Figure 13c) 2-ring structure (fused), and (Figure 13d) 2-ring structure (non-fused).
Figure 14 is an illustration of three mechanisms of estrogen activity: Figure 14A (anti-apoptotic effect of estrogen), Figure 14B (anti-remodeling effect of estrogen) and Figure 14 C
(feminizing effect of estrogen).
Figure 15 compares the activity of the anti resorptive (e.g., 17~i-estradiol) versus non-anti-resorptive agents [e.g., estratriene-3-of or intermittent PTH] on osteoblast and osteocyte apoptosis. Bone formation occurs only on sites of previous osteoclastic bone resorption, i.e., on sites undergoing remodeling. Each remodeling cycle is a transaction that, once consummated, is irrevocable. As shown in the right panel, agents with anti-apoptotic properties that do not have anti-resorptive/anti-remodeling properties rebuild more bone and therefore, increase the overall bone mass because they will not decrease the number of the remodeling units (i.e., the number of transactions). In addition, by decreasing the prevalence of osteoblast apoptosis, the active compounds expand the pool of mature osteoblasts at sites of new bone formation and allow th a s a cells more time to make bone. Moreover, by upholding th a osteocyte-canalicular network by preventing osteocyte apoptosis, both classical antiresorptive agents like 173-estradiol and agents that are not anti-resorptives are expected to have anti-fracture efficacy over and above that resulting from their effects on b o n a mass.
Figure 16A is a table of examples of R1 and R2 substitutions on the compound illustrated in Figure 1.
Figure 16B provides the molecular structures of a and ~i estradiol.
Figure 17 provides the chemical structures of estratrienes with anti-apoptotic properties.
WO 00/20007 PC'T/US99/23355 Figure 18 provides the chemical structures of estradiol, phenol and diphenols with anti-apoptotic properties.
Figure 19 depicts the effect of 17 (3 estradiol on th a transcriptional activity of a minimal ERE containing gene promoter and the blockade of this effect by a peptide (aII) recognizing the ligand-induced specific conformational change of the estrogen receptor protein. 293, human kidney cells, were transiently transfected with a plasmid carrying the ER-specific aII peptide with the GAL4-DNA binding domain inserted upstream of the peptide sequence, an ERE/IL-6 promoter-driven luciferase reporter plasmid and a ~3-galactosidase ((3-gal)-containing plasmid.
The ERE-luciferase construct carried three copies of the Xenopus vitellogenin ERE driving the luciferase gene in the pGL3-Basic vector (Promega). * indicates p<0.05 versus cells transfected with the peptide aII, by ANOVA (Student-Newman-Keuls method).
Figure 2 0 depicts the effect of 17 ~i estradiol on t h a transcriptional activity of the IL-6 promoter and the blockade of this effect by a peptide (aII) recognizing the ligand-induced specific conformational change of the estrogen receptor protein.
The IL-6-luciferase plasmid carried 225bp of the proximal IL-6 promoter cloned upstream of the luciferase gene in pGL3-Basic.
The aII peptide inhibited the transcriptional effects of estrogen on the ERE-dependent transcription model. aII was also shown to block transcription when mediated via protein/protein interaction between the ER and another transcription factor on the IL-6 gene model. * indicates p<0.05 versus cells transfected with the peptide aII, by ANOVA (Student-Newman-Keuls method).
Figure 21 demonstrates the anti-apoptotic effect of 17[3 estradiol conjugated with BSA and the lack of inhibition of this particular effect by the conformation sensitive peptide aII.
The effect of the peptide on apoptosis was assayed using etoposide as the apoptotic stimulus. Upon etoposide treatment, cells that had been transfected with the ER and treated with 17 (3-BSA were protected from apoptosis. Following co-transfection of the GAL4-driven peptide, cells remained resistant to etoposide-induced apoptosis indicating that the peptide did not inhibit the protective, anti-apoptotic action of the ER (Figure 21). * indicates p<0.05 versus cells transfected with the peptide aII, by ANOVA
(Student-Newman-Keuls method).
DETAILED DESCRIPTION OF THE INVENTION
The invention as disclosed provides a method to increase bone mass without compromising bone quality, through the administration to a host of an effective amount of a compound that binds to the estrogen or androgen receptor so as to trigger the anti-apoptotic signalling pathway, but with minimal or n o resultant transcriptional activity.
In an optimal embodiment using this invention, a n anabolic effect will be established by demonstrating increased bone formation, assessed by double tetracycline labeling (Weinstein R.S. In Disorders of Bone and Mineral Metabolism (eds.
Coe and Favus) Raven Press, 1992, pp. 455-474) and a continuous increase in BMD, assessed by DEXA (Jilka et al. J. Clin. Invest.
97:1732-1740, 1996} for at least five years, along with increased, or at least no decreased quality or strength.
This invention is based on the fundamental discovery that bone loss occurs because of an increase in osteoblast apoptosis, which can be inhibited by a compound that binds to a n estrogen or androgen receptor (which induces the phosphorylation of ERKs) with minimal or no resultant transcriptional activity. The discovery of this fundamental pathway allows the selection of compounds which provide a maximum effect on bone mass and strength.
Therefore, in a first embodiment, a method for increasing bone mass in a host at least 10% without a loss in bone quality or strength is provided that includes administering a n effective amount of a compound that (i) binds to the estrogen a o r 13 receptor (or the equivalent receptor in the host animal) with a n association constant of at least 108 M-', and preferably, at least 10'° M-'; (ii) (a) induces estrogenic gene transcriptional activity a t a level that is no greater than 10% that of 1713-estradiol, and preferably no greater than 5, 1 or even 0.1% that of 1713-estradiol when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in cells with natural estrogen receptors or transfected with estrogen receptors or (b) induces an increase i n uterine weight of no more than 10% that of estrogen (or the equivalent compound in a host animal); (iii) induces the phosphorylation of extracellular signal regulated kinase (ERK) when administered in vivo at a dosage of at least 0.1 ng/kg body weight or at a concentration of 10-" to 10'' M in vitro in cells with natural estrogen receptors or transfected with estrogen receptors.;
and (iv) has an anti-apoptotic effect on osteoblasts and osteocytes at an in vivo dosage of at least 0.1 ng/kg body weight or at a concentration of 10-" to 10'' M in vitro in cells with natural estrogen receptors or transfected with estrogen receptors. I n another aspect of this first embodiment of this invention, the compound is not an estrogen compound, as that term is defined herein. In another aspect of this first embodiment, the compound is an estrogen compound which is converted to a nonestrogen b y attaching a substituent which prevents the compound from entering the cell, but which does not significantly affect the binding of the compound to the estrogen cell-surface estrogen receptor.
In a second embodiment, a method for increasing b o n a mass in a host at least 10% per year without a loss in bone strength or quality is provided that includes administering a n effective amount of a compound that (i) binds to the androgen receptor (or the equivalent receptor in the host animal) with a n association constant of at least 108 M-', and preferably, at least 10 '° M-1: (ii) (a) induces androgenic gene transcriptional activity a t a level that is no greater than 10% that of testosterone, and preferably no greater than 5, 1 or even 0.1% that of testosterone when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in cells with the natural androgen receptor or transfected with the androgen receptor or (b) induces an increase in muscle weight of no more than 10% that which is induced b y testosterone (or the equivalent compound in a host animal); (iii) induces the phosphorylation of extracellular signal regulated kinase (ERK) when administered in vivo at a dosage of at least 0.1 ng/kg body weight, or at a concentration of 10-" to 10'' M in vitro in cells with the natural androgen receptor or transfected with the androgen receptor; and (iv) has an anti-apoptotic effect o n osteoblasts and osteocytes at an in vivo dosage of at least 0.1 ng/kg body weight or at a concentration of 10-" to 10-' M in vitro in cells with the natural androgen receptor or transfected with the androgen receptor. In another aspect of the second embodiment, the compound is not an androgen. In another aspect of this second embodiment, the compound is an androgen compound which is converted to a nonandrogen by attaching a substituent which prevents the compound from entering the cell containing the cell-surface androgen receptor.
In other aspects of the first or second embodiment of this invention, the compound also has a pro-apoptotic effect o n osteoclasts at an in vivo dosage of at least 0.1 ng/kg body weight or in vitro in cells with the natural androgen receptor or transfected with the androgen receptor.
Therefore, in a third embodiment, a method for selecting a compound that increases bone mass in a host at least 10% without a loss in bone strength or quality is provided that includes evaluating whether the compound (i) binds to the estrogen or androgen receptor (or the equivalent receptor in the host animal) with an association constant of at least 108 M-', and preferably, at least 10 '° M-': (ii) (a) induces estrogenic o r androgenic gene transcriptional activity at a level that is no greater than 10% that of testosterone or 17(3-estradiol, and preferably no greater than 5, 1 or even 0.1% that of 17~i-estradiol or testosterone, as appropriate, when administered in vivo at a dosage of at least 0.1 ng/kg body weight or at a concentration of 10-11 to 10-' M or in vitro in cells with the natural androgen or estrogen receptor or transfected with the androgen or estrogen receptor or (b) induces an increase in uterine or muscle weight, a s appropriate, of no more than 10% that which is induced by 17 (3-estradiol or testosterone (or the equivalent compound in a host animal); (iii) induces the phosphorylation of extracellular signal regulated kinase (ERK) when administered in vivo at a dosage of at least 0.1 ng/kg body weight or at a concentration of 10-" to 10-' M in vitro in cells with the natural androgen or estrogen receptor or transfected with the androgen or estrogen receptor; and (iv) has an anti-apoptotic effect on osteoblasts at an in vivo dosage of at least 0.1 ng/kg body weight or in vitro in cells with the natural androgen or estrogen receptor or transfected with the androgen or estrogen receptor.
Compounds selected according to the criteria provided herein can also be used as for the augmentation of bone mass and/or fracture prevention in diseases characterized by low bone mass and increased fragility. The compounds can be used to treat bone disease states in which osteoblastogenesis is decreased, such as senile osteoporosis, and glucocorticoid-induced osteoporosis--especially in growing children and adolescents, in whom interfering with bone remodeling is detrimental.
I. Definitions An estrogen compound, as used herein, refers to a four ring steroidal compound which possesses the biological activity of an estrus-producing hormone, or its conjugated and esterified derivative, or a derivative thereof of same chemical composition and structure but which does not possess the biological activity of the active form because it exhibits a different stereochemistry from the active form. Nonlimiting examples of estrogens include broparestrol, chlorotrianisene, dienoestrol, epimestrol, equilin, estrapronicate, estropipate, ethinylestradiol, fosfestrol, hydroxyesetrone, mestranol, estradiol, estriol, conjugated and esterified estrogens, estrone, polyestradiol, promestriene, .
quinestradol, quinestrol, stilbestrol, and zeranol.
An androgen compound, as used herein, refers to a four ring steroidal compound which can be produced in the testis or adrenal cortex, or is a synthetic hormone, which acts to regulate masculine secondary sexual characteristics, or a derivative thereof of same chemical composition and structure but which does not possess the biological activity of the active form because i t exhibits a different stereochemistry from the active form.
Nonlimiting examples include boldenone, clostebol, danazol, drosstanolone, epitiostanol, ethylestrenol, fluoxymesterone, formebolone, furazabol, mepitiostane, mesterolone, methandienone, methenolone, methyltestosterone, nandrolone, norethandrolone, oxabolone, oxymetholone, prasterone, quinbolone, staolone, stanozolol, testosterone, and trenbolone.
As known, estrogens and androgens have chiral carbons, and thus can exist in a number of stereochemical configurations. Typically, for example, the 17~i hydroxy estrogens have biological activity while the 17a hydroxy estrogens have very little effect on sexual characteristics (and induce little hormone-like gene transcriptional activation). For the purpose of this specification, any stereochemical configuration, including either the biologically active or the biologically inactive or less active structure, can be used, as long as the compound satisfies the specifically itemized criteria of the invention.
The catalogue entitled "Steroids" from Steraloids Inc., Wilton, N.H., provides a list of over 3000 steroids, with numerous estrogen and androgen derivatives. The catalog can be obtained by contacting the company and is also currently available on the Internet at http://www.steraloids.com. One can select and purchase compounds from this library, which are all commercially available and thus easy to obtain and evaluate, for use in this invention. One can also use known estrogen and androgen receptor binding compounds.
The term "bone mass" refers to the mass of bone mineral and is typically determined by Dual-Energy X-Ray Absorbtiometry (DEXA).
The term "bone strength" refers to resistance to mechanical forces and can be measured by any known method, including vertebrae compression strength or three point -bending of long bones.
The term "bone quality" refers to normal collagen orientation without excessive accumulation of unmineralized bone matrix, and can be measured by any known method, including undecalcified bone histomorphometry.
The term "bone anti-resorption agent" refers to a compound that blocks bone resorption by suppressing remodeling or the activity and/or lifespan of osteoclasts.
The term "osteopenia" refers to decreased bone m a s s below a threshold which compromises structural integrity.
As used herein, the terms "metabolic bone disease", "orthopedic bone disease" or "dental disease" are defined a s conditions characterized by decreased bone mass and/or structural deterioration of the skeleton and/or teeth.
As used herein, the term "apoptosis" refers to programmed cell death characterized by nuclear fragmentation and cell shrinkage as detected by morphological criteria and Terminal Uridine Deoxynucleotidal Transferase Nick End Labeling (TUNEL) staining.
The term "host", as used herein, refers to any bone-containing animal, including, but not limited to humans, other mammals, canines, equines, felines, bovines (including chickens, turkeys, and other meat producing birds), cows, and bulls.
II. Compounds Useful in the Invention A. Estrogen compounds that bind to the estrogen a or (3 receptor with an association constant of at 1 a a s t 10 8 M~1, and preferably, at least 101 ° M '', but w h i c h exhibit little transcriptional activation According to the present invention, one can easily select estrogen compounds that significantly increase bone mass by evaluating them according to the disclosed criteria.
1 . Binding to the estrogen a or ~i receptor A compound should be selected that binds to th a estrogen a or 13 receptor (or the equivalent receptor in the host animal) with an association constant of at least 10g M-', and preferably, at least 10'° M-' . This constant can be measured b y any known technique, including receptor binding assays whereby ligand binding affinities are determined by competitive radiometric binding assays using 10 nM [3H] estradiol as tracer, purified estrogen receptor preparations, or cell cytosol preparations, or intact cells, during one hour incubation at room temperature or overnight at 4°. Bound receptor-ligand complex is absorbed using hydroxylapatite.
The estrogen a and 13 receptor subtypes have significantly different primary sequences in their ligand binding and transactivation domains. ERa and E1t13 show a 56% amino acid homology in the hormone binding domain/activation function-1 region, and only 20% homology in their A/B domain/activation function-1 region. The difference between ERa and ER13 structure suggests that some compounds might bind ERa or E1t13, but not both. All such selectively binding compounds are considered to fall within the scope of this invention.
Estrogen compounds include those described in the 11th Edition of "Steroids" from Steraloids Inc., Wilton, N. H., which bind to the estrogen receptor with an association constant of a t least 108 M-', and preferably, at least 10'° M-'.
2. Minimal effect on estrogen-induced transcriptional activation In this embodiment, an estrogen compound is selected that has a minimal effect on estrogen-induced transcriptional activation (or suppression). The basis for this requirement is that it has been discovered that apoptosis of osteoblasts is decreased by receptor binding, in the absence of transcriptional activation by estrogen-type compounds. Therefore, to provide a maximum therapeutic efficacy on bone without causing unrelated and undesired side estrogen-related effects, estrogen receptor ligands with minimal transcriptional effects should be used.
To accomplish this separation of receptor binding a n d transcriptional activity, a compound should be selected that induces estrogenic gene transcriptional activity at a level that is no greater than 10% that of 1713-estradiol, and preferably n o greater than 5, 1 or even 0.1 % that of 1713-estradiol w h a n .
administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in cells with natural estrogen receptors or transfected with estrogen receptors or which induces an increase in uterine weight of no more than 10% that of estrogen (or the equivalent compound in a host animal).
One can determine whether a selected compound induces estrogenic transcriptional activity at a level that is n o greater than 10% that of 17(3-estradiol, and preferably no greater than 5, 1 or even 0.1 % that of 17 (3-estradiol when administered i n vivo at a dosage of at least 0.1 ng/kg body weight, b y administering the selected compound to a host, and then monitoring the level of induction or suppression of a surrogate marker of estrogenic transcriptional activity. Nonlimiting examples of surrogate markers of estrogenic transcriptional activation, include, but are not limited to, the expression of the complement C-3 gene and lactoferin in the uterus.
In an alternative embodiment, the level of estrogen induced transcriptional activity can be assessed in vitro. One can determine whether a selected compound induces transcriptional activity at a level that is no greater than 10% that of 1713-estradiol, and preferably no greater than 5, 1 or even 0.1% that of 1713 estradiol in vitro using cells with natural estrogen receptors or transfected with estrogen receptors, by monitoring the level of induction or suppression of a surrogate marker. Nonlimiting examples of genes induced or repressed by estrogen include, b a t are not limited to, complement C-3, lactoferin, or interleukin-6. A
preferred marker gene for estrogenic transcriptional activity is a minimal gene containing one or more copies of the ERE driving a reporter gene such as luciferase.
Examples of cell lines that can be used include h a m a n uterine HeLa cells, human embryonic kidney cells 293, murine osteocytic MLO-Y4 cells and murine osteoblastic calvaria derived cells.
One can assess the increase in uterine weight after administration of the selected compound in vivo. Preferred compounds induce an increase in uterine weight of no more than approximately 10% that of estrogen (or the equivalent compound in a host animal). This can be easily tested according to known pro~ocols. For example, in experimental mice, uteri are removed and cleaned of adjacent ligaments and fat. Wet weight is determined on a Mettler PB303 microgram balance (Toledo) and compared to total body weight (mg/100g BW) as an index of the estrogenic status of the animals. In women, similar assessment can be performed by uterine ultrasound.
Examples of estrogen compounds that do not induce significant estrogen-like transcriptional activity include, but are not limited to estratriene-3-ol, 17a-estradiol, 17[3-estradiol conjugated with BSA.
3 . Induction of the phosphorylation o f extracellular signal regulated kinase (ERK) The selected compound should induce t h a phosphorylation of ERKs at a concentration of 10-" to 10-' M in vitro in cells with natural estrogen receptors or transfected with estrogen receptors using any known method, including but not limited to, the method set out in Figures 8 and 9 and Examples 7 -9.
The phosphorylation of ERKs is easily assessed in vitro using osteoblastic or osteocytic cells with natural estrogen receptors or cells transfected with estrogen receptors. Examples of the evaluation of the phosphorylation of ERK in MLO-Y4 cells are provided in Figures 8 and 9 and Examples 7-9. Other appropriate cell models include osteoblastic cells isolated from neonatal murine calvaria.
4 . Anti-apoptotic effect on osteoblasts at an i n v i v o dosage of at least 0.1 ng/kg body weight or a t an in vitro concentration of 10'11 to 10-' M or less.
The anti-apoptotic effect on osteoblasts in vivo can b a assessed by any known method, including by the method described in Figure 2 and Example 3. The anti-apoptotic effect i n vitro can be assessed by any known method including the methods described in Figures 3-7 and 10, and Examples 2-6 and 9.
B. Nonestrogen compounds that bind to t h a estrogen a or ~3 receptor with an association c o n s t a n t WO 00/20007 PC"T/US99/23355 of at least 10 8 M m and preferably, at least 10' ° M -1, but which exhibit little transcriptional activation 1. Nonestrogen compound which binds to t h a estrogen a or (3 receptor A nonestrogen compound, as used herein, refers to a compound other than an estrogen, as that term is defined above, which binds to the estrogen a or (3 receptor with an association constant of at least 108 M'' and preferably, at least 10'° M-'~.
There are a number of reported compounds which are not estrogens but which bind to the estrogen receptor.
Examples include the aryl-substituted pyrazole described by Sun et al., Novel Ligands that Function as Selective Estrogens or Antiestrogens for Estrogen Receptor-a or Estrogen Receptor-(3, Endocrinology, Volume 140, No. 2 (1999), one example of which is illustrated below.
In an alternative embodiment, an estrogen o r nonestrogen compound is covalently linked to a second moiety that does not significantly interfere with the binding to the estrogen receptor but which does substantially prevent the estrogen from entering the cell. In one example, the second moiety is a protein such as bovine serum albumin, polyethelene glycol or dextran or liposomes. In another embodiment, the second moiety is not a protein or peptide, but for polar, steric, o r other reasons, prevents cell penetration. Examples of these types of moieties include carboxylate, ammonium, and sulfide. A
"linking moiety" as used herein, is any divalent group that links two chemical residues, including but not limited to alkyl, alkenyl, alkynyl, aryl, polyalkyleneoxy (for example, -[(CH2)"O-]"-), -C,_6alkoxy-C,_,oalkyl-, -C,_6alkylthio-C1_,o alkyl-, -NR3-, and -(CHOH)"CH20H, wherein n is independently 0, 1, 2, 3, 4, 5, or 6, which can be attached at either end of the linking moiety to t h a structures of interest by any suitable functional groups. In a n alternative embodiment, the linking moiety can be a bifunctional linker moiety of the formula X-(CH2)n Y, wherein X and Y are functional groups capable of linking, including those independently selected from the group consisting of hydroxyl, sulfhydryl, carboxyl and amine groups, and n can be any integer between one and twenty four.
C. Androgen compounds that bind to the a n d r o g a n receptor with an association constant of a t least 10 8 M '', and preferably, at least 10'° M -~, but which exhibit little transcriptional activation According to the present invention, one can also easily select androgenic compounds that significantly increase bone m a s s by evaluating them according to the disclosed criteria.
1. Binding to the androgen receptor A compound should be selected that binds to the androgen receptor (or the equivalent receptor in the host animal) with an association constant of at least 1 Og M-1, and preferably, a t least 10'° M''. The androgen receptor binding association constant is defined as the concentration of the ligand capable of saturating SO% of the unoccupied receptors. This constant can be measured by any known technique, including receptor binding assays whereby ligand binding affinities are determined by competitive radiometric binding assays using 10 nM [3H] of the synthetic androgen RU1881 as tracer, purified androgen receptor preparations, or cell cytosol preparations,or intact cells, during one hour incubation at room temperature or overnight at 4C.
Bound receptor-ligand complex is absorbed using hydroxylapatite.
Androgen compounds include those describ ed in the 11th Edition of "Steroids" from Steraloids Inc., Wilton, N.H., which bind to the androgen receptor with an association constant of at least 108 M-', and preferably, at least 10' M-' .
2. Minimal effect on androgen-induced transcriptional activation In this embodiment, an androgen compound is selected that has a minimal effect on androgen-induced transcriptional activation. The basis for this requirement, is that it has b a a n discovered that apoptosis of osteoblasts is decreased by receptor binding in the absence of transcriptional activation by androgen-type compounds. Therefore, to provide a maximum therapeutic efficacy on bone without causing unrelated and undesired androgen-related effects, androgen receptor ligands with minimal transcriptional activity should be used.
To accomplish this separation of receptor binding a n d transcriptional activity, a compound should be selected that induces androgenic transcriptional activity at a level that is n o greater than 10% that of testosterone, and preferably no greater than 5, 1 or even 0.1% that of testosterone when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in cells with natural androgen receptors or transfected with androgen receptors or induces an' increase in prostate specific antigen (PSA) prostatic serum androgen of no more than 10% that of testosterone (or the equivalent compound in a host animal).
One can determine whether a selected compound induces androgenic gene transcriptional activity at a level that is no greater than 10% that of testosterone, and preferably no greater than 5, 1 or even 0.1 % that of testosterone w h a n administered in vivo at a dosage of at least 0.1 ng/kg body weight, by administering the selected compound to a host, and then monitoring the level of induction or suppression of a surrogate marker of androgenic transcriptional activity. Nonlimiting examples of surrogate markers of androgenic transcriptional activation, include, but are not limited to prostate specific antigen (PSA).
In an alternative embodiment, the level of androgen-induced transcriptional activity can be assessed in vitro in osteoblastic or osteocytic cells with natural androgen receptors o r traf calvaria cells, MLO-Y4 osteocytic cells and HeLa cells.
Alternatively, one can assess the increase in PSA
serum levels after administration of the selected compound.
Appropriate compounds induce an increase in PSA cells transfected with androgen receptors. Examples of such cell types include, primary cultures of PSA of no more than approximately 10% that of testosterone (or the equivalent compound in a host animal). This can be easily tested according to known protocols.
Examples of androgenic compounds that do not induce significant androgenic-like transcriptional activity include, but are not limited to, testosterone 17~i-hemisuccinate conjugated with BSA.
3 . Induction of the phosphorylation o f extracellular signal regulated kinase (ERK) The selected compound should induce the phosphorylation of ERKs when administered in vivo at a dosage of at least 0.1 ng/kg body weight or at a concentration of 10-" to 10'' M in vitro in cells with natural androgenic receptors or transfected with androgenic receptors.
The phosphorylation of ERK in a host can be assessed in biopsies, for example from bone, using immunohistostaining with specific antibodies against phosphorylated ERKs.
Alternatively, the phosphorylation of ERK is also easily assessed i n vitro using osteoblastic or osteocytic cells with natural androgen receptors or cells transfected with androgen receptors. Examples of the evaluation of the phosphorylation of ERK in MLO-Y4 cells are provided Figures 8 and 9 and Examples 7-9.
4 . Anti-apoptotic effect on osteoblasts a n d osteocytes at an in vivo dosage of at least 0.1 n g / k g body weight or at an in v i tro concentration of 10 -1 ~
to 10'' M or less.
The anti-apoptotic effect on osteoblasts and osteocytes can be assessed in vivo any known method, including the by method described in Figure and Example 1; and in vitro any 2 by known method, including method described in Figures and the 3-7 10 and Examples 2-6 and 9.
D. Nonandrogen compounds that bind to t h a androgen receptor with an association constant of a t least 10 8 M -1, and preferably, at least 101 ° M -', b a t which exhibit little transcriptional activation A nonandrogenic compound, as used herein, refers to a compound other than an androgen, as that term is defined above, which binds to the androgenic receptor with an association constant of at least 10g M-' and preferably, at least 10'° M-'..
There are a number of reported compounds which are not androgens but which bind to the androgen receptor. Examples include testosterone 17~i-hemisuccinate conjugated with BSA.
In an alternative embodiment, an androgen compound is covalently linked to a second moiety that does not significantly interfere with the binding to the androgen receptor but which does substantially prevent the androgen from entering the cell. In one example, the second moiety is a protein such as bovine s a r a m albumin. In another embodiment, . the second moiety is not a protein or peptide, but for polar, steric, or other reasons, prevents cell penetration. Examples of these types of moieties include dextran or plyethelene glycol.
E. Other compounds that can be used to increase bone mass.
Other nonlimiting examples of compounds that can b a used in the present invention to increase bone mass include those having a terminal phenyl ring and at least a second carbon ring.
In addition to these required structures, the compound may h av a a number of R groups attached to any available site on the phenyl ring or elsewhere. These R groups may be selected from inorganic or organic atoms or moieties. Representative R groups are provided, although the invention is not to be limited by th a s a examples:
(a) The R, or RZ groups may include a hydroxyl group or an inorganic R group including any of a halogen, a n amide, a sulfate, a nitrate, fluoro, chloro, or bromo groups.
Additionally, R, or R2 groups such as sodium, potassium a n d / o r ammonium salts may be attached to the alpha or beta positions to replace hydrogen on any available carbon in the structure. The Rl or R2 groups may be organic or may include a mixture of organic molecules and ions. Organic R, or R2 groups may include alkanes, alkenes or alkynes containing up to six carbons in a linear o r branched array. For example, additional R, or RZ group substituents may include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, dimethyl, isobutyl, isopentyl, tert-butyl, sec-butyl, isobutyl, methylpentyl, neopentyl, isohexyl, hexenyl, hexadiene, 1,3-hexadiene-5-yne, vinyl, allyl, isopropenyl, ethynyl, ethylidine, vinylidine, isopropylidene, methylene, sulfate, mercapto, methylthio, ethylthio, propylthio, methylsulfinyl, methylsulfonyl, thiohexanyl, thiobenzyl, thiophenol, thicyanato, sulfoethylamide, thionitrosyl, thiophosphoryl, p-toluenesulfonate, amino, imino, cyano, carbamoyl, acetamido, hydroxyamino, nitroso, nitro, cyanato, selecyanato, arccosine, pyridinium, hydrazide, semicarbazone, carboxymethylamide, oxime, hydrazone, sulfurtrimethylammonium, semicarbazone, o -carboxymethyloxime, aldehyde hemiacetate, methylether, ethylether, propylether, butylether, benzylether, methylcarbonate, carboxylate, acetate, chloroacetate, trimethylacetate, cyclopentylpropionate, propionate, phenylpropionate, carboxylic acid methylether, formate, benzoate, butyrate, caprylate, cinnamate, decylate, heptylate, enanthate, glucosiduronate, succinate, hemisuccinate, palmitate, nonanoate, stearate, tosylate, valerate, valproate, decanoate, hexahydrobenzoate, laurate, myristate, phthalate, hydroxyl, ethyleneketal, diethyleneketal, formate, chloroformate, formyl, dichloroacetate, keto, difluoroacetate, ethoxycarbonyl, trichloroformate, hydroxymethylene, epoxy, peroxy, dimethyl ketal, acetonide, cyclohexyl, benzyl, phenyl, diphenyl, benzylidene, and cyclopropyl groups. R, or R2 groups may be attached to any of the constituent rings to form a pyridine, pyrazine, pyrimidine, or v-triazine.
Additional R, or RZ group substituents may include any of the six-member or five-member rings itemized in section (b) below.
( b ) Any compound having, in addition to t h a terminal phenyl group, at least one heterocyclic carbon ring (shown as R~ in Figure 1), which may be an aromatic or non-aromatic phenolic ring with any of the substitutions described in section (a) above, and further may be, for example, one or more of the following structures: phenanthrene, naphthalene, naphthols, diphenyl, benzene, cyclohexane, 1,2-pyran, 1,4-pyran, 1,2-pyrone, 1,4-pyrone, 1,2-dioxin, 1,3-dioxin (dihydro form), pyridine, pyridazine, pyrimidine, pyrazine, piperazine, s-triazine, a s -triazine, v-triazine, 1,2,4-oxazine, 1,3,2-oxazine, 1,3,6-oxazine (pentoxazole), 1,2,6-oxazine, 1,4-oxazine, o-isoxazine, p-isoxazine, 1,2,5-oxathiazine, 1,2,6-oxathiazine, 1,4,2-oxadiazine, 1,3,5,2-oxadiazine, morpholine (tetrahydro-p-isoxazine), any of the six-ringed structures listed above being a terminal group in the compound. Additionally, any of the above carbon ring structure may be linked directly, or via a linkage group, to any further heterocyclic aromatic or non aromatic carbon ring including: furan, thiophene (thiofuran), pyrrole (azole), isopyrrole (isoazole), 3 -isopyrrole (isoazole), pyrazole (1,2 diazole), 2-isoimidazole (1,3-isodiazole), 1,2,3-triazole, 1,2,4-triazole, 1,2-dithiazole, 1,2,3-oxathiazole, isoxazole (furo(a) monozole), oxazole (furo(b) monazole), thiazole, isothiazole, 1,2,3-oxathiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,5-oxadiazole, . 1,2,3,4-oxatriazole, 1,2,3,5-oxatriazole, 1,2,3-dioxazole, 1,2,4-dioxazole, 1,3,2-dioxazole, 1,3,4-dioxazole, 1,2,5-oxathiazole, 1,3-oxathiazole, cyclopentane. These compounds, in turn, may have associated R1 or R2 groups selected from section (a) or section (b) above that are substituted on t h a carbon ring at any of the available sites.
(c) Any compound, including those listed above, that may form a cyclopentanophen(a)anthrene ring compound and which, for example, may be selected from the group consisting of 1,3,5(10),6,8-estrapentaene, 1,3,5(10),6,8,1I-estrapentaene, 1,3,5(10),6,8,15-estrapentaene, 1,3,5(10),6-estratetraene, I,3,5(10),7-estratetraene, 1,3,5(10),8-estratetraene, 1,3,5(10),16-estratetraene, 1,3,5(10),15-estratetraene, I,3,5(10)-estratriene, 1,3,5( 10),15-estratriene.
( d ) Any compound including precursors o r derivatives selected from raloxifen, tamoxifen, androgenic compounds, and their salts, where an intact phenol ring is present with a hydroxyl group present on carbons 1, 2, 3 and 4 of the terminal phenol ring.
(e) Any compound in the form of a prodrug that may be metabolized to form an active polycyclic-phenolic compound having bone protective activity.
III. Methods for Using the Active Compounds The active compounds which satisfy the criteria set out in detain herein can be used to treat a wide variety of medical conditions, including any condition in which it is helpful o r necessary to build bone mass. Because of the discovery of the fundamental basis for bone loss (inappropriate osteoblastic apoptosis), one can for the first time envision the building of healthy bone as opposed to merely treating bone loss.
The active compounds can be used as bone anabolic agents in a host, including a human, to strengthen bone for strenuous physical activities such as sports or manual labor, and to strengthen bone in persons or other hosts who do not h av a osteoporosis but might be subject to osteoporosis in the future because the host is in a risk group for that disease. Other uses for a bone anabolic agent in humans include the treatment of hosts, including persons who are born with naturally thin, small, o r unusually fragile bones, including weak teeth, persons who have a genetic predisposition to a bone catabolic disease, or an orthopedic bone disease such as joint degeneration, non-union fractures, orthopedic problems caused by diabetes, periimplantitis, poor responses to bone grafts, implants, or fracture.
These compounds can be used to increase the bone mass in horses and dogs used for labor as well as those used i n sports such as racing. The compounds can also be used to increase the bone mass in chickens and turkeys used in meat production to increase the ease of processing.
Representative metabolic bone diseases are postmenopausal osteoporosis, senile osteoporosis in males and females, glucocorticoid-induced osteoporosis, immobilization induced osteoporosis, weightlessness-induced osteoporosis (as in space flights), post-transplantation osteoporosis, migratory osteoporosis, idiopathic osteoporosis, juvenile osteoporosis, Paget's Disease, osteogenesis imperfecta, chronic hyperparathyroidism, hyperthyroidism, rheumatoid arthritis, Gorham-Stout disease, McCune-Albright syndrome and osteolytic metastases of various cancers or multiple myeloma. Characteristics of the orthopedic bone diseases are loss of bone mass, general bone fragility, joint degeneration, non-union fractures, orthopedic and dental problems caused by diabetes, periimplantitis, poor responses to bone grafts/implants/bone substitute materials, periodontal diseases, and skeletal aging and its consequences.
I V . Method for Screening for Compounds that I n c r a a s a Bone Mass The present invention provides a method of screening for compounds that possess bone anabolic effects, comprising the steps of: a) contacting a sample of osteoblast cells with a compound; and b) comparing the number of osteoblast cells undergoing apoptosis in the compound-treated cells with the number of osteoblast cells undergoing apoptosis in an untreated sample of osteoblast cells. A lower number of apoptotic cells following contact with the compound indicates that the compound possesses bone anabolic effects. Preferred compounds also inhibit apoptosis of osteocytes. Generally, the compound may b a contacted with the sample either in vitro, e.g., in cell culture or in vivo, e.g., in an animal model. Typical methods of determining apoptosis are nuclear morphologic criteria, DNA end-labeling, DNA
fragmentation analysis and immunohistochemical analysis.
In another embodiment, a method for selecting a compound that increases bone mass at least 10% in a host without a loss in bone strength or quality is provided that includes evaluating whether the compound (i) binds to the estrogen o r androgen receptor (or the equivalent receptor in the host animal) with an association constant of at least 1 Og M'', and preferably, a t least 10'° M'': (ii) (a) induces estrogenic or androgenic gene transcriptional activity at a level that is no greater than 10% that of testosterone or 173-estradiol, and preferably no greater than 5, 1 or even 0.1 % that of 17 ~i-estradiol or testosterone, a s appropriate, when administered in .vivo at a dosage of at least 0.1 ng/kg body weight or in vitro at concentrations of 10'" to 10'' M
in cells with the natural androgen or estrogen receptor o r transfected with the androgen or estrogen receptor or (b} induces an increase in uterine or muscle weight or increase virilization i n females, as appropriate, of no more than 10% that which is induced by 17(3-estradiol or testosterone (or the equivalent compound in a host animal); (iii) induces the phosphorylation of extracellular signal regulated kinase (ERK) when administered i n vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in cells with the natural androgen or estrogen receptor or transfected with the androgen or estrogen receptor; and (iv) has an anti-apoptotic effect on osteoblasts at an in vivo dosage of at least 0.1 ng/kg body weight or in vitro in cells with the natural androgen or estrogen receptor or transfected with the androgen or estrogen receptor.
In another embodiment, a method for screening for compounds that bind to the estrogen or androgen receptor and activate the anti-apoptotic signalling pathway, without resultant transcriptional activation, is provided. This method is based on the fundamental discovery that the ligand-induced conformational changes of the estrogen receptor protein required for prevention of apoptosis, are distinct from the conformational changes required for transcriptional activity (Figures 19-21 ). This discovery allows for selecting compounds, from a large library of small molecules, which have anti-apoptotic, but not transcriptional, activity. Selection is accomplished using small peptides that can specifically block the transcriptional activity of ligand activated receptor, but do not interfere with the ability of the receptor to initiate the anti-apoptotic signalling cascade.
To accomplish this, cells are transfected with the estrogen or androgen receptor with or without a peptide that recognizes the conformation of the protein required for transcriptional activation, but not anti-apoptosis. Using this method, compounds that induce conformational changes resulting in both transcriptional and anti-apoptosis compatible conformations can be distinguished from compounds that only induce the latter conformational changes.
Nonlimiting examples of this method of screening include peptide binding assays for ERa or ER(3 whereby th a purified receptor protein is immobilized on streptavidin-coated plates using biotinylated vitellogenin ERE according to previously described methods of affinity selection (Sparks AB, Adey NB, Cwirla S, Kay BK. Screening phage-displayed peptide libraries. I n Phage Display of Peptides and Proteins, A Laboratory Manual, eds.
Kay BK, Winter J and McCafferty J. (Academic, San Diego), pp.227-253, 1996). Following incubation with various ligands, the peptide is added and after 30 min bound peptide is detected using a n anti-M 13 antibody coupled to horseradish peroxidase. Compounds that bind to the receptor and induce conformational changes recognized by the peptide (i.e. the peptide binds to the receptor) will be discarded. The remaining compounds are then screened for anti-apoptotic potency.
V . Combination Therapy In one aspect of the invention, one of the active compounds described herein can be administered to a host to increase bone mass in combination with a second pharmaceutical agent. The second pharmaceutical agent can be a bone anti resorption agent, a second bone mass anabolizing agent, a n antioxidant, a dietary supplement, or any other agent that increases the beneficial effect of the active compound on bone structure, strength, density, or mass.
Any member of the ten classes of drugs described i n the Background of the Invention that are used in the treatment of osteoporosis can be administered in combination with the primary active agent, including: an anabolic steroid, a bisphosphonate, a calcitonin, an estrogen or progesterone, an anti-estrogens such a s raloxifene or tamoxifene, parathyroid hormone ("PTH"), fluoride, Vitamin D or a derivative thereof, or a calcium preparations.
Nonlimiting examples of suitable agents for combination include, but are not limited to, alendronic acid, disodium clondronate, disodium etidronate, disodium medronate, disodium oxidronate, disodium pamidronate, neridronic acid, risedronic acid, teriparatide acetate, tiludronic acid, ipriflavone, potassium bicarbonate, progestogen, a thiazide, gallium nitrate, NSAIDS, plicamycin, aluminum hydroxide, calcium acetate, calcium .
carbonate, calcium, magnesium carbonate, and sucralfate.
Reducing agents, such as glutathione or other antioxidants may also be useful in combination with any of the compounds of the present invention. As used herein, the term antioxidant refers to a substance that prevents the oxidation of a n oxidizable compound under physiological conditions. In one embodiment, a compound is considered an antioxidant for purposes of this disclosure if it reduces endogenous oxygen radicals in vitro. The antioxidant can be added to a cell extract under oxygenated conditions and the effect on an oxidizable compound evaluated. As nonlimiting examples, antioxidants scavenge oxygen, superoxide anions, hydrogen peroxide, superoxide radicals, lipooxide radicals, hydroxyl radicals, or bind to reactive metals to prevent oxidation damage to lipids, proteins, nucleic acids, etc. The term antioxidant includes, but is not limited to, the following classes of compounds:
A) Dithiocarbamates: Dithiocarbamates have been extensively described in patents and in scientific literature.
Dithiocarbamates and related compounds have been reviewed extensively for example, by G. D. Thorn et al., entitled "The Dithiocarbamates and Related Compounds," Elsevier, New York, 1962. Dithiocarboxylates are compounds of the structure, A -SC(S)-B, which are members of the general class of compounds known as thiol antioxidants, and are alternatively referred to a s carbodithiols or carbodithiolates. ~ It appears that the -SC(S)-moiety is essential for therapeutic activity, and that A and B c an be any group that does not adversely affect the efficacy or toxicity of the compound. A and B can be selected by one of ordinary skill in the art to impart desired characteristics to the compound, including size, charge, toxicity, and degree of stability, (including stability in an acidic environment such as the stomach, or basic environment such as the intestinal tract). The selection of A and B
will also have an important effect on the tissue-distribution and pharmacokinetics of the compound. The compounds are preferably eliminated by renal excretion.
B) N-Acetyl Cysteine and its Derivatives Cysteine is an amino acid with one chiral carbon atom.
It exists as an L-enantiomer, a D-enantiomer, or a racemic mixture of the L- and D-enantiomers. The L-enantiomer is the naturally occurring configuration.
N-acetylcysteine (acetamido-mercaptopropionic acid, NAC) is the N-acetylated derivative of cysteine. It also exists as a n L-enantiomer, a D-enantiomer, an enantiomerically enriched composition of one of the enantiomers, or a racemic mixture of th a L and D enantiomers. The term "enantiomerically enriched composition or compound" refers to a composition or compound that includes at least 95%, and preferably, at least 97% by weight of a single enantiomer of the compound. Any of these forms of NAC can be delivered as an antioxidant in the present invention.
In one embodiment, a single isomer of a thioester or thioether of NAC or its salt, and most preferably, the naturally occurring L-enantiomer, is used in the treatment process.
N-acetylcysteine exhibits antioxidant activity (Smilkstein, Knapp, Kulig and Rumack, N. Engl. J. Med. 1988, Vol.
319, pp. 1557-62; Knight, K.R., MacPhadyen, K., Lepore, D.A., Kuwata, N., Eadie, P.A., O'Brien, B. Clinical Sci., 1991, Vol. 81, pp.
31-36; Ellis, E.F., Dodson, L.Y., Police, R.J., J. Neurosurg., 1991, Vol.
75, pp. 774-779). The sulfhydryl functional group is a well characterized, highly reactive free radical scavenger. N-acetylcysteine is known to promote the formation of glutathione (a tri-peptide, also known as g-glutamylcysteinylglycine), which is important in maintaining cellular constituents in the reduced state (Berggren, M., Dawson, J., Moldeus, P. FEBS Lett., 1984, Vol. 176, pp. 189-192). The formation of glutathione may enhance the activity of glutathione peroxidase, an enzyme which inactivates hydrogen peroxide, a known precursor to hydroxyl radicals (Lalitha, T., Kerem, D., Yanni, S., Pharmacology and Toxicology, 1990, Vo1.66, pp. 56-61) N-acetylcysteine exhibits low toxicity in vivo, and is significantly less toxic than deprenyl (for example, the LDso in rats has been measured at 1140 and 81 mg/kg intravenously, for N-acetylcysteine and deprenyl, respectively)..
N-acetyl cysteine and derivatives thereof are described, for example, in WO/95/26719. Any of the derivatives described in this publication can be used in accordance with this invention.
C) Scavengers ding but not limited to of Peroxides, inclu catalase and pyruvate.
D) T hiols includingdithiothreitoland 2-mercaptoethanol.
E) Antioxidants which are inhibitors of lipid peroxidation,including not limited to TroloxTM, BI3A, BI3'f, but aminosteroid antioxidants,tocopherol and its analogs, and lazaroids.
F) Dietary antioxidants, including antioxidant vitamins (vitamin C or E or synthetic or natural prodrugs or analogs thereof), either alone or in combination with each other, flavanoids, phenolic compounds, caratenoids, and alpha lipoic acid.
G) Inhibitors of lipoxygenases and cyclooxygenases, including but not limited to nonsteriodal antiinflammatory drugs, COX-2 inhibitors, aspirin-based compounds, and quercetin.
H) Antioxidants manufactured by the body, including b a t not limited to ubiquinols and thiol antioxidants, such as, and including glutathione, Se, and lipoic acid.
I ) Synthetic Phenolic Antioxidants: inducers of Phase I
and II drug-metabolizing enzymes.
V I . Pharmaceutical Compositions An active compound or its pharmaceutically acceptable salt, selected according to the criteria described in detail herein, can be administered in an effective amount to treat any of the conditions described herein, optionally in a pharmaceutically acceptable carrier or diluent.
The active materials can be administered by any appropriate route for systemic, local or topical delivery, for example, orally, parenterally, intravenously, intradermally, subcutaneously, buccal, intranasal, inhalation, vaginal, rectal or topically, in liquid or solid form. Methods of administering the compound of the invention may be by specific dose or b y controlled release vehicles.
A preferred mode of administration of the active compound is oral. Oral compositions will generally include a n inert diluent or an edible carrier. The active compound can b a enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the compound can b a incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent . such as sucrose or saccharin;
and/or a flavoring agent such as peppermint, methyl salicylate, o r orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.
The compound can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A
syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
The compound or a pharmaceutically acceptable derivative or salts thereof can also be mixed with other active .
materials that do not impair the desired action, or with materials that supplement the desired action, such as classical estrogen like 17 (3-estradiol or ethinyl estradiol; bisphosphonates like alendronate, etidronate, pamidronate, risedronate, tiludronate, zoledronate, cimadronate, clodronate, ibandronate, olpadronate, neridronate, EB-1053; calcitonin of salmon, eel or human origin;
and anti-oxidants like glutathione, ascorbic acid or sodium bisulfite. Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic, solvents; antibacterial agents such as benzyl alcohol or methyl parabens; chelating agents such as ethylenediaminetetraacetic acid (EI)TA); buffers such a s acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. If administered intravenously, preferred carriers are physiological saline o r phosphate buffered saline (PBS).
WO 00/20007 . PCT/US99/23355 In a preferred embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for ..
preparation of such formulations will be apparent to those skilled in the art.
Liposomal suspensions (including liposomes targeted with monoclonal antibodies to surface antigens of specific cells) are also pharmaceutically acceptable carriers. These may b a prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811 (which is incorporated herein by reference in its entirety}. For example, liposome formulations may be prepared by dissolving appropriate lipids) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and/or cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives) is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
The dose and dosage regimen will depend upon the nature of the metabolic bone disease, the characteristics of the particular active compound, e.g., its therapeutic index, the patient, the patient's history and other factors. The amount of an activator of non-genomic estrogen-like signaling compound administered will typically be in the range of about 1 pg/kg to about 10 m g / k g of patient weight. The schedule will be continued to optimize effectiveness while balanced against negative effects of treatment.
See Remington's Pharmaceutical Science, 17th Ed. (1990) Mark Publishing Co., Easton, Penn.; and Goodman and Gilman's: The Pharmacological Basis of Therapeutics 8th Ed (1990) Pergamon Press.
For parenteral administration, the active compound will most typically be formulated in a unit dosage injectable form (solution, suspension, emulsion) in association with a pharmaceutically acceptable parenteral vehicle. Such vehicles are preferably non-toxic and non-therapeutic. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils and ethyl oleate may also be used. Liposomes may be used a s carriers. The vehicle may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives. An activator of non-genomic estrogen-like signaling compound will typically be formulated in such vehicles at concentrations of about 10 pg/ml to about 10 mg/ml.
The concentration of the compound in the drug composition will depend on absorption, inactivation, and excretion rates of the drug as well as other factors known to those of skill i n the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. Additionally, the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time. It is to be further understood that for any particular patient, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope o r practice of the claimed composition.
V I I . Illustrative Examples The following examples are illustrations of the embodiments of the invention as described above, but are not intended to limit its scope.
As one example, 17~-estradiol, the synthetic steroid estratriene-3-ol, which is a potent neuroprotective compound, and 17a-estradiol, have potent anti-apoptotic effects on osteoblastic cells in vitro.
U.S. Patent No. 5,843,934 to Simpkins discloses that a n estrogen having insubstantial sex-relaxed activity, and i n particular, a-estrogens such as 17a-estradiol, can be administered to a patient to retard the adverse effects of osteoporosis in a male or female. The '934 patent does not address how to select a compound to increase bone mass opposed to treat osteoporosis.
Increasing bone mass is a different indication from the treatment of bone loss, as dramatically illustrated by the fact that the U.S.
Food and Drug Administration has approved a number of drugs for the treatment of osteoporosis, but has not approved any drugs to date as bone anabolic agents.
17~i-Estradiol is used in these illustrative examples even though it is a potent activator of estrogen-like gene transcription, because it tightly binds to the estrogen receptor and inhibits osteoblastic apoptosis. The compound must be modified to fall within the selection criteria for the present invention b y altering it in such a way that it cannot enter the cell to induce gene transcription. Such modifications can occur, for example, b y covalently attaching, either directly or through a linking moiety, a second moiety that prevents or limits cell penetration. Any other estrogen or androgen that binds appropriately to the relevant receptor can be likewise modified for use to increase bone mass.
It is noteworthy that (a) the anti-apoptotic effect of 17~i-estradiol on both osteoblasts and osteocytes are reproduced with a membrane impermeable 17~i-estradiol - BSA conjugate; (b) the anti-apoptotic effects of these compounds are diminished b y ICI 182780, a pure estrogen receptor antagonist; and (c) that the anti-apoptotic effects of all these compounds cannot be shown i n HeLa cells unless these cells are stably transfected with either the estrogen receptor a or the estrogen receptor ~3.
The following examples are given for the purpose of illustrating various embodiments of the invention and are n o t meant to limit the present invention in any fashion.
The increased rate of bone remodeling that follows loss of estrogen should cause a transient acceleration of mineral loss because bone resorption is faster than bone formation and the bone made by new BMUs are less dense than older ones.
However, increased remodeling alone cannot explain th a progressive bone loss that lasts long after the rate of bone remodeling has slowed. Indeed, in addition to changes in the number of osteoblast and osteoclast cells during/following estrogen deficiency, a qualitative abnormality also occurs;
osteoclasts erode deeper than normal cavities. This frequently leads to penetration through a trabecular structure causing removal of some cancellous elements entirely; the remainder are more widely separated and less well connected. The deeper erosion is explained by loss of estrogen's effect to promote apoptosis of osteoclasts (Hughes et al, Nature Med. 1996; 2:1132-1136; Kameda et al, J Exp Med. 1997; 186:489-495; Raisz, Nature Med. 1996; 2:1077-1078). 17 (3-estradiol increased the apoptosis of osteoclasts from approximately 0.5% to as much as 2.7%. This change could prolong the lifespan of osteoclasts and increase their numbers two- to three-fold, thus accounting for the perforation of trabeculae and grinding away of endocortical margins.
To determine whether the role of estrogen deficiency affects osteoblast and osteocyte apoptosis, the prevalence of these cells in murine vertebrae removed 28 days after ovariectomy was determined. In these experiments, four month old Swiss Webster mice were ovariectomized and 28 days later, the animals were sacrificed an d the vertebrae were isolated, and embedded fixed undecalcified in methacrylate. As shown in Figure 2, the prevalence of determined b y osteoblast and osteocyte apoptosis, TUNEL with CuS04 enhancement, increased ten-and four-fold, respectively.These results indicate that the accelerated loss of bone that occurs not only to a n after estrogen deficiency is due increase in osteoclast number and lifespan, but also to a .
premature reduction in the lifespan (work hours) of the osteoblasts. The increase in osteocyte apoptosis could further weaken the skeleton by impairment of the osteocyte-canalicular mechanosensory network.
Consistent with the in vivo data described under Example 1, 17 ~i-estradiol prevented apoptosis of osteoblastic cells isolated from murine calvaria, in a dose dependent manner.
Strikingly, inhibition of osteoblast apoptosis could also be shown by 17 (3-estradiol conjugated with bovine serum albumin, a membrane impermeable compound. The same effect could also b a shown with 17 a-estradiol, a compound heretofore thought to b a inactive. Moreover, inhibition of etoposide-induced osteoblastic cell apoptosis was demonstrated by estratriene-3-ol, an estrogenic compound thought to lack feminizing properties (Figure 3). In this experiment, osteoblastic cells were derived from murine calvaria and were pretreated with the sterols for 1 hour before the addition of the pro-apoptotic agent, etoposide.
In agreement with the in vivo results indicating that estrogen loss increases both osteoblast and osteocyte apoptosis, 17 (3-estradiol, 17 ~i-estradiol conjugated with BSA, 17a-estradiol, and estratriene-3-of dose-dependently inhibited also the apoptosis of an established osteocytic cell line (Figure 4). In this experiment, MLO-Y4 cells were pretreated with the indicated concentrations of the various compounds for 1 h before th a addition of the pro-apoptotic agent, etoposide. Apoptosis was determined after 6 h by trypan blue uptake as described in Figure 3.
As shown in Figure 5, the anti-apoptotic effect of 10-8 M 17~i-estradiol, 17[3-estradiol-BSA, 17a-estradiol, or estratriene-3-0l (E-3-ol) on osteoblastic cells was abrogated when the cells were pretreated for 1 h with the pure receptor antagonist ICI182,780 ( 10-' M) before the addition of the estrogenic compounds.
As in the case of the antiapoptotic effect of 17~3-estradiol, 17~i-estradiol-BSA, 17a-estradiol, or estratriene-3-of (E-3-0l) on osteoblastic cells, their antiapoptotic effect on osteocytes was abrogated when the cells were pretreated for 1 h with the WO OOI20007 ~ PCT/US99/23355 pure receptor antagonist ICI182,780 ( 10-' M). Collectively, th a results of examples 4 and 5 strongly suggest that the anti-apoptotic effects of these compounds on osteoblasts and osteocytes are mediated via the estrogen receptor (ER).
S
Definitive demonstration of the requirement of the estrogen receptor for the anti-apoptotic effects of 17~i-estradiol and the related compounds tested herein was provided by the results of the experiment shown in Figure 7. In this experiment, instead of calvaria cells, human HeLa cells which contain undetectable, if any, estrogen receptor were used. HeLa cells were stably transfected with either a CMV promoter-driven cDNA for the murine estrogen receptor-alpha (mERa) or a CMV promoter-driven cDNA for the murine estrogen receptor-beta (mER~i).
Subconfluent cultures of stable transfectants were treated for 1 h with 17[3-estradiol, or 17a-estradiol, estratriene-3-of (10-8 M), followed by a 6 hour incubation with etoposide (5x10-5 M). Cells were trypsinized, pelleted and trypan blue positive cells were enumerated. As shown in Figure 7, none of the three compounds had any effect on the apoptosis of the wild type HeLa cells, b a t they potently inhibited etoposide-induced apoptosis in HeLa cells transfected with the estrogen receptor a or estrogen receptor Vii.
The mechanism of the anti-apoptotic effect of the estrogenic compounds described herein was established b y demonstrating that 17a-estradiol, 17~i-estradiol, 17~i-estradiol-BSA or estratriene-3-ol, at 10-8 M concentrations, activated extracellular signal regulated kinases (ERKs). In this experiment, MLO-Y4 osteocytic cells were incubated for 25 minutes in serum-free medium. Subsequently, 17 a-estradial, 17 (3-estradiol, 17 ~3-estradiol-BSA or estratriene-3-of ( 10-8 M) were added and cells incubated for an additional 5, 15, or 30 minutes. CeII lysates were prepared and proteins were separated by electrophoresis in polyacrylamide gels and transferred to PVDF membranes.
Western blotting was performed using a specific antibody recognizing phosphorylated extracellular signal regulated kinases 1 and 2, followed by reblotting with an antibody recognizing total extracellular signal regulated kinases. Blots were developed b y enhanced chemiluminescence. As shown in Figure 8, all these compounds specifically increased the phosphorylated fraction of ERKl/2 without affecting the total amount of ERK1/2. This effect is too rapid to be accounted for by the classical mechanism of estrogen action. Instead, it is consistent with a non-genomic action mediated via membrane-associated estrogen receptors, as suggested by the experiments presented in Examples 4, 5 and 6.
The ability of 17 a-estradiol, 17 ~3-estradiol, 17 [3-estradiol-BSA or estratriene-3-of to activate ERKs was abrogated in the presence of the specific inhibitor of ERK kinase, PD98059.
WO 00/2000? PCT/US99/23355 In this experiment, MLO-Y4 osteocytic cells were incubated for 2 S
minutes in serum-free medium in the presence or absence of 5 0 p.M PD98059. Subsequently, 17 a-estradiol, 17 ~i-estradiol, 17 ~3 estradiol-BSA or estratriene-3-of ( 10-8 M) were added and cells incubated for another 5 minutes. Cell lysates were prepared and proteins were separated by electrophoresis in polyacrylamide gels and transferred to PVDF membranes. Western blotting was performed using a specific antibody recognizing phosphorylated extracellular signal regulated kinases 1 and 2, followed b y reblotting with an antibody recognizing total extracellular signal regulated kinases. Blots were developed by enhanced chemiluminescence.
That indeed the anti-apoptotic effect of all the compounds tested herein was mediated via activation of ERKs w a s established by the results of the experiments shown in Figure 10.
In this experiment, MLO-Y4 osteocytic cells were pretreated for 1 hour with the specific inhibitor of ERKs activation, PD98059, before the addition of 108 M 17 a-estradiol, 17 ~i-estradiol, or 17 (3-estradiol-BSA. Apoptosis was induced by incubation with the pro-apoptotic agent dexamethasone for 6 hours and quantified a s described in Figure 3. PD98059 prevented the anti-apoptotic effect of all three compounds tested in this experiment.
In conclusion, the results of the examples provided above demonstrate that loss of estrogen irc vivo leads to several-fold increase in the prevalence of apoptosis of osteoblasts and osteocytes. Consistent with the in vivo findings, 17a-estradiol, as well as 17(3-estradiol, 17(3-estradiol-BSA and estratriene-3-of inhibit the apoptosis of osteoblastic cells derived from murine calvaria or osteocytes, represented herein by the cell line MLO-Y4.
The anti-apoptotic effect of all these compounds requires the presence of either estrogen receptor a or estrogen receptor ~i and is mediated via the ability of these compounds to activate specific MAP kinases, namely the extracellular signal regulated kinases (ERKs).
Similar to the results with estrogenic compounds, androgenic compounds also inhibited apoptosis of osteoblastic cells derived from murine calvaria induced by etoposide (Table 3). I n these experiments, cells were pretreated with the indicated concentrations of the various compounds for 1 hour, in the absence or presence of the androgen receptor antagonist flutamide, before the addition of the proapoptotic agent etoposide.
Apoptosis was determined after 6 hours by trypan blue uptake a s described in Figure 3. Notably, as in the case of estrogenic compounds, all these effects were apparently mediated by the androgen receptor, as evidenced by the inhibition of the anti-apoptotic effects of the androgenic compounds by a specific androgen receptor antagonist. Moreover, and as in the case of estrogens, the androgen receptor-mediated protection of etoposide-induced apoptosis was seen with a membrane impermeable androgen (testosterone-17(3-hemisuccinate conjugated with BSA), strongly suggesting the existence of a membrane-associated androgen receptor, analogous to the membrane-associated estrogen receptor.
able 3 Inhibition of etoposide-induced osteoblast apoptosis by androgens and progestins ompound Lowest Suppression by 10'g M
Effective Flutamide Concentration Testosterone 10'9 M yes Testosterone 17(3- 10-g M y a s Hemisuccinate: BSA
5-a- 10-9 M y a s dihydrotestosterone 5-(3- 10-' M yes dihydrotestosterone Dehydroisoandroste 10-g M no*
rone-3-sulfate (DHES) 4-androstene-3,17- 10-8 M yes dione 5-androstene-3(3- 10-a M yes 17 -diol RU1881 10-8 M yes * Flutamide did block the anti-apoptotic effect of l~ti~ at higher ( 10-' M) concentration.
That the anti-apoptotic effects of estrogenic compounds is dissociated from their transcriptional activity w a s established by demonstrating that even though estratriene-3-of was as potent as 17 ~i estradiol in inhibiting apoptosis, unlike 17 [3 estradiol, it did not transactivate an estrogen response element through the estrogen receptor a. In this experiment, hERa was overexpressed in 293 cells (which lack constitutive ERa) along with a reporter construct containing 3 copies of an estrogen response element driving the luciferase gene. Light units were counted and normalized to coexpressed ~i-galactosidase activity to control for differences in transfection efficiency.
Herein, a general experimental protocol for studies aiming to evaluate compounds with anti-apoptotic efficacy, b a t decreased transcriptional activity (e.g., estratriene-3-ol) on osteoblasts and osteocytes in animal models is provided.
According to this design, estrogen-replete or estrogen-deficient mice, rats, dogs, primates, etc., or animals representing models of involutional osteoporosis and/or defective osteoblastogenesis (e.g., the senescence accelerated mouse, SAMP6: (Jilka et al., J Clin Invest 97:1732-1740, 1996)), or animal models of glucocorticoid excess (e.g., Weinstein et al. J Clin Invest, 102:274-282, 1998) are administered estratriene-3-of or other test compound to determine whether they can suppress osteoblast and osteocyte apoptosis and whether changes in apoptosis would be associated with changes in BMD, bone formation rate, or cancellous bone volume.
In a representative experiment of this sort, six 4 - 5 month old female mice per group are screened twice for BMD in a four week period immediately prior to the initiation of the experiment to establish that peak adult bone mass has been attained. A subset of mice are then ovariectomized. Intact a n d ovariectomized mice are treated with vehicle, or 20, 200 or 2 0 0 0 ng/g body weight estratriene-3-of or another test compound.
Ovariectomized mice are also treated with 20 ng/g body weight 17 ~i-estradiol for comparison purposes.
Stock solutions of the test agents (10,000 p,g/ml) are maintained in approximately 2.0 ml of 95% ethanol. These stocks are diluted in 95% ethanol to make 1000 ~,g/ml and 100 ~.g/ml concentrations. The concentration of the stocks is checked spectrophotometrically. For each animal injection, the test agent is diluted in sesame oil and sonicated. Test agents are administered for 28 days by subcutaneous injections on alternative days. The mice are weighed weekly and serum samples are collected a t appropriate times for analysis of bone biochemical markers, such as osteocalcin or collagen cross-links. Tetracycline labeling is performed by administration of the antibiotic (30 mg/kg) at 2 and 8 days prior to the end of each experiment. Table 1 shows a representative example of 25 g mice divided into 5 groups with each animal receiving 100 ~,l of the test agent per injection.
Treatment Injection (steroid + sesame oil) vehicle 100 pl 95% ethanol + 1900 p.l 20 ng/g estratriene-3-of 100 p.l 100 ~g/ml stock + 1900 p,l 200 ng/g estratriene-3-of 100 p.l 1000 ~g/ml stock + 1900 p.l 2000 ng/g estratriene-3-of 100 p,l 10,000 p.g/ml stock + 1900 p.l 20 ng/g 173-estradiol 50 p.l 100 p,g/ml stock + 950 p.l During the 28 day experiment, BMD is determined i n live animals at day 0, 14 and 28. Following animal sacrifice at the end of the experiment, the vertebral bones Ll-L4 are collected for fixation and embedded undecalcified in methylmethacrylate plastic for the determination of the prevalence of osteoblast and osteocyte apoptosis and other static and dynamic histomorphometric measurements. L5 vertebrae are isolated for determining anti-fracture efficacy of the compounds by assaying compression, 3 point bending and other appropriate biomechanical tests. Results confirming the expected efficacy of th a s a compounds show decreased prevalence of osteoblast and/or osteocyte apoptosis, and/or positive BMD changes, and/or increased cancellous bone area, and/or increased rate of bone formation, and/or increased biomechanical strength.
As an example, the results of an experiment w h a r a b y 2000 ng/g body weight of estratriene-3-of was administered for 28 days to estrogen-replete (intact) or estrogen-deficient (ovariectomized) mice are shown in Table 2.
T B~ LE 2 Increased BMD by estratriene-3-of administration intact-vehicle:
global global hindquart 1 hindquartpine 2 spine Ø0552 0.0585 0.0599 0.0533 0.0581 0.0595 0.0535 0.0586 0.0575 0.0546 0.0571 0.0599 0.0516 0.0557 0.0559 0.0503 0.0560 0.0544 0.0516 0.0513 0.0569 0.0492 0.0499 0.0527 , 0.0552 0.0553 0.0589 0.0492 0.0521 0.0531 0.0475 0.0494 0.0525 0.0480 0.0450 0.0539 0.0535 0.0524 0.0574 0.0524 0.0592 0.0553 0.0526 0.0544 0.0570 0.0510 0.0539 0.0555 (mean) 0.0027 0.0036 0.0024 0.0025 0.0052 0.0030 (std) 0.0552 0.0586 0.0599 0.0546 0.0592 0.0599 (max) 0.0475 0.0494 0.0525 0.0480 0.0450 0.0527 (min) intact-2000 3-0l:
ng/g _ lhindquar>apine global hindquart global 1 2 spine _ 0.0509 0.0511 0.0550 0.0585 0.0602 0.0486 0.0511 0.0565 0.0560 0.0543 0.0603 0.0604 0.0543 0.0605 0.0593 0.0541 0.0619 0.0601 0.0537 0.0577 0.0584 0.0568 0.0629 0.0613 0.0533 0.0546 0.0571 0.0568 0.0640 0.0620 0.0521 0.0544 0.0555 0.0537 0.0554 0.0588 0.0560 0.0587 0.0623 0.0574 0.0605 0.0632 0.0527 0.0562 0.0571 0.0554 0.0605 0.0609 (mean) 0.0024 0.0032 0.0035 0.0015 0.0029 0.0014 (std) 0.0560 0.0605 0.0623 0.0574 0.0640 0.0632 (max) 0.0486 0.0509 0.0511 0.0537 0.0554 0.0588 (min) __vehicle vs 2000 ng/g:
t-test 0.0036 0.0077 0.0037 Ovx-vehicle:
global lhindquarkpine global hindquart spine 2 _ 0.0539 0.0550 0.0493 0.0507 0.0548 0.0525 0.0479 0.0484 0.0538 0.0497 0.0569 0.0545 0.0510 0.0543 0.0565 0.0483 0.0509 0.0545 0.0538 0.0548 0.0583 0.0483 0.0515 0.0536 0.0567 0.0632 0.0620 0.0538 0.0584 0.0588 0.0533 0.0533 0.0572 0.0504 0.0507 0.0559 0.0543 0.0592 0.0583 0.0491 0.0526 0.0545 0.0490 0.0518 0.0551 0.0475 0.0487 0.0534 0.0523 0.0550 0.0570 0.0496 0.0528 0.0550 (mean) 0.0029 0.0049 0.0026 0.0019 0.0035 0.0017 (std) 0.0567 0.0632 0.0620 0.0538 0.0584 0.0588 (max) Ovx-2000 ng/g 3-0l:
global global hindquart spine lhindquar>,pine 2 Z
0.0505 0.0527 0.0547 0.0565 0.0602 0.0608 0.0542 0.0588 0.0581 0.0557 0.0632 0.0585 0.0496 0.0504 0.0542 0.0548 0.0599 0.0584 0.0540 0.0596 0.0586 0.0545 0.0624 0.0598 0.0526 0.0547 0.0580 0.0564 0.0598 0.0610 0.0569 0.0604 0.0628 0.0568 0.0647 0.0625 0.0565 0.0591 0.0603 0.0550 0.0630 0.0578 0.0528 0.0582 0.0568 0.0539 0.0599 0.0605 0.0534 0.0573 0.0579 0.0555 0.0618 0.0599 (mean) 0.0026 0.0036 0.0028 0.0011 0.0020 0.0016 (std) 0.0569 0.0604 0.0628 0.0568 0.0647 0.0625 (max) 0.0496 0.0504 0.0542 0.0539 0.0598 0.0578 (min) ovx vs 2000 n /
t-test 0.0000 0.0001 0.0001 Each row represents values for individual animals.
The first three sets of numbers represent the initial BMD
measurements (by dual-energy x-ray absorptiometry with Hologic QDR2000 plus, using customized software) at day 0 and the last three BMD measurements at the end of the experiment. Global =
BMD of the entire skeleton minus the head and tail; hindquarters =
the mean BMD of both hindlimbs; spine = the BMD of cervical, thoracic and lumbar spine.
EXAl~!~ LP E 13 Herein, a general experimental protocol evaluating the anti-fracture efficacy of compounds like estratriene-3-of is provided. According to this design, estrogen-replete or estrogen-deficient mice, rats, dogs, primates, etc., or animals representing models of involutional osteoporosis and/or defective osteoblastogenesis (e.g., the senescence accelerated mouse, SAMP6:
(Jilka et al., J Clin Invest 97:1732-1740, 1996)), or animal models of glucocorticoid excess (e.g., Weinstein et al. J Clin Invest, 102:274-282, 1998) are administered estratriene-3-of to determine whether they can increase bone strength.
In a representative experiment of this sort, seven 4-5 month old female mice per group are screened twice for BMD in a four week period immediately prior to the initiation of the experiment to establish that peak adult bone mass has been attained. A subset of mice are then ovariectomized. Intact and ovariectomized mice are treated with vehicle, or 20, 200 or 2000 ng/g body weight estratriene-3-of or another ANGEL compound.
Ovariectomized mice are also treated with 20 ng/g body weight 17 ~3-estradiol for comparison purposes. Ultimate load bearing properties of the fifth lumbar murine vertebrae (L5) i s determined. This is done using a servohydraulic axial-torsional material testing machine (Model MTS 810 Bionx; MTS Systems Corp., Eden Prairie, MN) and a Lebow load cell (Eaton Products, Troy, MI). Data are recorded and analyzed using the LabVIEW
software package and an acquisition/signal conditioning board (Model NB-MIO-16, National Instruments Corporation, Austin, TX).
The L5 specimens that is used for ultimate load bearing i s cleaned of surrounding soft tissue and the length and diameter recorded with a digital caliper at a resolution of 0.01 m m (Mitutoyo Model #500-196, Ace Tools, Ft. Smith, AR). The vertebrae are wrapped in saline-soaked gauge throughout preparation and testing and stored overnight at 4°C before testing.
Vertebrae are individually compressed between parallel loading platens along the cephalocaudad axis until failure and the ultimate load (in Newtons) and displacement (in mm) are recorded.
As an example, the results of an experiment whereby 2000 ng/g body weight of estratriene-3-of was administered for 28 days to estrogen-replete (intact) or estrogen-deficient (ovariectomized) mice (from the same animals shown in Example 12) is shown in Table 4.
Ta le Changes in Compression Strength (VCS*), Vertebral Induced by In v i v on of E-3-of o Administrati Demonstration CVS than BMD
of Greater Increase in {n - 7 per group}
Vertebral Global BMD (g/cm2) Compression (Newtons) Intact-v a h i c 66.78 17.47 0.0508 0.0026 l a 50.3 7.58 Ovx- 96.26 15.92 (p<0.006)0.0486 0.0011 vehicle 85.57 10.17 0.0554 0.0015 (p<0.002) Intact-E- (P<0.00001) 3-0l 0.0555 0.0011 Ovx-E-3- ~ ~ (p<0.00001) of *Each value represents the mean from seven animals.
The BMD values shown for comparison here are from the experiment described in Example 12.
iEXAMPLE 14 To determine whether the anti-apoptotic effects of estrogenic compounds are mechanistically dissociable from their transcriptional effects, specific conformational changes of the receptor protein leading to prevention of apoptosis versus transcriptional activity were sought. The rationale behind these studies was based on recent evidence that the transcriptional activity of the ER is greatly dependent on ligand-induced conformational changes of the receptor protein. Indeed, using phage display libraries, McDonnell and co-workers have recently screened for and isolated four classes of small (11 amino acids) peptides that recognize distinct conformational changes of the estrogen receptor, and can either selectively block transcription from specific ligands (e.g., estradiol but not tamoxifen and vice versa) or selectively block ERa but not ER~i -mediated transcription, and vice versa, when tested on a consensus )~~ERE
(Norris et al. Science 285:744-746, 1999). The first class contains the LX~~.L motif and can interact with both estradiol-activated ERa and ER~3. The second class displays specific interaction w i th estradiol- and tamoxifen-activated ERa, whereas the third class can interact specifically with tamoxifen-activated ER~3. Yet a fourth class with a SREWFXXXL conserved motif was found to complex t o tamoxifen-activated ERa and ER~i. Indeed, when fusion proteins made with these peptides and the Gal4-DNA binding domain and were co-expressed with ER in HeLa cells they functioned a s ligand-receptor complex-specific antagonists, demonstrating that ligand activation triggers transcriptional activity by conferring specific conformational changes on the receptor protein (Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, Change C-Y, Ballas LM, Hamilton PT, McDonnell DP, Fowlkes DM. Estrogen receptor (ER) modulators each induce distinct conformational changes in ERa and ERj3. Proc. Natl. Acad. Sci 96:3999-4004, 1999).
Based on the findings that estrogenic compounds like the conjugated 17-~i estradiol with BSA have, at least as potent anti-apoptotic effects as estrogen while have significantly decreased transcriptional activity, the hypothesis that the non genomic anti-apoptotic effects of estrogen can be initiated b y distinct ligand-dependent conformational changes of the ER, as compared to the conformational changes required for the transcriptional effects of the ER was tested. It was found that indeed there is dissociation of conformational changes. Based on this, one can explain the mechanistic basis of the apparent dissociation of the two sets of actions. This knowledge forms th a basis for the design of the screening strategies described herein for ligands which display non-transcriptional effects, but lack the ability to initiate transcriptional activation.
One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. The present examples, along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined b y the scope of the claims.
Fluor' .
The most thoroughly studied anabolic agent, sodium fluoride, can increase vertebral bone mass by 10% a year for a t least four years but there is controversy about the quality of the bone formed. Sodium fluoride has not been approved as a bone anabolic agent. It has been difficult to establish anti-fracture efficacy because of serious qualitative abnormalities. First, much of the new bone is initially woven rather than lamellar. Second and more important, there is severe impairment of bone mineralization, in spite of sodium fluoride's effectiveness i n increasing bone mass.
U.S. Patent No. 5,071,655 discloses a composition to increase bone mass that includes a fluoride source and a mitogenic hydantoin.
SERMs SERMs such as tamoxifen and raloxifene have also been used to treat osteoporosis. A recent study carried out with raloxifene indicated that after three years of treatment, women o n raloxifene had 30-50% fewer spinal fractures, and had 2-3%
increase in bone density in their hips and spine, but showed n o fewer nonspinal fractures, a category that includes hip fractures (Ettinger, B., JAMA, 282:637-645, 1999).
WO 00/20007 PG"T/US99/23355 U.S. Patent 4,970,237 discloses the use of No.
clomiphene to increase mass in premenopausalwomen.
bone Vitamin D deriva tives There have been conflicting reports the value of about Vitamin D or its derivativeson bone loss and bone anabolism.
Some studies on the hormonal D, calcitrioi, metabolite of vitamin have reported an increase spinal bone density, others h a v in but a .
found no effect.
The following patents describe the use of Vitamin D
derivatives to treat bone disease: U.S. Patent Nos. 4,973,584;
5,750,746; 5,593,833; 5,532,391; 5,414,098; 5,403,831; 5,260,290;
5,104,864; 5,001,118; 4,973,584; 4,619,920; and 4,588,716.
Other Compounds The following patents disclose the use of other compounds for the treatment of bone disease: U.S. Patent Nos.
5,753,649 and 5,593,988 (azepine derivative); 5,674,844 (morphogen); 5,663,195 (cyclooxygenase-2 inhibitor); 5,604,259 (ibuprofen or flurbiprofen); 5,354,773 (bafilomycine); 5,208,219 (activin); 5,164,368 (growth hormone releasing factor); an d 5,118,667, 4,870,054 and 4,710,382 (administration of a bone growth factor and an inhibitor of bone resorption).
U.S. Patent No. 5,859,001 discloses the use of non estrogen compounds having a terminal phenol group in a four-ring cyclopentanophenanthrene compound structure to confer neuroprotection to cells.
U.S. Patent No. 5,824,672 discloses a method for preserving tissues during transplantation procedures that includes administering an effective dose of a cyclopentanophenanthrene compound having a terminal phenol A ring.
WO 98/31381 filed by the University of Florida Research Foundation, Inc. discloses a method for enhancing the cytoprotective effect of polycyclic phenolic compounds on a population of cells that involves the steps of administering a combination of polycyclic phenolic compounds and anti-oxidants to achieve an enhanced effect. One disclosed combination is glutathione and estrogen.
It is an object of the present invention to provide a method to increase bone mass in a host by at least 10% per year without a loss in bone strength (defined by fracture incidence i n vivo and mechanical strength in vitro) and/or deterioration of bone quality (as defined by abnormal collagen orientation and excessive accumulation of unmineralized bone matrix, determined, for example, with histomorphometry).
It is another object of the present invention to provide a method to rebuild strong bones instead of preventing further loss of bone.
It is a further object of the present invention to provide a method to select compounds that increase bone mass in a host at least 10% per year without a loss in bone strength or quality.
It is a still further object of the present invention to provide a method to increase bone strength by at least 20%.
SUMMARY OF THE INVENTION
In a first embodiment, a method for increasing bone mass in a host at least 10% without a loss in bone strength o r quality is provided that includes administering an effective amount of a compound that (i) binds to the estrogen a or B
receptor (or the equivalent receptor in the host animal) with a n association constant of at least 108 M-', and preferably, at least 10'° M-': (ii) (a) induces estrogenic gene transcriptional activity at a level that is no greater than 10% that of 17B-estradiol, and preferably no greater than 5, 1 or even O.l.% that of 1713-estradiol when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic or osteocytic cells with natural estrogen receptors or cells transfected with estrogen receptors or 1 S (b) induces an increase in uterine weight of no more than 10% that of 1713-estradiol (or the equivalent compound in a host animal);
(iii) induces the phosphorylation of extracellular signal regulated kinase (ERK) when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic cells with natural estrogen receptors or cells transfected with estrogen receptors;
and (iv) has an anti-apoptotic effect on osteoblasts and osteocytes at an in vivo dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic or osteocytic cells with natural estrogen receptors or cells transfected with the estrogen receptor. In another aspect of this first embodiment of this invention, the compound is not a n estrogen compound, as that term is defined below. In yet another aspect of this first embodiment, the compound is an estrogen compound which is converted to a nonestrogen by attaching a substituent which prevents the compound from entering the cell but does not significantly affect the binding of the compound to the estrogen cell-surface receptor.
In a second embodiment, a method for increasing b o n a mass in a host at least 10% without a loss in bone strength o r quality is provided that includes administering an effective amount of a compound that (i) binds to the androgen receptor (or the equivalent receptor in the host animal) with an association constant of at least 108 M'', and preferably, at least 10'° M'': (ii) (a) induces androgenic gene transcriptional activity at a level that is no greater than 10% that of testosterone, and preferably no greater than 5, 1 or even 0.1 % that of testosterone w h a n administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic cells with the natural androgen receptor or cells transfected with the androgen receptor or (b) induces a n increase in muscle weight of no more than 10% that which is induced by testosterone (or the equivalent compound in a host animal); (iii) induces the phosphorylation. of extracellular signal regulated kinase (ERK) when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic cells with the natural androgen receptor or cells transfected with the androgen receptor; and (iv) has an anti-apoptotic effect o n osteoblasts and osteocytes at an in vivo dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic cells with the natural androgen receptor or transfected with the androgen receptor. I n another aspect of the second embodiment, the compound is not a n androgen. In yet another aspect of this second embodiment, the compound is an androgen compound which is converted to a nonandrogen by attaching a substituent which prevents the compound from entering the cell but which does not significantly affect the ability of the compound . to bind to the androgen cell-surface receptor.
In other aspects of the first or second embodiment of this invention, the compound has a pro-apoptotic effect o n osteoclasts at an in vivo dosage of at least 0.1 ng/kg body weight, or in osteoclastic cells with natural estrogen receptors or cells transfected with estrogen receptors.
The disclosed invention is based on the fundamental discovery that bone loss occurs because of an increase i n osteoblast and perhaps osteocyte apoptosis, which can be inhibited by a compound that binds to an estrogen or androgen receptor, which induces the phosphorylation of ERKs without significant hormonal transcriptional activation. The discovery of this fundamental pathway allows the selection of compounds which provide a maximum effect on bone mass and strength.
Therefore, in a third embodiment, a method for selecting a compound that increases bone mass in a host at least 10% without a loss in bone strength or quality is provided that includes evaluating whether the compound (i) binds to the estrogen or androgen receptor (or the equivalent receptor in the host animal) with an association constant of at least 10g M-1, and preferably, at least 10' ° M-' : (ii) (a) induces estrogenic o r androgenic gene transcriptional activity at a level that is no greater than 10% that of 173-estradiol or testosterone, and preferably no greater than 5, 1 or even 0.1% that of 17(3-estradiol or testosterone, as appropriate, when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic cells with the natural androgen or estrogen receptor or cells transfected with the androgen or estrogen receptor or (b) induces an increase in uterine weight of no more than 10% that which is induced by 173-estradiol or muscle weight of no more than 10%
that which is induced by testosterone (or the equivalent compound in a host animal); (iii) induces the phosphorylation of .
extracellular signal regulated kinase (ERK) when administered i n vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic or osteocytic cells with the natural androgen o r estrogen receptor or cells transfected with the androgen o r estrogen receptor; and (iv) has an anti-apoptotic effect o n osteoblasts and osteocytes at an in vivo dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic and osteocytic cells with the natural androgen or estrogen receptor or cells transfected with the androgen or estrogen receptor.
Estrogenic compounds like 17a-estradiol and synthetic polycyclic phenols, such as estratriene-3-of inhibit osteoblast and osteocyte apoptosis in vitro. Yet unlike the classical mechanism of estrogen receptor action that involves direct or indirect interaction with the transcriptional apparatus, the receptor-dependent anti-apoptotic effects of these compounds are nongenomic, as they are due to rapid (within S minutes) phosphorylation of ERKs.
Estratriene-3-of increases bone mass in both estrogen-replete and estrogen-deficient mice. Esstratriene-3-ol, when given in low doses, has little effect on estrogenic-type activity but also has little effect on bone mass. As the dosage increases, both effects increase. To optimize the use of this compound or others exhibiting this type of activity, one can derivatize the compound to preserve the estrogen-binding activity and decrease the transcriptional activity as described in detail herein, including b y attaching a substituent or moiety that inhibits cell penetration.
Compounds selected according to the criteria provided herein can also be used for the augmentation of bone mass a n d / o r fracture prevention in diseases characterized by low bone mass and increased fragility. The compounds can also be used to treat bone disease states in which osteoblastogenesis is decreased, such as senile osteoporosis, and glucocorticoid-induced osteoporosis--especially in growing children and adolescents, during which time in whom interfering with bone remodeling is detrimental.
BRIEF DESCRIPTION OF THE DRAWINGS
The Figures provided herein illustrate embodiments of the invention and are not intended to limit the scope of the invention.
Figure 1 provides nonlimiting examples of one class of compounds that can be used to increase bone mass without adversely affecting bone strength.
Figure 2 is a bar chart graph of the degree of apoptosis of osteoblasts and osteocytes in murine vertebral bone as a function of estrogen deficiency. Swiss Webster mice (four months old) were ovariectomized. Twenty eight days later, th a animals were sacrificed, vertebrae were isolated, fixed a n d embedded, and then undecalcified in methacrylate. The prevalence of osteoblast and osteocyte apoptosis was determined by the TUNEL method with CuS04 enhancement, and was found to be dramatically increased following loss of estrogen. ***P<
0.00001; *P < 0.0382.
Figure 3 is a series of bar chart graphs which illustrate the percentage of Etoposide-induced osteoblast apoptosis versus the log of the concentration of added estrogens 17 Vii-estradiol, 173-estradiol-BSA, 17a-estradiol, and estratriene-3-ol.
Osteoblastic cells derived from murine calvaria were pretreated with the sterols for 1 hour before the addition of the pro-apoptotic agent, etoposide. Apoptosis was determined after 6 hours b y trypan blue uptake (Jilka et al, J.Bone and Min. Res. 13:793:802, 1998). * indicates p<0.05 versus etoposide alone, by analysis of variance (ANOVA) (Student-Newman-Keuls method).
Figure 4 is a series of bar chart graphs of the inhibition of etoposide-induced apoptosis of osteocytes (MLO-Y4) by 173-estradiol, 173-estradiol-BSA, 17a-estradiol, and estratriene-3-ol. Cells were pretreated with the indicated concentrations of the compounds for 1 hour before the addition of the pro-apoptotic agent etoposide. Apoptosis was determined after 6 hour by trypan blue uptake as described in Figure 3.
indicates p<0.05 versus etoposide alone, by ANOVA (Student-Newman-Keuls method).
Figure 5 is a series of bar chart graphs that indicates that the anti-apoptotic effect of 17~i-estradiol, 173-estradiol-BSA, 17a-estradiol, and estratriene-3-of (E-3-ol) on etoposide-induced apoptosis of osteoblasts is abrogated by the estrogen receptor antagonist, ICI182,780. Osteoblastic cells derived from murine calvaria were pretreated for 1 hour with the pure receptor antagonist ICI182,780 (10-' M) before the addition of the test agents ( 10-g M). Apoptosis was induced and quantified a s described in Figure 3. * indicates p<0.05 versus etoposide alone, by ANOVA (Student-Newman-Keuls method).
Figure 6 is a series of bar chart graphs that indicates that the anti-apoptotic effect of 17(3-estradiol, 17~i-estradiol-BSA, 17a-estradiol, and estratriene-3-of (E-3-ol) on MLO-Y4 osteocytic cells is abrogated by the estrogen receptor antagonist, ICI182,780.
MLO-Y4 cells were pretreated for 1 hour with the pure receptor antagonist ICI182,780 ( 10-' M) before the addition of the test agents ( 10-8 M). Apoptosis was induced and quantified a s described in Figure 3. * indicates p<0.05 versus etoposide alone, by ANOVA (Student-Newman-Keuls method).
Figure 7 is a series of bar chart graphs which demonstrate that estrogen receptor a or ~i is required for the anti-apoptotic effects of 17~i-estradiol, 17a-estradiol, and estratriene-3-0l on the etoposide-induced apoptosis of osteoblasts. CMV
promoter alone and CMV promoter-driven cDNA for mERa or mEr~i were stably transfected into HeLa cells. Subconfluent cultures were treated for 1 hr with 10-g M 17 a-estradiol, 17 (3-estradiol, o r estratriene-3-of followed by a 6 hr incubation with etoposide (5x10-5 M). Cells were trypsinized, pelleted and trypan blue positive cells enumerated. Each bar represents mean of duplicate experiments ~ SEM. *P < 0.02 versus etoposide alone.
Figure 8 is Western blot which demonstrates th at 17~i-estradiol, 17a-estradiol, 17~-estradiol-BSA or estratriene-3-of activate the extracellular signal regulated kinases (ERKs). MLO-Y4 osteocytic cells were incubated for 25 minutes in serum-free medium. Subsequently, 17~i-estradiol, 17a-estradiol, 17~-estradiol-BSA or estratriene-3-of ( 10-g M) were added and cells incubated for an additional 5, I5, or 30 min. Cell lysates were prepared and proteins were separated by electrophoresis i n polyacrylamide gels and transferred to PVDF membranes.
Western blotting was performed using a specific antibody .
recognizing phosphorylated ERKs I and 2, followed by reblotting with an antibody recognizing total ERKs. Blots were developed b y enhanced chemiluminescence.
Figure 9 is a Western blot which demonstrates that the effect of estrogenic compounds on the activation of ERK1/2 is blocked by the specific inhibitor of ERK kinase, PD98059. MLO-Y4 cells were incubated for 25 minutes in serum-free medium in the presence or absence of 50 ~,M PD98059. Subsequently, 17 (3-estradiol, 17a-estradiol, 17~i-estradiol-BSA or estratriene-3-of ( 10-8 M) were added and cells incubated for an additional 5 min. Cell lysates were prepared and proteins were separated b y electrophoresis in polyacrylamide gels and transferred to PVDF
membranes. Western blotting was performed using a specific antibody recognizing phosphorylated ERKs 1 and 2, followed b y reblotting with an antibody recognizing total ERKs. Blots were developed by enhanced chemiluminescence.
Figure 10 is a series of bar chart graphs which demonstrate that the specific inhibitor of ERK activation, PD98059, abolishes the anti-apoptotic effect of 17~-estradiol and related compounds. MLO-Y4 osteocytic cells were pretreated for 1 hour with 50 ~,M PD98059 before the addition of 10-8 M 17~i-estradiol, 17a-estradiol, or 17~i-estradiol-BSA. Apoptosis was induced b y incubation with the pro-apoptotic agent dexamethasone for 6 hour and quantified as described in Figure 3. * indicates p<0.05 versus the corresponding control group without dexamethasone, b y ANOVA (Student-Newman-Keuls method).
Figure 11 illustrates that unlike 17 a estradiol, estratriene-3-of does not transactivate an estrogen response element through ERa. The human ERa was overexpressed in 2 9 3 cells lacking ERa along with a reporter construct containing 3 copies of an estrogen response element driving the luciferase gene. Light units were counted and normalized to coexpressed b -galactosidase activity to control for differences in transfection efficiency. Results represent percent stimulation compared to ERa transfected cells, but not treated with the two agents. Each b ar represents mean of duplicate experiments +/- SEM. *p<0.001 vs.
cells not exposed to the sterols.
Figure 12 is an illustration of the chemical structures of certain 3-ring compounds: [2S-(2a,4aa, l0a(3)]-1,2,3,4,4a,9,10, l0a-octahydro-7-hydroxy-2-methyl-2-phenanthrenemethanol (PAM) and [2S-(2a,4aa, l0a~i)]-1,2,3,4,4a,9,10, l0a-octahydro-7-hydroxy-2-methyl-2-phenanthrenecarboxaldehyde {PACA).
Figure 13 illustrates the generalized core ring structures with numbered carbons (Figure 13a) 4-ring structure, (Figure 13b) 3-ring structure, (Figure 13c) 2-ring structure (fused), and (Figure 13d) 2-ring structure (non-fused).
Figure 14 is an illustration of three mechanisms of estrogen activity: Figure 14A (anti-apoptotic effect of estrogen), Figure 14B (anti-remodeling effect of estrogen) and Figure 14 C
(feminizing effect of estrogen).
Figure 15 compares the activity of the anti resorptive (e.g., 17~i-estradiol) versus non-anti-resorptive agents [e.g., estratriene-3-of or intermittent PTH] on osteoblast and osteocyte apoptosis. Bone formation occurs only on sites of previous osteoclastic bone resorption, i.e., on sites undergoing remodeling. Each remodeling cycle is a transaction that, once consummated, is irrevocable. As shown in the right panel, agents with anti-apoptotic properties that do not have anti-resorptive/anti-remodeling properties rebuild more bone and therefore, increase the overall bone mass because they will not decrease the number of the remodeling units (i.e., the number of transactions). In addition, by decreasing the prevalence of osteoblast apoptosis, the active compounds expand the pool of mature osteoblasts at sites of new bone formation and allow th a s a cells more time to make bone. Moreover, by upholding th a osteocyte-canalicular network by preventing osteocyte apoptosis, both classical antiresorptive agents like 173-estradiol and agents that are not anti-resorptives are expected to have anti-fracture efficacy over and above that resulting from their effects on b o n a mass.
Figure 16A is a table of examples of R1 and R2 substitutions on the compound illustrated in Figure 1.
Figure 16B provides the molecular structures of a and ~i estradiol.
Figure 17 provides the chemical structures of estratrienes with anti-apoptotic properties.
WO 00/20007 PC'T/US99/23355 Figure 18 provides the chemical structures of estradiol, phenol and diphenols with anti-apoptotic properties.
Figure 19 depicts the effect of 17 (3 estradiol on th a transcriptional activity of a minimal ERE containing gene promoter and the blockade of this effect by a peptide (aII) recognizing the ligand-induced specific conformational change of the estrogen receptor protein. 293, human kidney cells, were transiently transfected with a plasmid carrying the ER-specific aII peptide with the GAL4-DNA binding domain inserted upstream of the peptide sequence, an ERE/IL-6 promoter-driven luciferase reporter plasmid and a ~3-galactosidase ((3-gal)-containing plasmid.
The ERE-luciferase construct carried three copies of the Xenopus vitellogenin ERE driving the luciferase gene in the pGL3-Basic vector (Promega). * indicates p<0.05 versus cells transfected with the peptide aII, by ANOVA (Student-Newman-Keuls method).
Figure 2 0 depicts the effect of 17 ~i estradiol on t h a transcriptional activity of the IL-6 promoter and the blockade of this effect by a peptide (aII) recognizing the ligand-induced specific conformational change of the estrogen receptor protein.
The IL-6-luciferase plasmid carried 225bp of the proximal IL-6 promoter cloned upstream of the luciferase gene in pGL3-Basic.
The aII peptide inhibited the transcriptional effects of estrogen on the ERE-dependent transcription model. aII was also shown to block transcription when mediated via protein/protein interaction between the ER and another transcription factor on the IL-6 gene model. * indicates p<0.05 versus cells transfected with the peptide aII, by ANOVA (Student-Newman-Keuls method).
Figure 21 demonstrates the anti-apoptotic effect of 17[3 estradiol conjugated with BSA and the lack of inhibition of this particular effect by the conformation sensitive peptide aII.
The effect of the peptide on apoptosis was assayed using etoposide as the apoptotic stimulus. Upon etoposide treatment, cells that had been transfected with the ER and treated with 17 (3-BSA were protected from apoptosis. Following co-transfection of the GAL4-driven peptide, cells remained resistant to etoposide-induced apoptosis indicating that the peptide did not inhibit the protective, anti-apoptotic action of the ER (Figure 21). * indicates p<0.05 versus cells transfected with the peptide aII, by ANOVA
(Student-Newman-Keuls method).
DETAILED DESCRIPTION OF THE INVENTION
The invention as disclosed provides a method to increase bone mass without compromising bone quality, through the administration to a host of an effective amount of a compound that binds to the estrogen or androgen receptor so as to trigger the anti-apoptotic signalling pathway, but with minimal or n o resultant transcriptional activity.
In an optimal embodiment using this invention, a n anabolic effect will be established by demonstrating increased bone formation, assessed by double tetracycline labeling (Weinstein R.S. In Disorders of Bone and Mineral Metabolism (eds.
Coe and Favus) Raven Press, 1992, pp. 455-474) and a continuous increase in BMD, assessed by DEXA (Jilka et al. J. Clin. Invest.
97:1732-1740, 1996} for at least five years, along with increased, or at least no decreased quality or strength.
This invention is based on the fundamental discovery that bone loss occurs because of an increase in osteoblast apoptosis, which can be inhibited by a compound that binds to a n estrogen or androgen receptor (which induces the phosphorylation of ERKs) with minimal or no resultant transcriptional activity. The discovery of this fundamental pathway allows the selection of compounds which provide a maximum effect on bone mass and strength.
Therefore, in a first embodiment, a method for increasing bone mass in a host at least 10% without a loss in bone quality or strength is provided that includes administering a n effective amount of a compound that (i) binds to the estrogen a o r 13 receptor (or the equivalent receptor in the host animal) with a n association constant of at least 108 M-', and preferably, at least 10'° M-'; (ii) (a) induces estrogenic gene transcriptional activity a t a level that is no greater than 10% that of 1713-estradiol, and preferably no greater than 5, 1 or even 0.1% that of 1713-estradiol when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in cells with natural estrogen receptors or transfected with estrogen receptors or (b) induces an increase i n uterine weight of no more than 10% that of estrogen (or the equivalent compound in a host animal); (iii) induces the phosphorylation of extracellular signal regulated kinase (ERK) when administered in vivo at a dosage of at least 0.1 ng/kg body weight or at a concentration of 10-" to 10'' M in vitro in cells with natural estrogen receptors or transfected with estrogen receptors.;
and (iv) has an anti-apoptotic effect on osteoblasts and osteocytes at an in vivo dosage of at least 0.1 ng/kg body weight or at a concentration of 10-" to 10'' M in vitro in cells with natural estrogen receptors or transfected with estrogen receptors. I n another aspect of this first embodiment of this invention, the compound is not an estrogen compound, as that term is defined herein. In another aspect of this first embodiment, the compound is an estrogen compound which is converted to a nonestrogen b y attaching a substituent which prevents the compound from entering the cell, but which does not significantly affect the binding of the compound to the estrogen cell-surface estrogen receptor.
In a second embodiment, a method for increasing b o n a mass in a host at least 10% per year without a loss in bone strength or quality is provided that includes administering a n effective amount of a compound that (i) binds to the androgen receptor (or the equivalent receptor in the host animal) with a n association constant of at least 108 M-', and preferably, at least 10 '° M-1: (ii) (a) induces androgenic gene transcriptional activity a t a level that is no greater than 10% that of testosterone, and preferably no greater than 5, 1 or even 0.1% that of testosterone when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in cells with the natural androgen receptor or transfected with the androgen receptor or (b) induces an increase in muscle weight of no more than 10% that which is induced b y testosterone (or the equivalent compound in a host animal); (iii) induces the phosphorylation of extracellular signal regulated kinase (ERK) when administered in vivo at a dosage of at least 0.1 ng/kg body weight, or at a concentration of 10-" to 10'' M in vitro in cells with the natural androgen receptor or transfected with the androgen receptor; and (iv) has an anti-apoptotic effect o n osteoblasts and osteocytes at an in vivo dosage of at least 0.1 ng/kg body weight or at a concentration of 10-" to 10-' M in vitro in cells with the natural androgen receptor or transfected with the androgen receptor. In another aspect of the second embodiment, the compound is not an androgen. In another aspect of this second embodiment, the compound is an androgen compound which is converted to a nonandrogen by attaching a substituent which prevents the compound from entering the cell containing the cell-surface androgen receptor.
In other aspects of the first or second embodiment of this invention, the compound also has a pro-apoptotic effect o n osteoclasts at an in vivo dosage of at least 0.1 ng/kg body weight or in vitro in cells with the natural androgen receptor or transfected with the androgen receptor.
Therefore, in a third embodiment, a method for selecting a compound that increases bone mass in a host at least 10% without a loss in bone strength or quality is provided that includes evaluating whether the compound (i) binds to the estrogen or androgen receptor (or the equivalent receptor in the host animal) with an association constant of at least 108 M-', and preferably, at least 10 '° M-': (ii) (a) induces estrogenic o r androgenic gene transcriptional activity at a level that is no greater than 10% that of testosterone or 17(3-estradiol, and preferably no greater than 5, 1 or even 0.1% that of 17~i-estradiol or testosterone, as appropriate, when administered in vivo at a dosage of at least 0.1 ng/kg body weight or at a concentration of 10-11 to 10-' M or in vitro in cells with the natural androgen or estrogen receptor or transfected with the androgen or estrogen receptor or (b) induces an increase in uterine or muscle weight, a s appropriate, of no more than 10% that which is induced by 17 (3-estradiol or testosterone (or the equivalent compound in a host animal); (iii) induces the phosphorylation of extracellular signal regulated kinase (ERK) when administered in vivo at a dosage of at least 0.1 ng/kg body weight or at a concentration of 10-" to 10-' M in vitro in cells with the natural androgen or estrogen receptor or transfected with the androgen or estrogen receptor; and (iv) has an anti-apoptotic effect on osteoblasts at an in vivo dosage of at least 0.1 ng/kg body weight or in vitro in cells with the natural androgen or estrogen receptor or transfected with the androgen or estrogen receptor.
Compounds selected according to the criteria provided herein can also be used as for the augmentation of bone mass and/or fracture prevention in diseases characterized by low bone mass and increased fragility. The compounds can be used to treat bone disease states in which osteoblastogenesis is decreased, such as senile osteoporosis, and glucocorticoid-induced osteoporosis--especially in growing children and adolescents, in whom interfering with bone remodeling is detrimental.
I. Definitions An estrogen compound, as used herein, refers to a four ring steroidal compound which possesses the biological activity of an estrus-producing hormone, or its conjugated and esterified derivative, or a derivative thereof of same chemical composition and structure but which does not possess the biological activity of the active form because it exhibits a different stereochemistry from the active form. Nonlimiting examples of estrogens include broparestrol, chlorotrianisene, dienoestrol, epimestrol, equilin, estrapronicate, estropipate, ethinylestradiol, fosfestrol, hydroxyesetrone, mestranol, estradiol, estriol, conjugated and esterified estrogens, estrone, polyestradiol, promestriene, .
quinestradol, quinestrol, stilbestrol, and zeranol.
An androgen compound, as used herein, refers to a four ring steroidal compound which can be produced in the testis or adrenal cortex, or is a synthetic hormone, which acts to regulate masculine secondary sexual characteristics, or a derivative thereof of same chemical composition and structure but which does not possess the biological activity of the active form because i t exhibits a different stereochemistry from the active form.
Nonlimiting examples include boldenone, clostebol, danazol, drosstanolone, epitiostanol, ethylestrenol, fluoxymesterone, formebolone, furazabol, mepitiostane, mesterolone, methandienone, methenolone, methyltestosterone, nandrolone, norethandrolone, oxabolone, oxymetholone, prasterone, quinbolone, staolone, stanozolol, testosterone, and trenbolone.
As known, estrogens and androgens have chiral carbons, and thus can exist in a number of stereochemical configurations. Typically, for example, the 17~i hydroxy estrogens have biological activity while the 17a hydroxy estrogens have very little effect on sexual characteristics (and induce little hormone-like gene transcriptional activation). For the purpose of this specification, any stereochemical configuration, including either the biologically active or the biologically inactive or less active structure, can be used, as long as the compound satisfies the specifically itemized criteria of the invention.
The catalogue entitled "Steroids" from Steraloids Inc., Wilton, N.H., provides a list of over 3000 steroids, with numerous estrogen and androgen derivatives. The catalog can be obtained by contacting the company and is also currently available on the Internet at http://www.steraloids.com. One can select and purchase compounds from this library, which are all commercially available and thus easy to obtain and evaluate, for use in this invention. One can also use known estrogen and androgen receptor binding compounds.
The term "bone mass" refers to the mass of bone mineral and is typically determined by Dual-Energy X-Ray Absorbtiometry (DEXA).
The term "bone strength" refers to resistance to mechanical forces and can be measured by any known method, including vertebrae compression strength or three point -bending of long bones.
The term "bone quality" refers to normal collagen orientation without excessive accumulation of unmineralized bone matrix, and can be measured by any known method, including undecalcified bone histomorphometry.
The term "bone anti-resorption agent" refers to a compound that blocks bone resorption by suppressing remodeling or the activity and/or lifespan of osteoclasts.
The term "osteopenia" refers to decreased bone m a s s below a threshold which compromises structural integrity.
As used herein, the terms "metabolic bone disease", "orthopedic bone disease" or "dental disease" are defined a s conditions characterized by decreased bone mass and/or structural deterioration of the skeleton and/or teeth.
As used herein, the term "apoptosis" refers to programmed cell death characterized by nuclear fragmentation and cell shrinkage as detected by morphological criteria and Terminal Uridine Deoxynucleotidal Transferase Nick End Labeling (TUNEL) staining.
The term "host", as used herein, refers to any bone-containing animal, including, but not limited to humans, other mammals, canines, equines, felines, bovines (including chickens, turkeys, and other meat producing birds), cows, and bulls.
II. Compounds Useful in the Invention A. Estrogen compounds that bind to the estrogen a or (3 receptor with an association constant of at 1 a a s t 10 8 M~1, and preferably, at least 101 ° M '', but w h i c h exhibit little transcriptional activation According to the present invention, one can easily select estrogen compounds that significantly increase bone mass by evaluating them according to the disclosed criteria.
1 . Binding to the estrogen a or ~i receptor A compound should be selected that binds to th a estrogen a or 13 receptor (or the equivalent receptor in the host animal) with an association constant of at least 10g M-', and preferably, at least 10'° M-' . This constant can be measured b y any known technique, including receptor binding assays whereby ligand binding affinities are determined by competitive radiometric binding assays using 10 nM [3H] estradiol as tracer, purified estrogen receptor preparations, or cell cytosol preparations, or intact cells, during one hour incubation at room temperature or overnight at 4°. Bound receptor-ligand complex is absorbed using hydroxylapatite.
The estrogen a and 13 receptor subtypes have significantly different primary sequences in their ligand binding and transactivation domains. ERa and E1t13 show a 56% amino acid homology in the hormone binding domain/activation function-1 region, and only 20% homology in their A/B domain/activation function-1 region. The difference between ERa and ER13 structure suggests that some compounds might bind ERa or E1t13, but not both. All such selectively binding compounds are considered to fall within the scope of this invention.
Estrogen compounds include those described in the 11th Edition of "Steroids" from Steraloids Inc., Wilton, N. H., which bind to the estrogen receptor with an association constant of a t least 108 M-', and preferably, at least 10'° M-'.
2. Minimal effect on estrogen-induced transcriptional activation In this embodiment, an estrogen compound is selected that has a minimal effect on estrogen-induced transcriptional activation (or suppression). The basis for this requirement is that it has been discovered that apoptosis of osteoblasts is decreased by receptor binding, in the absence of transcriptional activation by estrogen-type compounds. Therefore, to provide a maximum therapeutic efficacy on bone without causing unrelated and undesired side estrogen-related effects, estrogen receptor ligands with minimal transcriptional effects should be used.
To accomplish this separation of receptor binding a n d transcriptional activity, a compound should be selected that induces estrogenic gene transcriptional activity at a level that is no greater than 10% that of 1713-estradiol, and preferably n o greater than 5, 1 or even 0.1 % that of 1713-estradiol w h a n .
administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in cells with natural estrogen receptors or transfected with estrogen receptors or which induces an increase in uterine weight of no more than 10% that of estrogen (or the equivalent compound in a host animal).
One can determine whether a selected compound induces estrogenic transcriptional activity at a level that is n o greater than 10% that of 17(3-estradiol, and preferably no greater than 5, 1 or even 0.1 % that of 17 (3-estradiol when administered i n vivo at a dosage of at least 0.1 ng/kg body weight, b y administering the selected compound to a host, and then monitoring the level of induction or suppression of a surrogate marker of estrogenic transcriptional activity. Nonlimiting examples of surrogate markers of estrogenic transcriptional activation, include, but are not limited to, the expression of the complement C-3 gene and lactoferin in the uterus.
In an alternative embodiment, the level of estrogen induced transcriptional activity can be assessed in vitro. One can determine whether a selected compound induces transcriptional activity at a level that is no greater than 10% that of 1713-estradiol, and preferably no greater than 5, 1 or even 0.1% that of 1713 estradiol in vitro using cells with natural estrogen receptors or transfected with estrogen receptors, by monitoring the level of induction or suppression of a surrogate marker. Nonlimiting examples of genes induced or repressed by estrogen include, b a t are not limited to, complement C-3, lactoferin, or interleukin-6. A
preferred marker gene for estrogenic transcriptional activity is a minimal gene containing one or more copies of the ERE driving a reporter gene such as luciferase.
Examples of cell lines that can be used include h a m a n uterine HeLa cells, human embryonic kidney cells 293, murine osteocytic MLO-Y4 cells and murine osteoblastic calvaria derived cells.
One can assess the increase in uterine weight after administration of the selected compound in vivo. Preferred compounds induce an increase in uterine weight of no more than approximately 10% that of estrogen (or the equivalent compound in a host animal). This can be easily tested according to known pro~ocols. For example, in experimental mice, uteri are removed and cleaned of adjacent ligaments and fat. Wet weight is determined on a Mettler PB303 microgram balance (Toledo) and compared to total body weight (mg/100g BW) as an index of the estrogenic status of the animals. In women, similar assessment can be performed by uterine ultrasound.
Examples of estrogen compounds that do not induce significant estrogen-like transcriptional activity include, but are not limited to estratriene-3-ol, 17a-estradiol, 17[3-estradiol conjugated with BSA.
3 . Induction of the phosphorylation o f extracellular signal regulated kinase (ERK) The selected compound should induce t h a phosphorylation of ERKs at a concentration of 10-" to 10-' M in vitro in cells with natural estrogen receptors or transfected with estrogen receptors using any known method, including but not limited to, the method set out in Figures 8 and 9 and Examples 7 -9.
The phosphorylation of ERKs is easily assessed in vitro using osteoblastic or osteocytic cells with natural estrogen receptors or cells transfected with estrogen receptors. Examples of the evaluation of the phosphorylation of ERK in MLO-Y4 cells are provided in Figures 8 and 9 and Examples 7-9. Other appropriate cell models include osteoblastic cells isolated from neonatal murine calvaria.
4 . Anti-apoptotic effect on osteoblasts at an i n v i v o dosage of at least 0.1 ng/kg body weight or a t an in vitro concentration of 10'11 to 10-' M or less.
The anti-apoptotic effect on osteoblasts in vivo can b a assessed by any known method, including by the method described in Figure 2 and Example 3. The anti-apoptotic effect i n vitro can be assessed by any known method including the methods described in Figures 3-7 and 10, and Examples 2-6 and 9.
B. Nonestrogen compounds that bind to t h a estrogen a or ~3 receptor with an association c o n s t a n t WO 00/20007 PC"T/US99/23355 of at least 10 8 M m and preferably, at least 10' ° M -1, but which exhibit little transcriptional activation 1. Nonestrogen compound which binds to t h a estrogen a or (3 receptor A nonestrogen compound, as used herein, refers to a compound other than an estrogen, as that term is defined above, which binds to the estrogen a or (3 receptor with an association constant of at least 108 M'' and preferably, at least 10'° M-'~.
There are a number of reported compounds which are not estrogens but which bind to the estrogen receptor.
Examples include the aryl-substituted pyrazole described by Sun et al., Novel Ligands that Function as Selective Estrogens or Antiestrogens for Estrogen Receptor-a or Estrogen Receptor-(3, Endocrinology, Volume 140, No. 2 (1999), one example of which is illustrated below.
In an alternative embodiment, an estrogen o r nonestrogen compound is covalently linked to a second moiety that does not significantly interfere with the binding to the estrogen receptor but which does substantially prevent the estrogen from entering the cell. In one example, the second moiety is a protein such as bovine serum albumin, polyethelene glycol or dextran or liposomes. In another embodiment, the second moiety is not a protein or peptide, but for polar, steric, o r other reasons, prevents cell penetration. Examples of these types of moieties include carboxylate, ammonium, and sulfide. A
"linking moiety" as used herein, is any divalent group that links two chemical residues, including but not limited to alkyl, alkenyl, alkynyl, aryl, polyalkyleneoxy (for example, -[(CH2)"O-]"-), -C,_6alkoxy-C,_,oalkyl-, -C,_6alkylthio-C1_,o alkyl-, -NR3-, and -(CHOH)"CH20H, wherein n is independently 0, 1, 2, 3, 4, 5, or 6, which can be attached at either end of the linking moiety to t h a structures of interest by any suitable functional groups. In a n alternative embodiment, the linking moiety can be a bifunctional linker moiety of the formula X-(CH2)n Y, wherein X and Y are functional groups capable of linking, including those independently selected from the group consisting of hydroxyl, sulfhydryl, carboxyl and amine groups, and n can be any integer between one and twenty four.
C. Androgen compounds that bind to the a n d r o g a n receptor with an association constant of a t least 10 8 M '', and preferably, at least 10'° M -~, but which exhibit little transcriptional activation According to the present invention, one can also easily select androgenic compounds that significantly increase bone m a s s by evaluating them according to the disclosed criteria.
1. Binding to the androgen receptor A compound should be selected that binds to the androgen receptor (or the equivalent receptor in the host animal) with an association constant of at least 1 Og M-1, and preferably, a t least 10'° M''. The androgen receptor binding association constant is defined as the concentration of the ligand capable of saturating SO% of the unoccupied receptors. This constant can be measured by any known technique, including receptor binding assays whereby ligand binding affinities are determined by competitive radiometric binding assays using 10 nM [3H] of the synthetic androgen RU1881 as tracer, purified androgen receptor preparations, or cell cytosol preparations,or intact cells, during one hour incubation at room temperature or overnight at 4C.
Bound receptor-ligand complex is absorbed using hydroxylapatite.
Androgen compounds include those describ ed in the 11th Edition of "Steroids" from Steraloids Inc., Wilton, N.H., which bind to the androgen receptor with an association constant of at least 108 M-', and preferably, at least 10' M-' .
2. Minimal effect on androgen-induced transcriptional activation In this embodiment, an androgen compound is selected that has a minimal effect on androgen-induced transcriptional activation. The basis for this requirement, is that it has b a a n discovered that apoptosis of osteoblasts is decreased by receptor binding in the absence of transcriptional activation by androgen-type compounds. Therefore, to provide a maximum therapeutic efficacy on bone without causing unrelated and undesired androgen-related effects, androgen receptor ligands with minimal transcriptional activity should be used.
To accomplish this separation of receptor binding a n d transcriptional activity, a compound should be selected that induces androgenic transcriptional activity at a level that is n o greater than 10% that of testosterone, and preferably no greater than 5, 1 or even 0.1% that of testosterone when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in cells with natural androgen receptors or transfected with androgen receptors or induces an' increase in prostate specific antigen (PSA) prostatic serum androgen of no more than 10% that of testosterone (or the equivalent compound in a host animal).
One can determine whether a selected compound induces androgenic gene transcriptional activity at a level that is no greater than 10% that of testosterone, and preferably no greater than 5, 1 or even 0.1 % that of testosterone w h a n administered in vivo at a dosage of at least 0.1 ng/kg body weight, by administering the selected compound to a host, and then monitoring the level of induction or suppression of a surrogate marker of androgenic transcriptional activity. Nonlimiting examples of surrogate markers of androgenic transcriptional activation, include, but are not limited to prostate specific antigen (PSA).
In an alternative embodiment, the level of androgen-induced transcriptional activity can be assessed in vitro in osteoblastic or osteocytic cells with natural androgen receptors o r traf calvaria cells, MLO-Y4 osteocytic cells and HeLa cells.
Alternatively, one can assess the increase in PSA
serum levels after administration of the selected compound.
Appropriate compounds induce an increase in PSA cells transfected with androgen receptors. Examples of such cell types include, primary cultures of PSA of no more than approximately 10% that of testosterone (or the equivalent compound in a host animal). This can be easily tested according to known protocols.
Examples of androgenic compounds that do not induce significant androgenic-like transcriptional activity include, but are not limited to, testosterone 17~i-hemisuccinate conjugated with BSA.
3 . Induction of the phosphorylation o f extracellular signal regulated kinase (ERK) The selected compound should induce the phosphorylation of ERKs when administered in vivo at a dosage of at least 0.1 ng/kg body weight or at a concentration of 10-" to 10'' M in vitro in cells with natural androgenic receptors or transfected with androgenic receptors.
The phosphorylation of ERK in a host can be assessed in biopsies, for example from bone, using immunohistostaining with specific antibodies against phosphorylated ERKs.
Alternatively, the phosphorylation of ERK is also easily assessed i n vitro using osteoblastic or osteocytic cells with natural androgen receptors or cells transfected with androgen receptors. Examples of the evaluation of the phosphorylation of ERK in MLO-Y4 cells are provided Figures 8 and 9 and Examples 7-9.
4 . Anti-apoptotic effect on osteoblasts a n d osteocytes at an in vivo dosage of at least 0.1 n g / k g body weight or at an in v i tro concentration of 10 -1 ~
to 10'' M or less.
The anti-apoptotic effect on osteoblasts and osteocytes can be assessed in vivo any known method, including the by method described in Figure and Example 1; and in vitro any 2 by known method, including method described in Figures and the 3-7 10 and Examples 2-6 and 9.
D. Nonandrogen compounds that bind to t h a androgen receptor with an association constant of a t least 10 8 M -1, and preferably, at least 101 ° M -', b a t which exhibit little transcriptional activation A nonandrogenic compound, as used herein, refers to a compound other than an androgen, as that term is defined above, which binds to the androgenic receptor with an association constant of at least 10g M-' and preferably, at least 10'° M-'..
There are a number of reported compounds which are not androgens but which bind to the androgen receptor. Examples include testosterone 17~i-hemisuccinate conjugated with BSA.
In an alternative embodiment, an androgen compound is covalently linked to a second moiety that does not significantly interfere with the binding to the androgen receptor but which does substantially prevent the androgen from entering the cell. In one example, the second moiety is a protein such as bovine s a r a m albumin. In another embodiment, . the second moiety is not a protein or peptide, but for polar, steric, or other reasons, prevents cell penetration. Examples of these types of moieties include dextran or plyethelene glycol.
E. Other compounds that can be used to increase bone mass.
Other nonlimiting examples of compounds that can b a used in the present invention to increase bone mass include those having a terminal phenyl ring and at least a second carbon ring.
In addition to these required structures, the compound may h av a a number of R groups attached to any available site on the phenyl ring or elsewhere. These R groups may be selected from inorganic or organic atoms or moieties. Representative R groups are provided, although the invention is not to be limited by th a s a examples:
(a) The R, or RZ groups may include a hydroxyl group or an inorganic R group including any of a halogen, a n amide, a sulfate, a nitrate, fluoro, chloro, or bromo groups.
Additionally, R, or R2 groups such as sodium, potassium a n d / o r ammonium salts may be attached to the alpha or beta positions to replace hydrogen on any available carbon in the structure. The Rl or R2 groups may be organic or may include a mixture of organic molecules and ions. Organic R, or R2 groups may include alkanes, alkenes or alkynes containing up to six carbons in a linear o r branched array. For example, additional R, or RZ group substituents may include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, dimethyl, isobutyl, isopentyl, tert-butyl, sec-butyl, isobutyl, methylpentyl, neopentyl, isohexyl, hexenyl, hexadiene, 1,3-hexadiene-5-yne, vinyl, allyl, isopropenyl, ethynyl, ethylidine, vinylidine, isopropylidene, methylene, sulfate, mercapto, methylthio, ethylthio, propylthio, methylsulfinyl, methylsulfonyl, thiohexanyl, thiobenzyl, thiophenol, thicyanato, sulfoethylamide, thionitrosyl, thiophosphoryl, p-toluenesulfonate, amino, imino, cyano, carbamoyl, acetamido, hydroxyamino, nitroso, nitro, cyanato, selecyanato, arccosine, pyridinium, hydrazide, semicarbazone, carboxymethylamide, oxime, hydrazone, sulfurtrimethylammonium, semicarbazone, o -carboxymethyloxime, aldehyde hemiacetate, methylether, ethylether, propylether, butylether, benzylether, methylcarbonate, carboxylate, acetate, chloroacetate, trimethylacetate, cyclopentylpropionate, propionate, phenylpropionate, carboxylic acid methylether, formate, benzoate, butyrate, caprylate, cinnamate, decylate, heptylate, enanthate, glucosiduronate, succinate, hemisuccinate, palmitate, nonanoate, stearate, tosylate, valerate, valproate, decanoate, hexahydrobenzoate, laurate, myristate, phthalate, hydroxyl, ethyleneketal, diethyleneketal, formate, chloroformate, formyl, dichloroacetate, keto, difluoroacetate, ethoxycarbonyl, trichloroformate, hydroxymethylene, epoxy, peroxy, dimethyl ketal, acetonide, cyclohexyl, benzyl, phenyl, diphenyl, benzylidene, and cyclopropyl groups. R, or R2 groups may be attached to any of the constituent rings to form a pyridine, pyrazine, pyrimidine, or v-triazine.
Additional R, or RZ group substituents may include any of the six-member or five-member rings itemized in section (b) below.
( b ) Any compound having, in addition to t h a terminal phenyl group, at least one heterocyclic carbon ring (shown as R~ in Figure 1), which may be an aromatic or non-aromatic phenolic ring with any of the substitutions described in section (a) above, and further may be, for example, one or more of the following structures: phenanthrene, naphthalene, naphthols, diphenyl, benzene, cyclohexane, 1,2-pyran, 1,4-pyran, 1,2-pyrone, 1,4-pyrone, 1,2-dioxin, 1,3-dioxin (dihydro form), pyridine, pyridazine, pyrimidine, pyrazine, piperazine, s-triazine, a s -triazine, v-triazine, 1,2,4-oxazine, 1,3,2-oxazine, 1,3,6-oxazine (pentoxazole), 1,2,6-oxazine, 1,4-oxazine, o-isoxazine, p-isoxazine, 1,2,5-oxathiazine, 1,2,6-oxathiazine, 1,4,2-oxadiazine, 1,3,5,2-oxadiazine, morpholine (tetrahydro-p-isoxazine), any of the six-ringed structures listed above being a terminal group in the compound. Additionally, any of the above carbon ring structure may be linked directly, or via a linkage group, to any further heterocyclic aromatic or non aromatic carbon ring including: furan, thiophene (thiofuran), pyrrole (azole), isopyrrole (isoazole), 3 -isopyrrole (isoazole), pyrazole (1,2 diazole), 2-isoimidazole (1,3-isodiazole), 1,2,3-triazole, 1,2,4-triazole, 1,2-dithiazole, 1,2,3-oxathiazole, isoxazole (furo(a) monozole), oxazole (furo(b) monazole), thiazole, isothiazole, 1,2,3-oxathiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,5-oxadiazole, . 1,2,3,4-oxatriazole, 1,2,3,5-oxatriazole, 1,2,3-dioxazole, 1,2,4-dioxazole, 1,3,2-dioxazole, 1,3,4-dioxazole, 1,2,5-oxathiazole, 1,3-oxathiazole, cyclopentane. These compounds, in turn, may have associated R1 or R2 groups selected from section (a) or section (b) above that are substituted on t h a carbon ring at any of the available sites.
(c) Any compound, including those listed above, that may form a cyclopentanophen(a)anthrene ring compound and which, for example, may be selected from the group consisting of 1,3,5(10),6,8-estrapentaene, 1,3,5(10),6,8,1I-estrapentaene, 1,3,5(10),6,8,15-estrapentaene, 1,3,5(10),6-estratetraene, I,3,5(10),7-estratetraene, 1,3,5(10),8-estratetraene, 1,3,5(10),16-estratetraene, 1,3,5(10),15-estratetraene, I,3,5(10)-estratriene, 1,3,5( 10),15-estratriene.
( d ) Any compound including precursors o r derivatives selected from raloxifen, tamoxifen, androgenic compounds, and their salts, where an intact phenol ring is present with a hydroxyl group present on carbons 1, 2, 3 and 4 of the terminal phenol ring.
(e) Any compound in the form of a prodrug that may be metabolized to form an active polycyclic-phenolic compound having bone protective activity.
III. Methods for Using the Active Compounds The active compounds which satisfy the criteria set out in detain herein can be used to treat a wide variety of medical conditions, including any condition in which it is helpful o r necessary to build bone mass. Because of the discovery of the fundamental basis for bone loss (inappropriate osteoblastic apoptosis), one can for the first time envision the building of healthy bone as opposed to merely treating bone loss.
The active compounds can be used as bone anabolic agents in a host, including a human, to strengthen bone for strenuous physical activities such as sports or manual labor, and to strengthen bone in persons or other hosts who do not h av a osteoporosis but might be subject to osteoporosis in the future because the host is in a risk group for that disease. Other uses for a bone anabolic agent in humans include the treatment of hosts, including persons who are born with naturally thin, small, o r unusually fragile bones, including weak teeth, persons who have a genetic predisposition to a bone catabolic disease, or an orthopedic bone disease such as joint degeneration, non-union fractures, orthopedic problems caused by diabetes, periimplantitis, poor responses to bone grafts, implants, or fracture.
These compounds can be used to increase the bone mass in horses and dogs used for labor as well as those used i n sports such as racing. The compounds can also be used to increase the bone mass in chickens and turkeys used in meat production to increase the ease of processing.
Representative metabolic bone diseases are postmenopausal osteoporosis, senile osteoporosis in males and females, glucocorticoid-induced osteoporosis, immobilization induced osteoporosis, weightlessness-induced osteoporosis (as in space flights), post-transplantation osteoporosis, migratory osteoporosis, idiopathic osteoporosis, juvenile osteoporosis, Paget's Disease, osteogenesis imperfecta, chronic hyperparathyroidism, hyperthyroidism, rheumatoid arthritis, Gorham-Stout disease, McCune-Albright syndrome and osteolytic metastases of various cancers or multiple myeloma. Characteristics of the orthopedic bone diseases are loss of bone mass, general bone fragility, joint degeneration, non-union fractures, orthopedic and dental problems caused by diabetes, periimplantitis, poor responses to bone grafts/implants/bone substitute materials, periodontal diseases, and skeletal aging and its consequences.
I V . Method for Screening for Compounds that I n c r a a s a Bone Mass The present invention provides a method of screening for compounds that possess bone anabolic effects, comprising the steps of: a) contacting a sample of osteoblast cells with a compound; and b) comparing the number of osteoblast cells undergoing apoptosis in the compound-treated cells with the number of osteoblast cells undergoing apoptosis in an untreated sample of osteoblast cells. A lower number of apoptotic cells following contact with the compound indicates that the compound possesses bone anabolic effects. Preferred compounds also inhibit apoptosis of osteocytes. Generally, the compound may b a contacted with the sample either in vitro, e.g., in cell culture or in vivo, e.g., in an animal model. Typical methods of determining apoptosis are nuclear morphologic criteria, DNA end-labeling, DNA
fragmentation analysis and immunohistochemical analysis.
In another embodiment, a method for selecting a compound that increases bone mass at least 10% in a host without a loss in bone strength or quality is provided that includes evaluating whether the compound (i) binds to the estrogen o r androgen receptor (or the equivalent receptor in the host animal) with an association constant of at least 1 Og M'', and preferably, a t least 10'° M'': (ii) (a) induces estrogenic or androgenic gene transcriptional activity at a level that is no greater than 10% that of testosterone or 173-estradiol, and preferably no greater than 5, 1 or even 0.1 % that of 17 ~i-estradiol or testosterone, a s appropriate, when administered in .vivo at a dosage of at least 0.1 ng/kg body weight or in vitro at concentrations of 10'" to 10'' M
in cells with the natural androgen or estrogen receptor o r transfected with the androgen or estrogen receptor or (b} induces an increase in uterine or muscle weight or increase virilization i n females, as appropriate, of no more than 10% that which is induced by 17(3-estradiol or testosterone (or the equivalent compound in a host animal); (iii) induces the phosphorylation of extracellular signal regulated kinase (ERK) when administered i n vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in cells with the natural androgen or estrogen receptor or transfected with the androgen or estrogen receptor; and (iv) has an anti-apoptotic effect on osteoblasts at an in vivo dosage of at least 0.1 ng/kg body weight or in vitro in cells with the natural androgen or estrogen receptor or transfected with the androgen or estrogen receptor.
In another embodiment, a method for screening for compounds that bind to the estrogen or androgen receptor and activate the anti-apoptotic signalling pathway, without resultant transcriptional activation, is provided. This method is based on the fundamental discovery that the ligand-induced conformational changes of the estrogen receptor protein required for prevention of apoptosis, are distinct from the conformational changes required for transcriptional activity (Figures 19-21 ). This discovery allows for selecting compounds, from a large library of small molecules, which have anti-apoptotic, but not transcriptional, activity. Selection is accomplished using small peptides that can specifically block the transcriptional activity of ligand activated receptor, but do not interfere with the ability of the receptor to initiate the anti-apoptotic signalling cascade.
To accomplish this, cells are transfected with the estrogen or androgen receptor with or without a peptide that recognizes the conformation of the protein required for transcriptional activation, but not anti-apoptosis. Using this method, compounds that induce conformational changes resulting in both transcriptional and anti-apoptosis compatible conformations can be distinguished from compounds that only induce the latter conformational changes.
Nonlimiting examples of this method of screening include peptide binding assays for ERa or ER(3 whereby th a purified receptor protein is immobilized on streptavidin-coated plates using biotinylated vitellogenin ERE according to previously described methods of affinity selection (Sparks AB, Adey NB, Cwirla S, Kay BK. Screening phage-displayed peptide libraries. I n Phage Display of Peptides and Proteins, A Laboratory Manual, eds.
Kay BK, Winter J and McCafferty J. (Academic, San Diego), pp.227-253, 1996). Following incubation with various ligands, the peptide is added and after 30 min bound peptide is detected using a n anti-M 13 antibody coupled to horseradish peroxidase. Compounds that bind to the receptor and induce conformational changes recognized by the peptide (i.e. the peptide binds to the receptor) will be discarded. The remaining compounds are then screened for anti-apoptotic potency.
V . Combination Therapy In one aspect of the invention, one of the active compounds described herein can be administered to a host to increase bone mass in combination with a second pharmaceutical agent. The second pharmaceutical agent can be a bone anti resorption agent, a second bone mass anabolizing agent, a n antioxidant, a dietary supplement, or any other agent that increases the beneficial effect of the active compound on bone structure, strength, density, or mass.
Any member of the ten classes of drugs described i n the Background of the Invention that are used in the treatment of osteoporosis can be administered in combination with the primary active agent, including: an anabolic steroid, a bisphosphonate, a calcitonin, an estrogen or progesterone, an anti-estrogens such a s raloxifene or tamoxifene, parathyroid hormone ("PTH"), fluoride, Vitamin D or a derivative thereof, or a calcium preparations.
Nonlimiting examples of suitable agents for combination include, but are not limited to, alendronic acid, disodium clondronate, disodium etidronate, disodium medronate, disodium oxidronate, disodium pamidronate, neridronic acid, risedronic acid, teriparatide acetate, tiludronic acid, ipriflavone, potassium bicarbonate, progestogen, a thiazide, gallium nitrate, NSAIDS, plicamycin, aluminum hydroxide, calcium acetate, calcium .
carbonate, calcium, magnesium carbonate, and sucralfate.
Reducing agents, such as glutathione or other antioxidants may also be useful in combination with any of the compounds of the present invention. As used herein, the term antioxidant refers to a substance that prevents the oxidation of a n oxidizable compound under physiological conditions. In one embodiment, a compound is considered an antioxidant for purposes of this disclosure if it reduces endogenous oxygen radicals in vitro. The antioxidant can be added to a cell extract under oxygenated conditions and the effect on an oxidizable compound evaluated. As nonlimiting examples, antioxidants scavenge oxygen, superoxide anions, hydrogen peroxide, superoxide radicals, lipooxide radicals, hydroxyl radicals, or bind to reactive metals to prevent oxidation damage to lipids, proteins, nucleic acids, etc. The term antioxidant includes, but is not limited to, the following classes of compounds:
A) Dithiocarbamates: Dithiocarbamates have been extensively described in patents and in scientific literature.
Dithiocarbamates and related compounds have been reviewed extensively for example, by G. D. Thorn et al., entitled "The Dithiocarbamates and Related Compounds," Elsevier, New York, 1962. Dithiocarboxylates are compounds of the structure, A -SC(S)-B, which are members of the general class of compounds known as thiol antioxidants, and are alternatively referred to a s carbodithiols or carbodithiolates. ~ It appears that the -SC(S)-moiety is essential for therapeutic activity, and that A and B c an be any group that does not adversely affect the efficacy or toxicity of the compound. A and B can be selected by one of ordinary skill in the art to impart desired characteristics to the compound, including size, charge, toxicity, and degree of stability, (including stability in an acidic environment such as the stomach, or basic environment such as the intestinal tract). The selection of A and B
will also have an important effect on the tissue-distribution and pharmacokinetics of the compound. The compounds are preferably eliminated by renal excretion.
B) N-Acetyl Cysteine and its Derivatives Cysteine is an amino acid with one chiral carbon atom.
It exists as an L-enantiomer, a D-enantiomer, or a racemic mixture of the L- and D-enantiomers. The L-enantiomer is the naturally occurring configuration.
N-acetylcysteine (acetamido-mercaptopropionic acid, NAC) is the N-acetylated derivative of cysteine. It also exists as a n L-enantiomer, a D-enantiomer, an enantiomerically enriched composition of one of the enantiomers, or a racemic mixture of th a L and D enantiomers. The term "enantiomerically enriched composition or compound" refers to a composition or compound that includes at least 95%, and preferably, at least 97% by weight of a single enantiomer of the compound. Any of these forms of NAC can be delivered as an antioxidant in the present invention.
In one embodiment, a single isomer of a thioester or thioether of NAC or its salt, and most preferably, the naturally occurring L-enantiomer, is used in the treatment process.
N-acetylcysteine exhibits antioxidant activity (Smilkstein, Knapp, Kulig and Rumack, N. Engl. J. Med. 1988, Vol.
319, pp. 1557-62; Knight, K.R., MacPhadyen, K., Lepore, D.A., Kuwata, N., Eadie, P.A., O'Brien, B. Clinical Sci., 1991, Vol. 81, pp.
31-36; Ellis, E.F., Dodson, L.Y., Police, R.J., J. Neurosurg., 1991, Vol.
75, pp. 774-779). The sulfhydryl functional group is a well characterized, highly reactive free radical scavenger. N-acetylcysteine is known to promote the formation of glutathione (a tri-peptide, also known as g-glutamylcysteinylglycine), which is important in maintaining cellular constituents in the reduced state (Berggren, M., Dawson, J., Moldeus, P. FEBS Lett., 1984, Vol. 176, pp. 189-192). The formation of glutathione may enhance the activity of glutathione peroxidase, an enzyme which inactivates hydrogen peroxide, a known precursor to hydroxyl radicals (Lalitha, T., Kerem, D., Yanni, S., Pharmacology and Toxicology, 1990, Vo1.66, pp. 56-61) N-acetylcysteine exhibits low toxicity in vivo, and is significantly less toxic than deprenyl (for example, the LDso in rats has been measured at 1140 and 81 mg/kg intravenously, for N-acetylcysteine and deprenyl, respectively)..
N-acetyl cysteine and derivatives thereof are described, for example, in WO/95/26719. Any of the derivatives described in this publication can be used in accordance with this invention.
C) Scavengers ding but not limited to of Peroxides, inclu catalase and pyruvate.
D) T hiols includingdithiothreitoland 2-mercaptoethanol.
E) Antioxidants which are inhibitors of lipid peroxidation,including not limited to TroloxTM, BI3A, BI3'f, but aminosteroid antioxidants,tocopherol and its analogs, and lazaroids.
F) Dietary antioxidants, including antioxidant vitamins (vitamin C or E or synthetic or natural prodrugs or analogs thereof), either alone or in combination with each other, flavanoids, phenolic compounds, caratenoids, and alpha lipoic acid.
G) Inhibitors of lipoxygenases and cyclooxygenases, including but not limited to nonsteriodal antiinflammatory drugs, COX-2 inhibitors, aspirin-based compounds, and quercetin.
H) Antioxidants manufactured by the body, including b a t not limited to ubiquinols and thiol antioxidants, such as, and including glutathione, Se, and lipoic acid.
I ) Synthetic Phenolic Antioxidants: inducers of Phase I
and II drug-metabolizing enzymes.
V I . Pharmaceutical Compositions An active compound or its pharmaceutically acceptable salt, selected according to the criteria described in detail herein, can be administered in an effective amount to treat any of the conditions described herein, optionally in a pharmaceutically acceptable carrier or diluent.
The active materials can be administered by any appropriate route for systemic, local or topical delivery, for example, orally, parenterally, intravenously, intradermally, subcutaneously, buccal, intranasal, inhalation, vaginal, rectal or topically, in liquid or solid form. Methods of administering the compound of the invention may be by specific dose or b y controlled release vehicles.
A preferred mode of administration of the active compound is oral. Oral compositions will generally include a n inert diluent or an edible carrier. The active compound can b a enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the compound can b a incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent . such as sucrose or saccharin;
and/or a flavoring agent such as peppermint, methyl salicylate, o r orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.
The compound can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A
syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
The compound or a pharmaceutically acceptable derivative or salts thereof can also be mixed with other active .
materials that do not impair the desired action, or with materials that supplement the desired action, such as classical estrogen like 17 (3-estradiol or ethinyl estradiol; bisphosphonates like alendronate, etidronate, pamidronate, risedronate, tiludronate, zoledronate, cimadronate, clodronate, ibandronate, olpadronate, neridronate, EB-1053; calcitonin of salmon, eel or human origin;
and anti-oxidants like glutathione, ascorbic acid or sodium bisulfite. Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic, solvents; antibacterial agents such as benzyl alcohol or methyl parabens; chelating agents such as ethylenediaminetetraacetic acid (EI)TA); buffers such a s acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. If administered intravenously, preferred carriers are physiological saline o r phosphate buffered saline (PBS).
WO 00/20007 . PCT/US99/23355 In a preferred embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for ..
preparation of such formulations will be apparent to those skilled in the art.
Liposomal suspensions (including liposomes targeted with monoclonal antibodies to surface antigens of specific cells) are also pharmaceutically acceptable carriers. These may b a prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811 (which is incorporated herein by reference in its entirety}. For example, liposome formulations may be prepared by dissolving appropriate lipids) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and/or cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives) is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
The dose and dosage regimen will depend upon the nature of the metabolic bone disease, the characteristics of the particular active compound, e.g., its therapeutic index, the patient, the patient's history and other factors. The amount of an activator of non-genomic estrogen-like signaling compound administered will typically be in the range of about 1 pg/kg to about 10 m g / k g of patient weight. The schedule will be continued to optimize effectiveness while balanced against negative effects of treatment.
See Remington's Pharmaceutical Science, 17th Ed. (1990) Mark Publishing Co., Easton, Penn.; and Goodman and Gilman's: The Pharmacological Basis of Therapeutics 8th Ed (1990) Pergamon Press.
For parenteral administration, the active compound will most typically be formulated in a unit dosage injectable form (solution, suspension, emulsion) in association with a pharmaceutically acceptable parenteral vehicle. Such vehicles are preferably non-toxic and non-therapeutic. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils and ethyl oleate may also be used. Liposomes may be used a s carriers. The vehicle may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives. An activator of non-genomic estrogen-like signaling compound will typically be formulated in such vehicles at concentrations of about 10 pg/ml to about 10 mg/ml.
The concentration of the compound in the drug composition will depend on absorption, inactivation, and excretion rates of the drug as well as other factors known to those of skill i n the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. Additionally, the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time. It is to be further understood that for any particular patient, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope o r practice of the claimed composition.
V I I . Illustrative Examples The following examples are illustrations of the embodiments of the invention as described above, but are not intended to limit its scope.
As one example, 17~-estradiol, the synthetic steroid estratriene-3-ol, which is a potent neuroprotective compound, and 17a-estradiol, have potent anti-apoptotic effects on osteoblastic cells in vitro.
U.S. Patent No. 5,843,934 to Simpkins discloses that a n estrogen having insubstantial sex-relaxed activity, and i n particular, a-estrogens such as 17a-estradiol, can be administered to a patient to retard the adverse effects of osteoporosis in a male or female. The '934 patent does not address how to select a compound to increase bone mass opposed to treat osteoporosis.
Increasing bone mass is a different indication from the treatment of bone loss, as dramatically illustrated by the fact that the U.S.
Food and Drug Administration has approved a number of drugs for the treatment of osteoporosis, but has not approved any drugs to date as bone anabolic agents.
17~i-Estradiol is used in these illustrative examples even though it is a potent activator of estrogen-like gene transcription, because it tightly binds to the estrogen receptor and inhibits osteoblastic apoptosis. The compound must be modified to fall within the selection criteria for the present invention b y altering it in such a way that it cannot enter the cell to induce gene transcription. Such modifications can occur, for example, b y covalently attaching, either directly or through a linking moiety, a second moiety that prevents or limits cell penetration. Any other estrogen or androgen that binds appropriately to the relevant receptor can be likewise modified for use to increase bone mass.
It is noteworthy that (a) the anti-apoptotic effect of 17~i-estradiol on both osteoblasts and osteocytes are reproduced with a membrane impermeable 17~i-estradiol - BSA conjugate; (b) the anti-apoptotic effects of these compounds are diminished b y ICI 182780, a pure estrogen receptor antagonist; and (c) that the anti-apoptotic effects of all these compounds cannot be shown i n HeLa cells unless these cells are stably transfected with either the estrogen receptor a or the estrogen receptor ~3.
The following examples are given for the purpose of illustrating various embodiments of the invention and are n o t meant to limit the present invention in any fashion.
The increased rate of bone remodeling that follows loss of estrogen should cause a transient acceleration of mineral loss because bone resorption is faster than bone formation and the bone made by new BMUs are less dense than older ones.
However, increased remodeling alone cannot explain th a progressive bone loss that lasts long after the rate of bone remodeling has slowed. Indeed, in addition to changes in the number of osteoblast and osteoclast cells during/following estrogen deficiency, a qualitative abnormality also occurs;
osteoclasts erode deeper than normal cavities. This frequently leads to penetration through a trabecular structure causing removal of some cancellous elements entirely; the remainder are more widely separated and less well connected. The deeper erosion is explained by loss of estrogen's effect to promote apoptosis of osteoclasts (Hughes et al, Nature Med. 1996; 2:1132-1136; Kameda et al, J Exp Med. 1997; 186:489-495; Raisz, Nature Med. 1996; 2:1077-1078). 17 (3-estradiol increased the apoptosis of osteoclasts from approximately 0.5% to as much as 2.7%. This change could prolong the lifespan of osteoclasts and increase their numbers two- to three-fold, thus accounting for the perforation of trabeculae and grinding away of endocortical margins.
To determine whether the role of estrogen deficiency affects osteoblast and osteocyte apoptosis, the prevalence of these cells in murine vertebrae removed 28 days after ovariectomy was determined. In these experiments, four month old Swiss Webster mice were ovariectomized and 28 days later, the animals were sacrificed an d the vertebrae were isolated, and embedded fixed undecalcified in methacrylate. As shown in Figure 2, the prevalence of determined b y osteoblast and osteocyte apoptosis, TUNEL with CuS04 enhancement, increased ten-and four-fold, respectively.These results indicate that the accelerated loss of bone that occurs not only to a n after estrogen deficiency is due increase in osteoclast number and lifespan, but also to a .
premature reduction in the lifespan (work hours) of the osteoblasts. The increase in osteocyte apoptosis could further weaken the skeleton by impairment of the osteocyte-canalicular mechanosensory network.
Consistent with the in vivo data described under Example 1, 17 ~i-estradiol prevented apoptosis of osteoblastic cells isolated from murine calvaria, in a dose dependent manner.
Strikingly, inhibition of osteoblast apoptosis could also be shown by 17 (3-estradiol conjugated with bovine serum albumin, a membrane impermeable compound. The same effect could also b a shown with 17 a-estradiol, a compound heretofore thought to b a inactive. Moreover, inhibition of etoposide-induced osteoblastic cell apoptosis was demonstrated by estratriene-3-ol, an estrogenic compound thought to lack feminizing properties (Figure 3). In this experiment, osteoblastic cells were derived from murine calvaria and were pretreated with the sterols for 1 hour before the addition of the pro-apoptotic agent, etoposide.
In agreement with the in vivo results indicating that estrogen loss increases both osteoblast and osteocyte apoptosis, 17 (3-estradiol, 17 ~i-estradiol conjugated with BSA, 17a-estradiol, and estratriene-3-of dose-dependently inhibited also the apoptosis of an established osteocytic cell line (Figure 4). In this experiment, MLO-Y4 cells were pretreated with the indicated concentrations of the various compounds for 1 h before th a addition of the pro-apoptotic agent, etoposide. Apoptosis was determined after 6 h by trypan blue uptake as described in Figure 3.
As shown in Figure 5, the anti-apoptotic effect of 10-8 M 17~i-estradiol, 17[3-estradiol-BSA, 17a-estradiol, or estratriene-3-0l (E-3-ol) on osteoblastic cells was abrogated when the cells were pretreated for 1 h with the pure receptor antagonist ICI182,780 ( 10-' M) before the addition of the estrogenic compounds.
As in the case of the antiapoptotic effect of 17~3-estradiol, 17~i-estradiol-BSA, 17a-estradiol, or estratriene-3-of (E-3-0l) on osteoblastic cells, their antiapoptotic effect on osteocytes was abrogated when the cells were pretreated for 1 h with the WO OOI20007 ~ PCT/US99/23355 pure receptor antagonist ICI182,780 ( 10-' M). Collectively, th a results of examples 4 and 5 strongly suggest that the anti-apoptotic effects of these compounds on osteoblasts and osteocytes are mediated via the estrogen receptor (ER).
S
Definitive demonstration of the requirement of the estrogen receptor for the anti-apoptotic effects of 17~i-estradiol and the related compounds tested herein was provided by the results of the experiment shown in Figure 7. In this experiment, instead of calvaria cells, human HeLa cells which contain undetectable, if any, estrogen receptor were used. HeLa cells were stably transfected with either a CMV promoter-driven cDNA for the murine estrogen receptor-alpha (mERa) or a CMV promoter-driven cDNA for the murine estrogen receptor-beta (mER~i).
Subconfluent cultures of stable transfectants were treated for 1 h with 17[3-estradiol, or 17a-estradiol, estratriene-3-of (10-8 M), followed by a 6 hour incubation with etoposide (5x10-5 M). Cells were trypsinized, pelleted and trypan blue positive cells were enumerated. As shown in Figure 7, none of the three compounds had any effect on the apoptosis of the wild type HeLa cells, b a t they potently inhibited etoposide-induced apoptosis in HeLa cells transfected with the estrogen receptor a or estrogen receptor Vii.
The mechanism of the anti-apoptotic effect of the estrogenic compounds described herein was established b y demonstrating that 17a-estradiol, 17~i-estradiol, 17~i-estradiol-BSA or estratriene-3-ol, at 10-8 M concentrations, activated extracellular signal regulated kinases (ERKs). In this experiment, MLO-Y4 osteocytic cells were incubated for 25 minutes in serum-free medium. Subsequently, 17 a-estradial, 17 (3-estradiol, 17 ~3-estradiol-BSA or estratriene-3-of ( 10-8 M) were added and cells incubated for an additional 5, 15, or 30 minutes. CeII lysates were prepared and proteins were separated by electrophoresis in polyacrylamide gels and transferred to PVDF membranes.
Western blotting was performed using a specific antibody recognizing phosphorylated extracellular signal regulated kinases 1 and 2, followed by reblotting with an antibody recognizing total extracellular signal regulated kinases. Blots were developed b y enhanced chemiluminescence. As shown in Figure 8, all these compounds specifically increased the phosphorylated fraction of ERKl/2 without affecting the total amount of ERK1/2. This effect is too rapid to be accounted for by the classical mechanism of estrogen action. Instead, it is consistent with a non-genomic action mediated via membrane-associated estrogen receptors, as suggested by the experiments presented in Examples 4, 5 and 6.
The ability of 17 a-estradiol, 17 ~3-estradiol, 17 [3-estradiol-BSA or estratriene-3-of to activate ERKs was abrogated in the presence of the specific inhibitor of ERK kinase, PD98059.
WO 00/2000? PCT/US99/23355 In this experiment, MLO-Y4 osteocytic cells were incubated for 2 S
minutes in serum-free medium in the presence or absence of 5 0 p.M PD98059. Subsequently, 17 a-estradiol, 17 ~i-estradiol, 17 ~3 estradiol-BSA or estratriene-3-of ( 10-8 M) were added and cells incubated for another 5 minutes. Cell lysates were prepared and proteins were separated by electrophoresis in polyacrylamide gels and transferred to PVDF membranes. Western blotting was performed using a specific antibody recognizing phosphorylated extracellular signal regulated kinases 1 and 2, followed b y reblotting with an antibody recognizing total extracellular signal regulated kinases. Blots were developed by enhanced chemiluminescence.
That indeed the anti-apoptotic effect of all the compounds tested herein was mediated via activation of ERKs w a s established by the results of the experiments shown in Figure 10.
In this experiment, MLO-Y4 osteocytic cells were pretreated for 1 hour with the specific inhibitor of ERKs activation, PD98059, before the addition of 108 M 17 a-estradiol, 17 ~i-estradiol, or 17 (3-estradiol-BSA. Apoptosis was induced by incubation with the pro-apoptotic agent dexamethasone for 6 hours and quantified a s described in Figure 3. PD98059 prevented the anti-apoptotic effect of all three compounds tested in this experiment.
In conclusion, the results of the examples provided above demonstrate that loss of estrogen irc vivo leads to several-fold increase in the prevalence of apoptosis of osteoblasts and osteocytes. Consistent with the in vivo findings, 17a-estradiol, as well as 17(3-estradiol, 17(3-estradiol-BSA and estratriene-3-of inhibit the apoptosis of osteoblastic cells derived from murine calvaria or osteocytes, represented herein by the cell line MLO-Y4.
The anti-apoptotic effect of all these compounds requires the presence of either estrogen receptor a or estrogen receptor ~i and is mediated via the ability of these compounds to activate specific MAP kinases, namely the extracellular signal regulated kinases (ERKs).
Similar to the results with estrogenic compounds, androgenic compounds also inhibited apoptosis of osteoblastic cells derived from murine calvaria induced by etoposide (Table 3). I n these experiments, cells were pretreated with the indicated concentrations of the various compounds for 1 hour, in the absence or presence of the androgen receptor antagonist flutamide, before the addition of the proapoptotic agent etoposide.
Apoptosis was determined after 6 hours by trypan blue uptake a s described in Figure 3. Notably, as in the case of estrogenic compounds, all these effects were apparently mediated by the androgen receptor, as evidenced by the inhibition of the anti-apoptotic effects of the androgenic compounds by a specific androgen receptor antagonist. Moreover, and as in the case of estrogens, the androgen receptor-mediated protection of etoposide-induced apoptosis was seen with a membrane impermeable androgen (testosterone-17(3-hemisuccinate conjugated with BSA), strongly suggesting the existence of a membrane-associated androgen receptor, analogous to the membrane-associated estrogen receptor.
able 3 Inhibition of etoposide-induced osteoblast apoptosis by androgens and progestins ompound Lowest Suppression by 10'g M
Effective Flutamide Concentration Testosterone 10'9 M yes Testosterone 17(3- 10-g M y a s Hemisuccinate: BSA
5-a- 10-9 M y a s dihydrotestosterone 5-(3- 10-' M yes dihydrotestosterone Dehydroisoandroste 10-g M no*
rone-3-sulfate (DHES) 4-androstene-3,17- 10-8 M yes dione 5-androstene-3(3- 10-a M yes 17 -diol RU1881 10-8 M yes * Flutamide did block the anti-apoptotic effect of l~ti~ at higher ( 10-' M) concentration.
That the anti-apoptotic effects of estrogenic compounds is dissociated from their transcriptional activity w a s established by demonstrating that even though estratriene-3-of was as potent as 17 ~i estradiol in inhibiting apoptosis, unlike 17 [3 estradiol, it did not transactivate an estrogen response element through the estrogen receptor a. In this experiment, hERa was overexpressed in 293 cells (which lack constitutive ERa) along with a reporter construct containing 3 copies of an estrogen response element driving the luciferase gene. Light units were counted and normalized to coexpressed ~i-galactosidase activity to control for differences in transfection efficiency.
Herein, a general experimental protocol for studies aiming to evaluate compounds with anti-apoptotic efficacy, b a t decreased transcriptional activity (e.g., estratriene-3-ol) on osteoblasts and osteocytes in animal models is provided.
According to this design, estrogen-replete or estrogen-deficient mice, rats, dogs, primates, etc., or animals representing models of involutional osteoporosis and/or defective osteoblastogenesis (e.g., the senescence accelerated mouse, SAMP6: (Jilka et al., J Clin Invest 97:1732-1740, 1996)), or animal models of glucocorticoid excess (e.g., Weinstein et al. J Clin Invest, 102:274-282, 1998) are administered estratriene-3-of or other test compound to determine whether they can suppress osteoblast and osteocyte apoptosis and whether changes in apoptosis would be associated with changes in BMD, bone formation rate, or cancellous bone volume.
In a representative experiment of this sort, six 4 - 5 month old female mice per group are screened twice for BMD in a four week period immediately prior to the initiation of the experiment to establish that peak adult bone mass has been attained. A subset of mice are then ovariectomized. Intact a n d ovariectomized mice are treated with vehicle, or 20, 200 or 2 0 0 0 ng/g body weight estratriene-3-of or another test compound.
Ovariectomized mice are also treated with 20 ng/g body weight 17 ~i-estradiol for comparison purposes.
Stock solutions of the test agents (10,000 p,g/ml) are maintained in approximately 2.0 ml of 95% ethanol. These stocks are diluted in 95% ethanol to make 1000 ~,g/ml and 100 ~.g/ml concentrations. The concentration of the stocks is checked spectrophotometrically. For each animal injection, the test agent is diluted in sesame oil and sonicated. Test agents are administered for 28 days by subcutaneous injections on alternative days. The mice are weighed weekly and serum samples are collected a t appropriate times for analysis of bone biochemical markers, such as osteocalcin or collagen cross-links. Tetracycline labeling is performed by administration of the antibiotic (30 mg/kg) at 2 and 8 days prior to the end of each experiment. Table 1 shows a representative example of 25 g mice divided into 5 groups with each animal receiving 100 ~,l of the test agent per injection.
Treatment Injection (steroid + sesame oil) vehicle 100 pl 95% ethanol + 1900 p.l 20 ng/g estratriene-3-of 100 p.l 100 ~g/ml stock + 1900 p,l 200 ng/g estratriene-3-of 100 p.l 1000 ~g/ml stock + 1900 p.l 2000 ng/g estratriene-3-of 100 p,l 10,000 p.g/ml stock + 1900 p.l 20 ng/g 173-estradiol 50 p.l 100 p,g/ml stock + 950 p.l During the 28 day experiment, BMD is determined i n live animals at day 0, 14 and 28. Following animal sacrifice at the end of the experiment, the vertebral bones Ll-L4 are collected for fixation and embedded undecalcified in methylmethacrylate plastic for the determination of the prevalence of osteoblast and osteocyte apoptosis and other static and dynamic histomorphometric measurements. L5 vertebrae are isolated for determining anti-fracture efficacy of the compounds by assaying compression, 3 point bending and other appropriate biomechanical tests. Results confirming the expected efficacy of th a s a compounds show decreased prevalence of osteoblast and/or osteocyte apoptosis, and/or positive BMD changes, and/or increased cancellous bone area, and/or increased rate of bone formation, and/or increased biomechanical strength.
As an example, the results of an experiment w h a r a b y 2000 ng/g body weight of estratriene-3-of was administered for 28 days to estrogen-replete (intact) or estrogen-deficient (ovariectomized) mice are shown in Table 2.
T B~ LE 2 Increased BMD by estratriene-3-of administration intact-vehicle:
global global hindquart 1 hindquartpine 2 spine Ø0552 0.0585 0.0599 0.0533 0.0581 0.0595 0.0535 0.0586 0.0575 0.0546 0.0571 0.0599 0.0516 0.0557 0.0559 0.0503 0.0560 0.0544 0.0516 0.0513 0.0569 0.0492 0.0499 0.0527 , 0.0552 0.0553 0.0589 0.0492 0.0521 0.0531 0.0475 0.0494 0.0525 0.0480 0.0450 0.0539 0.0535 0.0524 0.0574 0.0524 0.0592 0.0553 0.0526 0.0544 0.0570 0.0510 0.0539 0.0555 (mean) 0.0027 0.0036 0.0024 0.0025 0.0052 0.0030 (std) 0.0552 0.0586 0.0599 0.0546 0.0592 0.0599 (max) 0.0475 0.0494 0.0525 0.0480 0.0450 0.0527 (min) intact-2000 3-0l:
ng/g _ lhindquar>apine global hindquart global 1 2 spine _ 0.0509 0.0511 0.0550 0.0585 0.0602 0.0486 0.0511 0.0565 0.0560 0.0543 0.0603 0.0604 0.0543 0.0605 0.0593 0.0541 0.0619 0.0601 0.0537 0.0577 0.0584 0.0568 0.0629 0.0613 0.0533 0.0546 0.0571 0.0568 0.0640 0.0620 0.0521 0.0544 0.0555 0.0537 0.0554 0.0588 0.0560 0.0587 0.0623 0.0574 0.0605 0.0632 0.0527 0.0562 0.0571 0.0554 0.0605 0.0609 (mean) 0.0024 0.0032 0.0035 0.0015 0.0029 0.0014 (std) 0.0560 0.0605 0.0623 0.0574 0.0640 0.0632 (max) 0.0486 0.0509 0.0511 0.0537 0.0554 0.0588 (min) __vehicle vs 2000 ng/g:
t-test 0.0036 0.0077 0.0037 Ovx-vehicle:
global lhindquarkpine global hindquart spine 2 _ 0.0539 0.0550 0.0493 0.0507 0.0548 0.0525 0.0479 0.0484 0.0538 0.0497 0.0569 0.0545 0.0510 0.0543 0.0565 0.0483 0.0509 0.0545 0.0538 0.0548 0.0583 0.0483 0.0515 0.0536 0.0567 0.0632 0.0620 0.0538 0.0584 0.0588 0.0533 0.0533 0.0572 0.0504 0.0507 0.0559 0.0543 0.0592 0.0583 0.0491 0.0526 0.0545 0.0490 0.0518 0.0551 0.0475 0.0487 0.0534 0.0523 0.0550 0.0570 0.0496 0.0528 0.0550 (mean) 0.0029 0.0049 0.0026 0.0019 0.0035 0.0017 (std) 0.0567 0.0632 0.0620 0.0538 0.0584 0.0588 (max) Ovx-2000 ng/g 3-0l:
global global hindquart spine lhindquar>,pine 2 Z
0.0505 0.0527 0.0547 0.0565 0.0602 0.0608 0.0542 0.0588 0.0581 0.0557 0.0632 0.0585 0.0496 0.0504 0.0542 0.0548 0.0599 0.0584 0.0540 0.0596 0.0586 0.0545 0.0624 0.0598 0.0526 0.0547 0.0580 0.0564 0.0598 0.0610 0.0569 0.0604 0.0628 0.0568 0.0647 0.0625 0.0565 0.0591 0.0603 0.0550 0.0630 0.0578 0.0528 0.0582 0.0568 0.0539 0.0599 0.0605 0.0534 0.0573 0.0579 0.0555 0.0618 0.0599 (mean) 0.0026 0.0036 0.0028 0.0011 0.0020 0.0016 (std) 0.0569 0.0604 0.0628 0.0568 0.0647 0.0625 (max) 0.0496 0.0504 0.0542 0.0539 0.0598 0.0578 (min) ovx vs 2000 n /
t-test 0.0000 0.0001 0.0001 Each row represents values for individual animals.
The first three sets of numbers represent the initial BMD
measurements (by dual-energy x-ray absorptiometry with Hologic QDR2000 plus, using customized software) at day 0 and the last three BMD measurements at the end of the experiment. Global =
BMD of the entire skeleton minus the head and tail; hindquarters =
the mean BMD of both hindlimbs; spine = the BMD of cervical, thoracic and lumbar spine.
EXAl~!~ LP E 13 Herein, a general experimental protocol evaluating the anti-fracture efficacy of compounds like estratriene-3-of is provided. According to this design, estrogen-replete or estrogen-deficient mice, rats, dogs, primates, etc., or animals representing models of involutional osteoporosis and/or defective osteoblastogenesis (e.g., the senescence accelerated mouse, SAMP6:
(Jilka et al., J Clin Invest 97:1732-1740, 1996)), or animal models of glucocorticoid excess (e.g., Weinstein et al. J Clin Invest, 102:274-282, 1998) are administered estratriene-3-of to determine whether they can increase bone strength.
In a representative experiment of this sort, seven 4-5 month old female mice per group are screened twice for BMD in a four week period immediately prior to the initiation of the experiment to establish that peak adult bone mass has been attained. A subset of mice are then ovariectomized. Intact and ovariectomized mice are treated with vehicle, or 20, 200 or 2000 ng/g body weight estratriene-3-of or another ANGEL compound.
Ovariectomized mice are also treated with 20 ng/g body weight 17 ~3-estradiol for comparison purposes. Ultimate load bearing properties of the fifth lumbar murine vertebrae (L5) i s determined. This is done using a servohydraulic axial-torsional material testing machine (Model MTS 810 Bionx; MTS Systems Corp., Eden Prairie, MN) and a Lebow load cell (Eaton Products, Troy, MI). Data are recorded and analyzed using the LabVIEW
software package and an acquisition/signal conditioning board (Model NB-MIO-16, National Instruments Corporation, Austin, TX).
The L5 specimens that is used for ultimate load bearing i s cleaned of surrounding soft tissue and the length and diameter recorded with a digital caliper at a resolution of 0.01 m m (Mitutoyo Model #500-196, Ace Tools, Ft. Smith, AR). The vertebrae are wrapped in saline-soaked gauge throughout preparation and testing and stored overnight at 4°C before testing.
Vertebrae are individually compressed between parallel loading platens along the cephalocaudad axis until failure and the ultimate load (in Newtons) and displacement (in mm) are recorded.
As an example, the results of an experiment whereby 2000 ng/g body weight of estratriene-3-of was administered for 28 days to estrogen-replete (intact) or estrogen-deficient (ovariectomized) mice (from the same animals shown in Example 12) is shown in Table 4.
Ta le Changes in Compression Strength (VCS*), Vertebral Induced by In v i v on of E-3-of o Administrati Demonstration CVS than BMD
of Greater Increase in {n - 7 per group}
Vertebral Global BMD (g/cm2) Compression (Newtons) Intact-v a h i c 66.78 17.47 0.0508 0.0026 l a 50.3 7.58 Ovx- 96.26 15.92 (p<0.006)0.0486 0.0011 vehicle 85.57 10.17 0.0554 0.0015 (p<0.002) Intact-E- (P<0.00001) 3-0l 0.0555 0.0011 Ovx-E-3- ~ ~ (p<0.00001) of *Each value represents the mean from seven animals.
The BMD values shown for comparison here are from the experiment described in Example 12.
iEXAMPLE 14 To determine whether the anti-apoptotic effects of estrogenic compounds are mechanistically dissociable from their transcriptional effects, specific conformational changes of the receptor protein leading to prevention of apoptosis versus transcriptional activity were sought. The rationale behind these studies was based on recent evidence that the transcriptional activity of the ER is greatly dependent on ligand-induced conformational changes of the receptor protein. Indeed, using phage display libraries, McDonnell and co-workers have recently screened for and isolated four classes of small (11 amino acids) peptides that recognize distinct conformational changes of the estrogen receptor, and can either selectively block transcription from specific ligands (e.g., estradiol but not tamoxifen and vice versa) or selectively block ERa but not ER~i -mediated transcription, and vice versa, when tested on a consensus )~~ERE
(Norris et al. Science 285:744-746, 1999). The first class contains the LX~~.L motif and can interact with both estradiol-activated ERa and ER~3. The second class displays specific interaction w i th estradiol- and tamoxifen-activated ERa, whereas the third class can interact specifically with tamoxifen-activated ER~3. Yet a fourth class with a SREWFXXXL conserved motif was found to complex t o tamoxifen-activated ERa and ER~i. Indeed, when fusion proteins made with these peptides and the Gal4-DNA binding domain and were co-expressed with ER in HeLa cells they functioned a s ligand-receptor complex-specific antagonists, demonstrating that ligand activation triggers transcriptional activity by conferring specific conformational changes on the receptor protein (Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, Change C-Y, Ballas LM, Hamilton PT, McDonnell DP, Fowlkes DM. Estrogen receptor (ER) modulators each induce distinct conformational changes in ERa and ERj3. Proc. Natl. Acad. Sci 96:3999-4004, 1999).
Based on the findings that estrogenic compounds like the conjugated 17-~i estradiol with BSA have, at least as potent anti-apoptotic effects as estrogen while have significantly decreased transcriptional activity, the hypothesis that the non genomic anti-apoptotic effects of estrogen can be initiated b y distinct ligand-dependent conformational changes of the ER, as compared to the conformational changes required for the transcriptional effects of the ER was tested. It was found that indeed there is dissociation of conformational changes. Based on this, one can explain the mechanistic basis of the apparent dissociation of the two sets of actions. This knowledge forms th a basis for the design of the screening strategies described herein for ligands which display non-transcriptional effects, but lack the ability to initiate transcriptional activation.
One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. The present examples, along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined b y the scope of the claims.
Claims (45)
1. A method for increasing bone mass at least 10%
in a host without a loss in bone strength or quality is provided that includes administering an effective amount of a compound that (i) binds to the estrogen .alpha. or .beta. receptor (or the equivalent receptor in the host animal) with an association constant of at least 10 8 M-1, and preferably, at least 10 10 M-1: (ii) (a) induces estrogenic gene transcriptional activity at a level that is no greater than 10% that of 17.beta.-estradiol, and preferably no greater than 5, 1 or even 0.1% that of 17.beta.-estradiol when administered in vivo at concentrations of 10 -11 to 10 -7 M a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic or osteocytic cells with natural estrogen receptors or cells transfected with estrogen receptors or (b} induces an increase in uterine weight of no more than 10% that of 17.beta.-estradiol (or the equivalent compound in a host animal); (iii) induces the phosphorylation of extracellular signal regulated kinase (ERK) when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro at concentrations of 10 -11 to 10 -7 M in osteoblastic cells with natural estrogen receptors or cells transfected with estrogen receptors;
and (iv) has an anti-apoptotic effect on osteoblasts at an in vivo dosage of at least 0.1 ng/kg body weight in vitro in osteoblastic or osteocytic cells with natural estrogen receptors or cells transfected with estrogen receptors.
in a host without a loss in bone strength or quality is provided that includes administering an effective amount of a compound that (i) binds to the estrogen .alpha. or .beta. receptor (or the equivalent receptor in the host animal) with an association constant of at least 10 8 M-1, and preferably, at least 10 10 M-1: (ii) (a) induces estrogenic gene transcriptional activity at a level that is no greater than 10% that of 17.beta.-estradiol, and preferably no greater than 5, 1 or even 0.1% that of 17.beta.-estradiol when administered in vivo at concentrations of 10 -11 to 10 -7 M a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic or osteocytic cells with natural estrogen receptors or cells transfected with estrogen receptors or (b} induces an increase in uterine weight of no more than 10% that of 17.beta.-estradiol (or the equivalent compound in a host animal); (iii) induces the phosphorylation of extracellular signal regulated kinase (ERK) when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro at concentrations of 10 -11 to 10 -7 M in osteoblastic cells with natural estrogen receptors or cells transfected with estrogen receptors;
and (iv) has an anti-apoptotic effect on osteoblasts at an in vivo dosage of at least 0.1 ng/kg body weight in vitro in osteoblastic or osteocytic cells with natural estrogen receptors or cells transfected with estrogen receptors.
2. The method of claim 1, wherein the compound is not an estrogen compound.
3. The method of claim 1, wherein the compound is an estrogen.
4. The method of claim 3, wherein the estrogen compound is converted to a nonestrogen by attaching a substituent which prevents the compound from entering the cell but does not significantly affect the binding of the compound to the estrogen cell-surface receptor.
5. A method for increasing bone mass at least 10%
in a host without a loss in bone strength or quality is provided that includes administering an effective amount of a compound that (i) binds to the androgen receptor (or the equivalent receptor in the host animal) with an association constant of at least 10 8 M-1, and preferably, at least 10 10 M-1: (ii) (a) induces androgenic gene transcriptional activity at a level that is no greater than 10% that of testosterone, and preferably no greater than 5, 1 or even 0.1%
that of testosterone when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro at concentrations of 10 -11 to 10 -7 M in osteoblastic cells with the natural androgen receptor or cells transfected with the androgen receptor or (b) induces an increase in muscle weight or virilization in women of no more than 10% that which is induced by testosterone (or the equivalent compound in a host animal); (iii) induces the phosphorylation of extracellular signal regulated kinase (ERK) when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic cells with the natural androgen receptor or cells transfected with the androgen receptor; and (iv) has an anti-apoptotic effect on osteoblasts at an in vivo dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic cells with the natural androgen receptor or transfected with the androgen receptor.
in a host without a loss in bone strength or quality is provided that includes administering an effective amount of a compound that (i) binds to the androgen receptor (or the equivalent receptor in the host animal) with an association constant of at least 10 8 M-1, and preferably, at least 10 10 M-1: (ii) (a) induces androgenic gene transcriptional activity at a level that is no greater than 10% that of testosterone, and preferably no greater than 5, 1 or even 0.1%
that of testosterone when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro at concentrations of 10 -11 to 10 -7 M in osteoblastic cells with the natural androgen receptor or cells transfected with the androgen receptor or (b) induces an increase in muscle weight or virilization in women of no more than 10% that which is induced by testosterone (or the equivalent compound in a host animal); (iii) induces the phosphorylation of extracellular signal regulated kinase (ERK) when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic cells with the natural androgen receptor or cells transfected with the androgen receptor; and (iv) has an anti-apoptotic effect on osteoblasts at an in vivo dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic cells with the natural androgen receptor or transfected with the androgen receptor.
6 . The method of claim 6, wherein the compound is not an androgen.
7. The method of claim 6, wherein the compound is an androgen.
8. The method of claim 8, wherein the androgen is converted to a nonandrogen by attaching a substituent which prevents the compound from entering the cell but which does not significantly affect the ability of the compound to bind to the androgen cell-surface receptor.
9. The method of claim 1, wherein the compound also has a pro-apoptotic effect on osteoclasts at an in vivo dosage of at least 0.1 ng/kg body weight, or in osteoclastic cells with natural estrogen receptors or cells transfected with estrogen receptors.
10. The method of claim 7, wherein the compound also has a pro-apoptotic effect on osteoclasts at an in vivo dosage of at least 0.1 ng/kg body weight, or in osteoclastic cells with natural estrogen receptors or cells transfected with estrogen receptors.
11. A method for selecting a compound that increases bone mass in a host at least 10% without a loss in bone strength or quality is provided that includes evaluating whether the compound {i) binds to the estrogen or androgen receptor (or the equivalent receptor in the host animal) with an association constant of at least 10 8 M-1, and preferably, at least 10 10 M-1: (ii) (a) induces estrogenic or androgenic gene transcriptional activity at a level that is no greater than 10% that of 17.beta.-estradiol or testosterone, and preferably no greater than 5, 1 or even 0.1% that of 17.beta.-estradiol or testosterone, as appropriate, when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic cells with the natural androgen or estrogen receptor or cells transfected with the androgen or estrogen receptor or (b) induces an increase in uterine weight of no more than 10% that which is induced by 17.beta.-estradiol or muscle weight or virilization in women of no more than 10% that which is induced by testosterone (or the equivalent compound in a host animal); (iii) induces the phosphorylation of extracellular signal regulated kinase (ERK) when administered in vivo at a dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic or osteocytic cells with the natural androgen or estrogen receptor or cells transfected with the androgen or estrogen receptor; and (iv) has an anti-apoptotic effect on osteoblasts at an in vivo dosage of at least 0.1 ng/kg body weight or in vitro in osteoblastic cells with the natural androgen or estrogen receptor or cells transfected with the androgen or estrogen receptor.
12. A method for screening for compounds that possess bone anabolic effects, comprising the steps of: a) contacting a sample of osteoblast cells with a compound; and b) comparing the number of osteoblast cells undergoing apoptosis in the compound-treated cells with the number of osteoblast cells undergoing apoptosis in an untreated sample of osteoblast cells.
13. A method for conferring bone protection on a population of cells in a subject through osteoblast/osteocyte anti-apoptotic effects, comprising the step of: administering a n effective dose of a compound to said population of cells, wherein said compound has a terminal phenol group and at least a second ring, wherein said compound has a molecular weight of less than 1000.
14. The method of claim 14, wherein said compound has a molecular weight greater than 170.
15. The method of claim 14, wherein said terminal phenyl ring is a non-steroidal compound.
16. The method of claim 16, wherein said terminal phenyl ring is a phenolic A ring.
17. The method of claim 14, wherein said effective dose of said compound results in a plasma concentration of less than 500 nM.
18. The method of claim 18, wherein said plasma concentration is from about 0.02 nM to about 500 nM.
19. The method of claim 19, wherein said plasma concentration is from about 0.1 nM to about 1 nM.
20. The method of claim 14, wherein said compound is selected from the group consisting of a four-ring structure, a three-ring structure and a two-ring structure.
21. The method of claim 21, wherein when said compound is a four-ring structure, said effective dose is that which achieves a plasma concentration of less than 500 nM.
22. The method of claim 21, wherein when said compound is a three-ring structure, said three-ring structure is a phenanthrene compound.
23. The method of claim 23, wherein said phenanthrene compound is selected from the group consisting of a tetrahydrophenanthrene and an octahydrophenanthrene.
24. The method of claim 23, wherein said phenanthrene compound is selected from the group consisting of a phenanthrenemethanol and a phenanthrenecarboxyaldehyde.
25. The method of claim 21, wherein when said compound is a two-ring structure, said two-ring structure is fused.
26. The method of claim 26, wherein said fused two-ring structure is selected from the group consisting of naphthol and naphthalene.
27. The method of claim 21, wherein when said compound is a two-ring structure, said two-ring structure is non-fused.
28. The method of claim 28, wherein said non-fused two-ring structure comprises a linkage group.
29. The method of claim 14, wherein said compound is administered in combination with a reducing agent.
30. The method of claim 1, further comprising administering the compound in combination with a second pharmaceutical agent.
31. The method of claim 31, wherein the second pharmaceutical agent is bone anti-resorption agent.
32. The method of claim 31, wherein the second pharmaceutical agent is a bone mass anabolizing agent.
33. The method of claim 31 wherein the second pharmaceutical agent is an antioxidant.
34. The method of claim 31, wherein the second pharmaceutical agent is a dietary supplement.
35. The method of claim 31, wherein the second pharmaceutical agent increases the beneficial effect of the active compound on bone structure, strength, or mass.
36. The method of claim 31, wherein the second pharmaceutical agent is selected from the group consisting of an anabolic steroid, a bisphosphonate, a calcitonin, an estrogen or progestogen, an anti-estrogens such as raloxifene or tamoxifene, parathyroid hormone, fluoride, Vitamin D or a derivative thereof, or a calcium preparation.
37. The method of claim 31, wherein the second pharmaceutical agent is selected from the group consisting of alendronic acid, disodium clondronate, disodium etidronate, disodium medronate, disodium oxidronate, disodium pamidronate, neridronic acid, risedronic acid, teriparatide acetate, tiludronic acid, ipriflavone, potassium bicarbonate, progestogen, a thiazide, gallium nitrate, NSAIDS, plicamycin, aluminum hydroxide, calcium acetate, calcium carbonate, calcium, magnesium carbonate, and sucralfate.
38. The method of claim 6, further comprising administering the compound in combination with a second pharmaceutical agent.
39. The method of claim 39, wherein the second pharmaceutical agent is bone anti-resorption agent.
40. The method of claim 39, wherein the second pharmaceutical agent is a bone mass anabolizing agent.
41. The method of claim 39, wherein the second pharmaceutical agent is an antioxidant.
42. The method of claim 39, wherein the second pharmaceutical agent is a dietary supplement.
43. The method of claim 39, wherein the second pharmaceutical agent increases the beneficial effect of the active compound on bone structure, strength, or mass.
44. The method of claim 39, wherein the second pharmaceutical agent is selected from the group consisting of an anabolic steroid, a bisphosphonate, a calcitonin, an estrogen or progestogen, an anti-estrogens such as raloxifene or tamoxifene, parathyroid hormone, fluoride, Vitamin D or a derivative thereof, or a calcium preparation.
45. The method of claim 36, wherein the second pharmaceutical agent is selected from the group consisting of alendronic acid, disodium clondronate, disodium etidronate, disodium medronate, disodium oxidronate, disodium pamidronate, neridronic acid, risedronic acid, teriparatide acetate, tiludronic acid, ipriflavone, potassium bicarbonate, progestogen, a thiazide, gallium nitrate, NSAIDS, plicamycin, aluminum hydroxide, calcium acetate, calcium carbonate, calcium, magnesium carbonate, and sucralfate.
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10338598P | 1998-10-07 | 1998-10-07 | |
US60/103,385 | 1998-10-07 | ||
US10580598P | 1998-10-27 | 1998-10-27 | |
US60/105,805 | 1998-10-27 | ||
US11640999P | 1999-01-19 | 1999-01-19 | |
US60/116,409 | 1999-01-19 | ||
US10338599P | 1999-02-08 | 1999-02-08 | |
US13626099P | 1999-05-27 | 1999-05-27 | |
US60/136,260 | 1999-05-27 | ||
US15148699P | 1999-08-30 | 1999-08-30 | |
US60/151,486 | 1999-08-30 | ||
PCT/US1999/023355 WO2000020007A1 (en) | 1998-10-07 | 1999-10-07 | Method and compositions for increasing bone mass |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2346456A1 true CA2346456A1 (en) | 2000-04-13 |
Family
ID=27557662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002346456A Abandoned CA2346456A1 (en) | 1998-10-07 | 1999-10-07 | Method and compositions for increasing bone mass |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2003535018A (en) |
CA (1) | CA2346456A1 (en) |
WO (1) | WO2000020007A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6660468B1 (en) | 1998-10-27 | 2003-12-09 | Board Of Trustees Of The University Of Arkansas | Vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction |
CA2412998A1 (en) * | 2000-06-13 | 2001-12-20 | The Board Of Trustees For The University Of Arkansas | Methods of dissociating nongenotropic from genotropic activity of steroid receptors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5189212A (en) * | 1990-09-07 | 1993-02-23 | University Of Georgia Research Foundation, Inc. | Triarylethylene carboxylic acids with estrogenic activity |
ZA924811B (en) * | 1991-06-28 | 1993-12-29 | Endorecherche Inc | Controlled release systems and low dose androgens |
-
1999
- 1999-10-07 CA CA002346456A patent/CA2346456A1/en not_active Abandoned
- 1999-10-07 WO PCT/US1999/023355 patent/WO2000020007A1/en not_active Application Discontinuation
- 1999-10-07 JP JP2000573366A patent/JP2003535018A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2000020007A1 (en) | 2000-04-13 |
JP2003535018A (en) | 2003-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6416737B1 (en) | Increasing bone strength with selected bisphosphonates | |
Bassett et al. | Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism | |
Gu et al. | Rapid action of 17β-estradiol on kainate-induced currents in hippocampal neurons lacking intracellular estrogen receptors | |
Nuttall et al. | Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats | |
Roman-Blas et al. | Osteoarthritis associated with estrogen deficiency | |
Lösel et al. | Nongenomic actions of steroid hormones | |
MacRitchie et al. | Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium | |
Ke et al. | Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat | |
DuSell et al. | The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis | |
Vandenput et al. | Evidence from the aged orchidectomized male rat model that 17β‐estradiol is a more effective bone‐sparing and anabolic agent than 5α‐dihydrotestosterone | |
Xiao et al. | Effects of estrogen agonists on amphetamine‐stimulated striatal dopamine release | |
Belcher et al. | Rapid estrogenic regulation of extracellular signal-regulated kinase 1/2 signaling in cerebellar granule cells involves a G protein-and protein kinase A-dependent mechanism and intracellular activation of protein phosphatase 2A | |
Syed et al. | Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways | |
Brennan et al. | Selective modification of bone quality by PTH, pamidronate, or raloxifene | |
US20040224884A1 (en) | Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof | |
US20050026223A1 (en) | Method and compositions for increasing bone mass | |
Olivier et al. | Sodium nitroprusside-induced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene | |
US6605603B1 (en) | Uses of 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid | |
Fujita et al. | Transactivation of core binding factor α1 as a basic mechanism to trigger parathyroid hormone-induced osteogenesis | |
Jaubert et al. | Nongenomic estrogen effects on nitric oxide synthase activity in rat adipocytes | |
Syed et al. | Effects of loss of classical estrogen response element signaling on bone in male mice | |
CA2346456A1 (en) | Method and compositions for increasing bone mass | |
Takarada et al. | Interference by adrenaline with chondrogenic differentiation through suppression of gene transactivation mediated by Sox9 family members | |
AU1103600A (en) | Method and compositions for increasing bone mass | |
AU2004208703A1 (en) | Method and compositions for increasing bone mass |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |